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Abstract 
 
Human immunodeficiency virus type 1 is a major cause of morbidity and mortality worldwide and there 
is urgent demand for a protective vaccine. A major goal of vaccine development is the elicitation of 
antibodies capable of neutralizing diverse strains. In order to achieve this goal it is necessary to 
understand the dynamic relationship between neutralizing antibodies (NAbs) and HIV-1, in vivo. 
In humans, HIV-1 rapidly escapes from NAbs, confirming that humoral responses inhibit virus 
replication. However, neutralizing responses are commonly detected in viraemic patients and the clinical 
impact of NAbs on HIV-1 control is unclear. To investigate this further, viral load (VL) and NAb activity 
were assessed longitudinally in patients enrolled into a clinical trial of short-course antiretroviral therapy 
(ART), administered in early infection. The aims of this study were two-fold: i) to understand the 
importance of VL in the control of NAb responses and ii) to assess whether NAbs contribute to durable 
control of VL set-point. 
A high-throughput pseudovirus neutralization assay was developed, using automated counting 
procedures to quantify infected TZM-bl reporter cells. The assay was used to assess NAb responses with 
autologous viruses derived from 22 patients. Seven patients with low VL set-points (<104 RNA copies/ml) 
failed to develop neutralizing responses throughout the 48-144 week follow-up period. In contrast, the 
remaining patients developed progressively-increasing neutralizing plasma titres (IC50) that correlated 
with the extent and timing of VL rebound after cessation of ART. This suggests that the production of 
NAbs depends on the duration and extent of viraemia in early infection. Viral load was poorly predictive 
of neutralizing responses against heterologous isolates assayed in 38 patients, suggesting that other 
factors are important in the production of antibodies with cross-neutralizing activity. 
Depletion of specific immunological compartments can yield crucial information as to their functional 
importance in vivo. We took advantage of a unique opportunity to investigate the role of NAbs and the 
consequences of their depletion in an HIV-1 infected human. Three years after cessation of short-course 
ART, the patient was treated for pre-existing low-grade lymphoplasmacytic lymphoma by antibody-
mediated depletion of CD20+ B cells using rituximab.  This treatment was followed by a 1.7 log10 rise in 
HIV-1 VL which spontaneously reversed. Autologous NAb responses decreased as viraemia flared, and 
recovered as VL was controlled. Antibodies were found to target the CD4 binding site (CD4bs), as shown 
by competitive-binding assays. Sequence analysis revealed diversification through generation of new 
variants as NAbs decreased, with subsequent selection of NAb-resistant mutants at sites consistent with 
the binding data.  These data suggest that B cell function contributed to long-term control of VL in this 
individual and that NAbs may be more important in controlling HIV-1 infection than previously 
suspected. 
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In June 1981 the Centers for Disease Control (United States of America) reported five unexplained cases 
of an acquired immunodeficiency syndrome (AIDS) in men co-infected with Pneumocystis pneumonia 
and cytomegalovirus (CMV) (Gottlieb, 2006). Since then more than 25 million people worldwide have 
died from AIDS-related complications (UNAIDS, epidemic update 2009, www.unaids.org). Despite these 
harrowing figures, rapid progress has been made towards controlling the AIDS pandemic. Two years 
after the first diagnoses, human immunodeficiency virus type 1 (HIV-1) was identified as the causative 
agent of AIDS (Barre-Sinoussi et al., 1983, Popovic et al., 1984) and by 1985, phase 1 clinical trials had 
begun on the first drug to treat HIV-1 infection (Fischl et al., 1987). Today, rates of AIDS-related 
mortality are now declining in several countries, which is largely due to the introduction of combination 
antiretroviral therapy (ART) (Bhaskaran et al., 2008, Jahn et al., 2008). Nevertheless, approximately 0.8% 
of the adult population, worldwide, are infected with HIV-1 (UNAIDS, 2008), and the need for a 
protective vaccine is greater than ever (Figure 1.1).  
In HIV-1 infection, T cells that express the CD4 antigen are the principle targets of virus infection, while 
CD8+ T cells are considered important in controlling viral replication (Carrington and O'Brien, 2003, 
Crawford et al., 2007, Pereyra et al., 2008a, Schmitz et al., 1999). B cells are the producers of antibodies 
and are also involved in regulation of T cell responses. For a vaccine to achieve sterilizing immunity to 
HIV-1 it may be necessary to induce T and B lymphocyte responses, and there has been some success 
following a vaccination trial that aimed to do this. A randomized, placebo-controlled trial (RV144) 
conducted on 16,000 participants showed a 31% reduced risk of HIV-1 infection in individuals vaccinated 
with recombinant-canarypox vector (ALVAC) and recombinant HIV-1 envelope glycoprotein (AIDSVAX) 
(Rerks-Ngarm et al., 2009). Antibodies may have been responsible for this protective effect, as 
individuals vaccinated with ALVAC/AIDSVAX as part of a previous study produced HIV-1 specific  
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Figure 1.1  The percentage of adults (15-49) infected with HIV-1 worldwide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The map is colour coordinated to show the prevalence (%) of HIV-1 infections in men and 
women aged 15-49, per region. Data are taken from the UNAIDS/WHO epidemic update (2008), in 
accordance with the terms and conditions stated on the web-site (http://unaids.org/en). 
Epidemiological estimates are based on anonymous monitoring at designated ‘sentinel surveillance’ 
sites. These estimates are supported by national surveys conducted in 33 countries.  
  
Global: 0.8% 
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antibodies that had antiviral effects in vitro (Karnasuta et al., 2005). Other vaccination trials have been 
less successful. The phase-2 STEP trial of an adenovirus vector-based vaccine failed to protect against 
infection despite inducing HIV-1 specific T cell responses (Buchbinder et al., 2008). Post-hoc analyses 
indicated a modest increase in infection rates in uncircumcised vaccine recipients and those with 
previously acquired immune responses to adenovirus serotype 5 (Robertson, 2008b, Robertson, 2008a, 
Hutnick et al., 2009, Sekaly, 2008). The immunological correlates of these dichotomous clinical 
outcomes have yet to be determined. 
Some HIV-1 infected individuals produce antibodies that neutralize autologous and heterologous strains 
of HIV-1, in vitro (Carotenuto et al., 1998b, Deeks et al., 2006a, Sather et al., 2009). Understanding the 
mechanisms that control the production of neutralizing responses in these patients, particularly during 
the early stages of infection, is central to the development of HIV-1 vaccines. Additionally, it is important 
to understand the role of neutralizing antibodies (NAbs) in established HIV-1 infection as this may 
identify novel targets for drug interventions that could potentiate protective immunity and delay 
progression to AIDS. 
1.2 The origins of the HIV-1 pandemic 
The human immunodeficiency viruses, HIV-1 and HIV-2, are lentiviruses belonging to the family of 
Retroviridae.  Each virus originated from separate zoonotic transmissions from species of African 
primates infected with simian immunodeficiency virus (SIV). The most likely ancestor of HIV-2 is an SIV 
strain that infects sooty mangabeys and was probably transmitted to humans in the 1940’s (Lemey et 
al., 2003). HIV-2 is endemic in West Africa and is less infectious and less virulent than HIV-1 (Pepin et al., 
1991). The closest ancestor of HIV-1 is SIVcpz, which infects the common chimpanzee, Pan troglodytes 
(Gao et al., 1999).  Two separate SIV strains closely resemble distinct parts of the SIVcpz genome, 
indicating that separate cross-species transmissions produced a hybrid virus capable of infecting humans 
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in parts of Africa where primates are hunted and eaten (Bailes et al., 2003). The earliest confirmed case 
of HIV-1, for which genetic material has been recovered, dates back to 1957. By comparing differences 
between this viral genome with those of other early cases, Worobey et al. estimated that HIV-1 entered 
the human population near the beginning of the 20th century (Worobey et al., 2008). It is likely that SIV 
has been transmitted to humans on at least four separate occasions, thus founding four separate HIV-1 
lineages: major (M), outlier (O), N and P. An SIV strain that infects gorillas (SIVgor) is the most likely 
ancestor of HIV-1 groups O and P (Takehisa et al., 2009, Plantier et al., 2009). 
The majority of HIV-1 infections belong to group M, which is sub-divided further into nine distinct 
subtypes: A, B, C, D, F, G, H, J and K. Viruses from separate clades occasionally recombine within super-
infected individuals and, if transmitted, become known as circulating recombinant forms (reviewed in 
(Carr et al., 1998). Subtype B infections predominate in Europe and North America, while subtype C 
infections predominate in Sub-Saharan Africa and are responsible for approximately half of all HIV-1 
infections worldwide (Osmanov et al., 2002). 
1.3 HIV-1 genome 
The HIV-1 genome consists of a dimer of single-stranded RNA molecules of approximately 9 kilobases 
(kb) in length. Each sense-stranded RNA genome contains nine genes that encode fifteen proteins 
classified as accessory proteins (Vpu, Vpr, Vif, and Nef), regulatory proteins (Tat and Rev) and nine 
structural proteins cleaved from precursor proteins (Gag, Pol, and Env). (Figure 1.2 and Table 1.1). 
Because the HIV-1 genome is transcribed by cellular RNA polymerase (pol) II, the 5’ terminus is capped 
via a 5’-5’ phosphodiester bond to an M7 GTP group and the 3’ terminus ends with approximately 200 
adenosine bases (polyA). Immediately internal to the 5’ cap and the 3’ adenosines are non-coding 
sequences that play important roles in DNA replication. The organization of these sequences and the 
protein-coding portions of the genome are shown in Figures 1.2 and 1.4. 
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Table 1.1 Classification and functions of the HIV-1 proteins  
 Protein type Precursor
Viral 
protein
Other names
Size 
(kDa)
Localization Functions and interactions
MA Matrix 17 Virion •Anchors Gag and Gag-Pol into the membrane
•Interacts with the cytoplasmic tail of gp41
CA Core capsid 24 Virion •Provides structure to the virion core
NC Nucleocapsid 7 Virion •Encapsidates viral RNA
p6 - 6 Virion •Binds and incorporates Vpr into virion
PR Protease 15 Virion •Cleaves Gag and Gag‐Pol precursor proteins
RT Reverse 
Transcriptase
66, 51 Virion •Reverse transcribes viral RNA
RNAse H* - Virion •Degrades RNA template
IN Integrase 31 Virion •Integration of DNA provirus
gp120 Envelope surface 
subunit
120 Virion                     
Plasma membrane
•Binds to the host antigen, CD4, and to the 
chemokine receptors CCR5 and/or CXCR4
gp41 Envelope 
transmembrane 
subunit
41 Virion                     
Plasma membrane
•Mediates virus:cell fusion
Tat 16/14 Nucleus •Transactivator of HIV‐1 gene expression
Nucleolus •Binds to the TAR RNA element
•Prevents 5' polyadenylation signal from causing 
premature termination of transcription
Rev 19 Nucleus •Interacts with Rev response element in env
Nucleolus •Shuttles mRNA from nucleus to cytoplasm
Cytoplasm
Vif Viral protein F 23 Cytoplasm •Promotes virion maturation and infectivity
Membrane                                       
Virion
•Promotes polyubiquitination of the antiviral 
host cell protein, APOBEC 3G, which deaminates 
viral RNA:DNA heteroduplexes
Vpr Viral protein R 10-15 Virion                                         
(Nuclear membrane?)
•Promotes nuclear localization of preintegration 
complex
•Inhibits cell division
•Induces cell differentiation
•Interacts with p6 part of the Gag precursor
Vpu Viral protein U 16 Plama membrane •Enhances virion release by inhibiting host‐cell 
protein, CD134 (tetherin), activity.
•Promotes degradation of CD4 in the 
endoplasmic reticulum
•Promotes Env maturation
•Increases cell susceptibility to Fas‐mediated 
apoptosis
Nef Negative factor 25 Plasma membrane •Enhances virion production
Cytoplasm                                                 
(Virion?)
•Down‐regulates CD4 and MHC class I molecules 
•Interacts with clatherin‐dependant protein 
sorting pathways
•Binds to Src kinases and modulates cell signal 
transduction 
Accessory
Regulatory
Gag                   
Gag-Pol
Gag-Pol
gp160
Structural
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Table 1.1 Classification and function of the HIV-1 proteins 
The fifteen HIV-1 proteins are divided into three categories: structural proteins, regulatory proteins and 
accessory proteins. The functions and localization of each protein are shown.  Reverse transcriptase is a 
multifunctional enzyme, which exhibits RNA and DNA dependent polymerase activity and ribonuclease 
H (RNase H) activity. The active sites of both enzymes are located on the p66 subunit of the p66/p51 
heterodimer (*). 
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1.4 Virion structure 
The HIV-1 virion is approximately 100 nm in diameter and is surrounded by a lipid bi-layer, enriched with 
cholesterol and sphingomyelin (Liao et al., 2001). Embedded in the viral membrane are the envelope 
(Env) glycoproteins that mediate virus entry. The 120 kilo Dalton surface subunit of Env, gp120, is non-
covalently attached to the transmembrane subunit, gp41. Both glycoproteins form 7-14 trimers on the 
virion surface (Chertova et al., 2002, Lu et al., 1995, Weiss et al., 1990, Chan et al., 1997). Several host 
proteins have been detected within the virus envelope, including complement-regulatory proteins CD55 
and CD59 that protect against antibody-dependant and antibody-independent mechanisms of viral 
inactivation (Marschang et al., 1995, Saifuddin et al., 1997, Saifuddin et al., 1995).  
Nascent virions are non-infectious due to highly-stable associations between the Gag and Gag-Pol 
precursors that make up the interior-core structure (Gottlinger et al., 1989) (Figure 1.3A).  Myristoyl 
groups at the N-termini of Gag and Gag-Pol interact with the internal leaflet of the lipid envelope. 
During virion maturation, Gag-Pol precursors dimerize to form the active site of viral protease (PR), 
which cleaves Gag-Pol to form the HIV-1 enzymes: PR, reverse transcriptase (RT) and integrase (IN). 
Additionally, PR cleaves Gag to form the membrane-associated matrix protein (MA), capsid (CA), 
nucleocapsid (NC), C-terminal domain (p6), and two spacer domains (Henderson et al., 1992, Mervis et 
al., 1988) (reviewed in (Gottlinger, 2001)). Mature virus particles are recognized by their electron-dense 
cone-shaped cores, which consist of hexagonal lattices of CA, beneath which resides the dimeric RNA 
genome, encapsidated by NC (Gelderblom, 1991) (Figure 1.3B).   
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Figure 1.3  Models of HIV-1 virion structure 
   
A 
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Figure 1.3 Models of HIV-1 virion structure 
 
 
 
 
 
 
 
 
 
Figure 1.3 A: The immature HIV-1 virion is shown. The interior-core structure is formed by stable 
interactions between Gag and Gag-Pol precursors. The different colours show domains that correspond 
to the mature proteins, formed when PR cleaves these precursors. Trimers of gp120 and gp41 are 
shown embedded in the lipid membrane 
 
Figure 1.3 B: The mature HIV-1 virion is shown with cleaved Gag and Pol proteins. The conical core is 
formed from a hexagonal lattice of CA proteins. Beneath the core resides the dimeric-RNA genome, 
encapsidated by NC. Several viral-accessory proteins have also been detected in the virus core (not 
shown; see Table 1.1 for details) 
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1.5 The early phase of the HIV-1 life cycle 
The HIV-1 life cycle is divided into early and late phases (Figure 1.4). The early phase begins with 
virus entry. The mechanism of HIV-1 entry was thought to be independent of pH and and 
endocytosis (McClure et al., 1988). However, recently Miyauchi et al. tracked single virus particles 
using live-cell imaging and showed that HIV enters cells via dynamin-dependent endocytosis prior to 
fusion (Miyauchi et al., 2010). The majority of virions that attach to the cell membrane are 
endocytosed, but this generally leads to degradation of the virus by the endocytic pathway 
(Fredericksen et al., 2002, Schwartz et al., 1998). Virus attachment may be facilitated by 
electrostatic interactions between gp120 and cell-surface proteoglycans (Mondor et al., 1998, 
Moulard et al., 2000). Additionally, lectin-binding proteins such as dendritic cell-specific ICAM3 
grabbing non-integrin (DC-SIGN) bind to mannose type carbohydrates attached to gp120 (ICAM3 
stands for intra-cellular adhesion molecule 3) (Geijtenbeek et al., 2000). These interactions enhance 
virus infection in vitro, but they are not essential for virus entry.  
The primary receptor for HIV-1 entry is CD4, which is expressed on T-helper cells, regulatory-T cells, 
macrophages and dendritic cells (Klatzmann et al., 1984, McDougal et al., 1986). Additionally, the 
seven transmembrane G protein-coupled chemokine receptors, CXCR4 and CCR5, are critical co-
factors required for HIV-1 entry (Alkhatib et al., 1996, Deng et al., 1996, Feng et al., 1996). 
Transmitted viruses are usually CCR5 tropic (R5), while CXCR4-tropic variants (X4) tend to arise later 
in infection, although subtype C viruses are rarely CXCR4 tropic (Salazar-Gonzalez et al., 2009). 
Variants that enter the cell independently of CD4 have been reported, as have isolates capable of 
binding to alternative chemokine receptors, in vitro, such as CXCR6 and CCR8 (reviewed in (Clapham 
and McKnight, 2001)). Virus entry is subject to inhibition by NAbs, which are the subject of this 
thesis. Therefore, structural aspects of virus entry will be described in detail in subsequent sections. 
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Figure 1.4 Schematic representation of the HIV-1 life cycle 
a. 
b. 
c. 
d. 
e. 
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Figure 1.4 Schematic representation of the HIV-1 life cycle 
The stages of the HIV-1 replication cycle are shown. The early phase is shaded blue and the late phase is 
shaded red. 
1. The surface subunit of viral Env (gp120) binds to the CD4 host antigen and the CCR5 or CXCR4 
chemokine receptor leading to gp41-mediated fusion of virus and cell membranes. 
2. The virus core is released into the cytoplasm and MA and CA layers disassemble, releasing the 
RNA genome. 
3. Reverse transcriptase synthesizes DNA while RNase H (also part of RT) digests the RNA template. 
a. tRNA primes transcription of –sssDNA from the 5’ PB site 
b. –sssDNA is transported to the 3’ PB sequence of viral RNA 
c. Reverse transcription of the full-length minus strand is primed by –sssDNA, while 
RNAase H degrades the RNA template, sparing the polypurine (PP) tracts. 
d. Plus-strand DNA synthesis is primed from the PP tracts 
e. After removal of all viral RNA and tRNA, the PB sequence of the plus-strand base-pairs 
with the complementary PB sequence of the minus strand, leading to the synthesis of 
full-length duplex viral DNA. 
4. Viral DNA forms the PIC which is transported into the nucleus through nuclear pores. 
5. Viral DNA integrates into the host genome forming the provirus 
6. The initial phase of transcription is initiated by host transcription factors (including NFκB) 
7. Fully-spliced viral mRNA translocates to the cytoplasm, leading to translation of Tat and Rev 
8. Viral Tat is require for transcription of full-length viral RNA, while Rev is required to export 
mRNA to the cytoplasm 
9. Unspliced and partially-spliced viral mRNA is translated to produce Gag, Gag-Pol and gp160 
10. The Gag and Gag-Pol precursors assemble around viral RNA. Trimeric gp160 is cleaved by 
cellular-furin proteases into gp120 and gp41 subunits, which are transported to the plasma 
membrane. The cytoplasmic tail of gp41 associates with the MA domain of Gag. 
11. Immature virus particles bud from the plasma membrane.  
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Upon fusion with the host cell membrane, MA dissociates and the core of the virion is released into the 
cytoplasm (Fassati and Goff, 2001, Zhang et al., 2000). Metastable interactions between CA proteins 
allow the core to uncoat by a simple dilution effect and secondary to the pH of the cytoplasm (Briggs et 
al., 2004) and reviewed in (Lehmann-Che and Saib, 2004). The RNA genome is released into the 
cytoplasm, which leads to the formation of the reverse transcriptase complex (RTC) that consists of viral 
proteins RT, IN, Vpr and p17 and several host factors (Fassati and Goff, 2001). Reverse transcription is 
primed by a molecule of transfer RNA (tRNA, lys3) that binds to the primer binding (PB) sequence at the 
5’ end of the genome (Mak et al., 1994). Initially, a short product known as minus-strand strong-stop 
DNA (-sssDNA) is synthesized by the transcriptase activity of RT, while a second enzyme activity of RT, 
RNase H, digests the RNA template. Subsequently, -sssDNA is released from the 5’-end of the genome 
and is transported to a short repeated sequence (R) at the 3’ end, where it primes reverse transcription 
of the full-length minus strand (Ghosh et al., 1995, Wohrl and Moelling, 1990, Wang et al., 1994, 
Klarmann et al., 1997, Driscoll and Hughes, 2000). Short stretches of purines, called polypurine tracts 
(PPt), escape degradation by RNase H, and serve as primers for the synthesis of plus-strand DNA 
(reviewed in(Telesnitsky and Goff, 1997).  
The final product of reverse transcription is a linear, double-stranded (ds) DNA molecule flanked by 
sequences called long-terminal repeats (LTRs). The dsDNA genome forms the pre-integration complex 
(PIC) by binding to several host and viral proteins, including IN (Farnet and Bushman, 1997, Miller et al., 
1997). The PIC is transported into the nucleus where it interacts with several host proteins including 
lens-epithelium derived growth factor (LEDGF). Chromatin binds to the PIC through interactions with 
LEDGF, which results in the targeted integration of the viral genome, usually into active transcription 
sites of chromosomal DNA (Cherepanov et al., 2003, Maertens et al., 2003). Integration heralds the end 
of the early phase of the virus life cycle.  
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1.6 The late phase of the HIV-1 life cycle 
The integrated form of the virus is known as the provirus. The 5’ LTR contains elements that bind to 
cellular transcription factors that promote RNA-pol II dependant transcription, while the 3’ LTR overlaps 
nef and is responsible for transcription termination. During the early phase of transcription, fully-spliced 
viral RNA transcripts translocate from the nucleus to the cytoplasm for expression of Nef, Rev and Tat. 
An RNA stem loop in the 5’ LTR, known as the trans-acting responsive element (TAR), binds to viral Tat 
protein, which promotes transcription of full-length mRNA (Karn, 1999). Unspliced and partially-spliced 
mRNA transcripts encoding the structural precursors Env, Gag, and Gag-Pol are transported from the 
nucleus by Rev, which binds to another RNA stem loop in env, known as the Rev-response element (RRE) 
(Malim et al., 1990) (Figure 1.4).  
The uncleaved MA domain of Gag binds to phosphatidylinositol-(4,5)-bisphosphate in the plasma 
membrane. This interaction is thought to expose N-terminal myristate moieties of Gag that anchors the 
precursor into the phosphor-lipid membrane, specifically within microdomains known as lipid rafts (Saad 
et al., 2006). Viral RNA is encapsidated by Gag through interactions between zinc-finger domains in NC 
that bind to structurally-conserved RNA stem loops that constitute the psi site (ψ). The process of RNA 
encapsidation serves as a scaffold for CA-mediated multimerization of Gag and Gag-pol around the 
dimeric genome (Muriaux et al., 2001). Virus assembly ends with budding of the virus particle from the 
plasma membrane, which is facilitated by host-derived endosomal sorting machinery including the 
clathirin adapter complex and the endosomal sorting complex required for transport (ESCRT-I), which 
localize to the site of virus assembly through interactions with p6 and MA, respectively (Camus et al., 
2007). 
Gag alone is sufficient to produce virus particles, but the formation of infectious virions requires the 
incorporation of Env glycoproteins. Both gp120 and gp41 are cleaved by the cellular protease, furin, 
from the 160 kDa trimeric-precursor, gp160, which is encoded by HIV-1 env and translated on 
endoplasmic-reticulum-bound polyribosomes (Allan et al., 1985, Hallenberger et al., 1992, Veronese et 
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al., 1985).  Oligosaccharides are attached to gp120 and gp41 by host cellular machinery in the ER and 
Golgi. Specifically, these are linked to asparagine side chains in amino acid sequences NXS or NXT, where 
the second residues can be any amino acid except proline. This sequence is known as a glycosylation 
sequon. In primary CD4+ T cells and macrophages, interactions between the cytoplasmic tail of gp41 and 
the MA domain of Gag are essential for Env incorporation. However, truncation of the gp41 cytoplasmic 
domain has little effect on the infectivity of virions produced in some cell lines (eg. HeLa), suggesting 
that Env may also be incorporated in a non-specific manner. The host factor, TIP47, probably acts as co-
factor for Env incorporation, since this protein has been shown to bind gp41 and MA (Lopez-Verges et 
al., 2006). 
 1.7 Structural features of the HIV-1 Envelope glycoproteins that facilitate virus entry. 
Sequence analyses of diverse HIV-1 strains demonstrate that gp120 is divided into five variable regions 
and five conserved regions (Starcich et al., 1986). Kwong et al. solved the X-ray crystal structure of the 
gp120 core in complex with the two N-terminal domains of CD4, which revealed gp120 has two domains 
linked by a bridging sheet and held together by seven disulphide bridges (Figure 1.5 A). The N-terminus 
of the inner domain interacts with gp41 (Figure 1.5 B), while the outer domain forms the exposed face 
of the envelope trimer (Kwong et al., 1998) (Figure 1.5 C). The gp41 subunit consists of an N-terminal 
hydrophobic fusion peptide (FP), two heptad repeats (N-HR and C-HR), a transmembrane domain and a 
cytoplasmic tail. In solution, peptides consisting of the N-HR and C-HR domains naturally form trimeric 
structures consisting of coiled coils of alpha-helices known as six-helix bundles. Strong associations 
between the ectodomains of gp41 are largely responsible for the trimeric arrangement of Env. (Chan et 
al., 1997, Weissenhorn et al., 1997). The primary HIV-1 receptor, CD4, consists of four immunoglobulin- 
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Figure 1.5 Structure of HIV-1 envelope 
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Figure 1.5 Structure of HIV-1 envelope 
 
 
 
 
 
 
Figure 1.5 A: The atomic-level crystal structure of the gp120 core is shown (2.5 Å). This structure was 
solved by Dr Peter Kwong in 1998 (Kwong et al., 1998). The structure was obtained from crystals of 
gp120, the N-terminal domains of CD4 (D1-D2) and a Fab fragment from neutralizing antibody, 17b. The 
gp120 core has deletions at the N and C termini and at the V1/V2 and V3 loops. The positions of the N-
linked glycans are highlighted with red spheres. The structure was downloaded from the Research 
Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) and PyMol software was used 
to construct ribbon diagrams and highlight domains. Only the gp120 core is shown; the CD4 domains 
and Fab fragment of 17b are hidden. (PDB ID: 1GC1) 
Figure 1.5 B: The crystal structure of the gp120 core bound to CD4 (D1-D2) and the 17b Fab fragment is 
shown superimposed on a 3 dimensional cryo-electron tomogram, solved by Liu et al. (20 Å) (Liu et al., 
2008). The image is available in the cryo-electron microscopy data bank (EMDB ID: 3DNN). 
Figure 1.5 C: The relative positions of each gp120 monomer within an unbound Env trimer are shown. 
The colour scheme is the same as for Figure 1.5A (PDB ID: 3DNN) (Liu et al., 2008). 
Figure 1.5 D: The relative positions of each gp120 monomer within a CD4-bound Env trimer are shown. 
The binding of gp120 to CD4 causes each monomer to rotate by approximately 45°. (PDB ID: 3DNO)  (Liu 
et al., 2008). 
All structures are taken from the RCSB protein and electron microscopy data banks in accordance with 
the terms of use stated on the website (www.pdb.org) (Berman et al., 2000) 
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like extracellular domains with a flexible hinge separating domains three and four (Littman et al., 1988, 
Maddon et al., 1985, Wu et al., 1997)#101}. The amino terminal domain (D1) interacts with the 
conserved CD4-binding site on gp120, which consists of residues that are discontinuous in the primary 
amino acid sequence. Part of the CD4-binding site is recessed into the gp120 core, while other parts are 
more exposed, especially the CD4-binding loop formed from the α-3 helix and the β-15 strand (Figure 
1.5 A) (Kwong et al., 1998, Chen et al., 2005). In its unbound state, the CD4-binding sites are situated on 
top of the trimer and are protected by the V1/V2 loops and N-linked carbohydrate moieties. 
Upon binding to CD4, gp120 undergoes a conformational change in its tertiary structure. Specifically, the 
β-20 and β-21 strands re-orientate to stabilize the bridging sheet and the CD4-binding loop dislocates to 
make contact with CD4 (Huang et al., 2005, Kwong et al., 2000, Kwong et al., 1998). Cyro-electron 
tomography, in conjunction with X-ray crystallography, has shown how CD4 binding affects the 
quaternary and tertiary conformations of Env trimers. Binding to CD4 causes each gp120 monomer to 
rotate by approximately 45 degrees which places the gp41 stalk in close proximity to the target cell 
membrane (Figure 1.5 D). Concomitantly, the V3 loop is repositioned to point directly toward the target 
cell, readying it for chemokine receptor binding (Liu et al., 2008).  
Binding of gp120 to CCR5 or CXCR4 transduces a conformational change in gp41 that causes the FP to 
penetrate the outer leaflet of the target-cell membrane (Liu et al., 2008, Dimitrov et al., 2005). This 
results in the formation of a pre-hairpin intermediate, which connects the virus with the target cell. 
Subsequently, gp41 rearranges to form six-helix bundles that results in the formation of fusion pores 
and the merger of viral and cellular membranes (Markosyan et al., 2003, Melikyan et al., 2000). 
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1.8 Antibody structure and function 
Antibodies are immunglobulins that are the secreted form of the B cell receptor (BCR). All 
immunoglobulins consist of multimeric complexes of two proteins known as the heavy (H) and light (L) 
chains. There are two types of light chain (κ and λ) and five types of heavy chain (μ, δ, γ, α, and ε) that 
define the major antibody isotypes (IgM, IgD, IgG, IgA and IgE, respectively) (Edelman, 1991). The IgG 
isotype has two heavy chains that each consist of an N-terminal variable domain and three constant 
domains with a flexible hinge linking domains two and three. Disulphide bonds attach each heavy chain 
to a light chain consisting of one variable and one constant domain. This configuration produces a 
characteristic Y-shaped antibody molecule. A constant domain consisting of the heavy chains only 
constitute the Fc portion, while the two arms of the ‘Y’ shaped molecule are known as the Fab portions. 
Loops protruding from the variable domains of each Fab portion form the complementary-determining 
regions CDR1, CDR2 and CDR3. In total, six CDRs (three from each heavy and light chain) make up the 
antigen-binding site, or paratope, of each Fab portion (Saphire et al., 2001). The chemical composition 
and electrostatic properties of the paratope determine its specificity for particular epitopes (antigenic 
determinants) (McCoy et al., 1997). Specificity is also a function of “shape complementarity” that 
defines how well epitope and paratope structures fit together (Lawrence and Colman, 1993) and 
reviewed in (Epa V.C. and Colman P.M., 2001). 
1.9 The production and function of antibodies are both linked to the same variables: functional 
affinity and antigen concentration 
Immature B cells express membrane-bound IgM monomers in complex with invariant Igα and Igβ 
proteins that together form the B cell receptor complex (BCR). During early B cell development, gene 
segments encoding the immunoglobulin variable domains (designated V, D and J) undergo somatic 
recombination involving a complex of enzymes that includes proteins encoded by the recombination 
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activating genes RAG1 and RAG2 (Agrawal and Schatz, 1997). Consequently, immature B cells carry 
diverse BCRs that bind differentially to antigens such as HIV-1 Env. Antigen binding cross-links BCR 
complexes and transduces signals through immuno-receptor tyrosine based activation motifs (ITAM) 
located on the cytoplasmic tails of Igα and Igβ proteins, which leads to the differentiation of B cells 
(Cornall et al., 2000). Alternative splicing of mRNA results in modifications to the immunoglobulin heavy 
chain and the synthesis and secretion of soluble IgM, which is the major isotype of primary immune 
responses. Subsequent differentiation to memory B cells and plasma cells involves further modifications 
to the H chain that switches protein expression from IgM to IgG; a process that requires direct contact 
with CD4+ T helper cells (Aruffo et al., 1993).  
Immunoglobulin variable domains are modified further by a process known as affinity maturation, 
whereby activation induced cytidine deaminase (AID) introduces mutations that alter the affinities of 
BCRs. Those B cell clones that express mutated BCRs with high affinity to antigen are selected, while 
BCRs that lose affinity to antigen cease to transduce survival signals, causing the B cell to die by 
apoptosis (Clarke et al., 1985, Petersen-Mahrt et al., 2002). The antigen-dependent stages of B cell 
maturation occurs at sites in the lymphoid tissue known as germinal centres and involves Follicular 
dendritic cells (FDCs) and CD4+ T cells (Schwickert et al., 2007).  Follicular helper T cells (Tfh) that express 
CD4 and the CXCR5 chemokine receptor play a critical role in forming germinal centres by expressing 
cytokines IL-4 and IL-21 (Breitfeld et al., 2000).  Interactions between the BCR and cognate antigen, as 
well as interactions between the CD40 antigen of B cells and the CD40 ligand of CD4+ T cells, are both 
required for antibody isotype switching, affinity maturation and B cell proliferation. If either of these 
interactions is absent the B cell will die by apoptosis. The outcome of affinity maturation is the 
production of antibodies that bind strongly to antigen. 
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The strength of association between immunoglobulins and antigen, HIV-1 Env for example, is defined by 
the intrinsic affinity of monovalent interactions and the avidity of multivalent interactions. The 
interaction between monovalent antibody paratopes (P) and antigen epitopes (E) that forms epitope-
paratope complexes (PE) can be defined by the following equilibrium equation: 
1.                                                                           P + E   PE 
At equilibrium the association rate of P and E equals the dissocation rate of PE such that concentrations 
P, E and PE remain constant. Thus, at equilibrium, concentrations of P, E and PE are related to the 
association equilibrium constant (Ka), by the Law of Mass Action: 
2.                                                                  Ka =  
Equation 2 indicates that the concentration of PE at equilibrium is proportional to the concentration of P 
and E and the affinity of the interaction (reviewed in(George et al., 1997). Importantly, the Law of Mass 
Action governs the interactions between viral antigen and BCRs and also the interaction between 
antibodies and viral antigen. When an immature B cell is exposed to a novel antigen the proportion of 
BCRs that will become cross-linked will depend on the functional affinity (avidity) of the BCR to the 
antigen and the concentration of that antigen. However, in chronic HIV-1 infection, antibody is normally 
present in vast molar excess over viral antigen (Klasse and Moore, 2004), therefore, the proportion of 
viral epitopes bound as equilibrium is approached, approximately depends on the avidity of the 
interaction and the concentration of the antibodies.  
The relationship between intrinsic affinity and avidity is non-additive because of co-operative effects 
involving distinct binding sites. The degree of co-operativity that produces this synergy depends upon 
the relative spatial distributions of the epitopes and paratopes, and also the entropic penalty incurred 
by stabilizing Fab domains and envelope conformations that are otherwise free to move (reviewed in 
[PE] 
[P][E] 
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(Greenspan, 2001)). A case in point: Torsional flexibility afforded by the IgG3 hinge region results in 
higher levels of HIV-1 neutralization than IgG1 molecules bearing the same Fab portions. This was 
originally attributed to increased steric hindrance afforded by the larger Fc portion of IgG3 (Cavacini et 
al., 1995). However, Scharff et al. demonstrated that hinge flexibility was more important. In these 
experiments, polyclonal IgG1 and IgG3 antibodies were digested with papain to produce monovalent 
Fab fragments and with pepsin to generate divalent F(ab’)2 fragments (covalently linked by a disulphide 
bond, but lacking the heavy chain Fc portion). The F(ab’)2 fragments of IgG3 neutralized more efficiently 
than those of IgG1, while Fab fragments derived from both isotypes neutralized similar amounts (Scharf 
et al., 2001).  
1.10 Structural features of Env that limit binding to antibodies and BCRs 
The human immunodeficiency virus has evolved several mechanisms that allow functional Env trimers to 
avoid high affinity interactions with immunologlobulins. Structurally-critical sites in HIV-1 envelope are 
conserved amongst successive generations of the virus quasispecies. However, other sites in Env exhibit 
structural plasticity and accommodate mutations without affecting Env functionality. Genetic diversity 
of HIV-1 is greatest in the envelope gene, which can differ by 20% between viruses from the same clade 
and by up to 35% between viruses from separate clades (Los Alamos HIV-1 sequence database). 
Mutations commonly arise because mechanisms that replicate HIV-1 genetic material are highly prone 
to error (Preston et al., 1988). Additionally, HIV-1 RT can “jump” between strands of the dimeric RNA 
genome, resulting in high rates of recombination (Jetzt et al., 2000). Mutations in Env accumulate over 
the course of infection, particularly in the variable loops. Consequently, antibodies that neutralize virus 
by binding to non-conserved sites rapidly select escape variants (Richman et al., 2003, Wei et al., 2003). 
Several structural features of HIV-1 envelope protect the conserved sites from binding to antibodies. 
I. The gp120 core is shielded by N-linked glycans (Wei et al., 2003). 
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II. Structurally conserved sites are sterically hindered within the gp120 core, while other sites are 
occluded within the Env trimer. (Labrijn et al., 2003) 
III. Conformational epitopes, such as those induced by interactions with CD4, are only transiently 
exposed, which provides a short-kinetic window for antibody binding.  
IV. Antibodies that bind to conformational epitopes incur an entropic penalty which limits the 
strength of antibody binding by conformational masking (Kwong et al., 2002). 
The latter mechanism of antibody escape is determined by the thermodynamics of antibody binding to 
HIV-1 Env. The free energy that corresponds to the binding affinity of an epitope-paratope interaction 
has two components. The first component is enthalpy, which corresponds to the internal energy of 
covalent and non-covalent bonds. The second component is entropy, which acts to disrupt the order 
imposed by these bonds. Antibodies that bind to the receptor binding sites of gp120 must stabilize the 
highly flexible structure and induce unfavourable changes in entropy and compensatory changes in 
enthalpy.  Consequently, affinity-guided selection of antibodies favours epitope-paratope interactions 
that do not incur entropic penalties. This includes epitopes on monomeric gp120 that are not present 
within native envelope trimers and are therefore non-neutralizing (Kwong et al., 2002). 
1.11 Antibodies that circumvent the structural defenses of Env 
In spite of the evolving structural defenses of HIV-1 envelope glycoproteins, most chronically infected 
patients produce antibodies that neutralize virus, in vitro, to some extent (Deeks et al., 2006b). There is 
considerable variation in the neutralizing efficacy of antibody responses between patients, and a 
minority develop antibodies capable of inhibiting a diverse range of virus isolates.  Investigations of 
these patients have occasionally led to the discovery of monoclonal antibodies with potent neutralizing 
activity. Most of these NAbs have unusual structural features that circumvent the structural defences of 
HIV-1 Env. These antibodies can be divided into categories defined by the following epitopes:  
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I. Epitopes overlapping the CD4 binding site (CD4bs). 
II. Conserved motifs within the variable loops. 
III. High-mannose moieties of N-linked carbohydrates. 
IV. CD4 induced (CD4i) epitopes (ie. the co-receptor binding site). 
V. Epitopes in gp41. 
VI. Epitopes that are only exposed on Env trimers. 
Antibodies b12 (Burton et al., 1994), m14 (Zhang et al., 2004b) and VRC01 (Zhou et al., 2010) all target 
the CD4bs. Atomic level structures have revealed that b12 and m14 have unusually long heavy-chain 
CDR3 loops (HCDR3) that are the product of atypical V(D)J recombination events (Saphire et al., 2001). It 
was thought that these protruding loops were required to access a recessed cavity in the CD4bs; 
however, crystal structures of b12 in complex with gp120 core demonstrated that this was not the case. 
Interestingly, only the heavy chain of b12 makes contact with gp120 and the long HCDR3 loop separates 
the envelope from the light chain CDRs (Zhou et al.,2007). Thus, the b12 epitope is restricted to 
conserved residues in and around the CD4bs. It remains to be seen whether this is true for the other 
CD4bs antibodies. 
The co-receptor binding site is highly conserved and is the target of neutralizing antibodies 17b, X5 and 
48d. The binding affinities and the neutralizing activities of these antibodies increase in the presence of 
soluble CD4 (Moulard et al., 2002). Antibodies 17b and X5 also have long HCDR3 loops that include 
acidic residues to mimic the N-terminal gp120-binding domain of CCR5. Additionally, sulphated tyrosines 
in the CDR3 region mimic post-translational modifications of the CCR5 receptor (Huang et al., 2004). Fab 
domains of 17b, X5 and 48d bind and neutralize virus better than whole IgG, suggesting that the Fc 
domains pose steric constraints that limit access to the coreceptor binding site of CD4-bound Env 
(Labrijn et al., 2003).  
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Steric constraints may also limit antibody access to the gp41 domain. Neutralizing antibodies 2F5 and 
4E10 have been shown to bind to the membrane proximal external region (MPER) of gp41 and have long 
hydrophobic HCDR3 domains that bind to lipid moieties in the cell membrane. This autoreactivity is 
essential for neutralizing activity, but non-essential for gp41 binding. Ontogenic analyses of murine B 
cells have revealed that autoreactivity precedes Env-specificity in the development of MPER-specific 
antibodies (Barton Hayes; presented at Keystone 2010, abstract #X5006), suggesting that self-reactivity 
of immunoglobublin BRCs may be important in the development of this type of antibody response. 
Another example of partial autoreactivity has recently been demonstrated for the CD4i antibody 21c.  
Crystal structures demonstrated that this antibody contacts both the CD4 antigen and the CCR5 
coreceptor binding site of gp120 (Diskin et al.,)2010).  
High mannose moieties within carbohydrates are the targets of antibody 2G12 (Scanlan et al., 2002). 
Carbohydrates are attached to the envelope glycoprotein by host cellular machinery and are generally 
not immunogenic. However, 2G12 has a unique structure whereby the two VH domains are interlocked 
producing a single paratope consisting of four variable domains (Calarese et al., 2003). The neutralizing 
activity of this antibody is highly potent, yet attempts to elicit 2G12-like antibodies by vaccination have 
so far proved unsuccessful. 
As mentioned, the majority of antibodies targeting the variable loops rapidly select escape mutants at 
minimal expense to viral fitness. Consequently, the neutralizing activity of these antibodies is generally 
restricted to the autologous virus that primed the original response. However, V3 contains a conserved 
motif at its crown (GPG(R/Q)) which is the target of NAb, 447-52D. Additionally, 447-52D has been 
shown to interact with atoms on the amino acid main-chain of V3, which facilitates binding to diverse 
strains (Stanfield et al., 2004). The majority of clade B isolates have GPGR sequences. By contrast, the 
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majority of clade C isolates have GPGQ motifs at the same position and are generally resistant to 
neutralization by this antibody. 
Two recently discovered antibodies, PG9 and PG16, have been shown to bind preferentially to Env 
trimers and potently neutralize approximately 80% of HIV-1 isolates from all clades (Walker et al., 2009). 
Crystal structures of these antibodies have revealed long CDR3 loops with sulphated tyrosine residues 
(Pancera et al.,)2010). Mutagenesis analyses suggest that PG9 and PG16 bind to epitopes on gp120 
formed from conserved parts of V2, V3, the V1/V2 stem and part of the co-receptor binding site. 
Inducing antibodies that target trimeric envelope is a desirable outcome of HIV-1 vaccination because 
antibodies that bind to monomeric gp120, without binding to oligomeric envelope, are non-neutralizing 
(Moore et al., 1995).  
Passive infusions of neutralizing antibodies have been shown to protect macaques against chimeric SIV 
viruses that express the HIV-1 envelope (SHIV) (Baba et al., 2000, Emini et al., 1992, Mascola et al., 1999, 
Mascola et al., 2003, Mascola et al., 2000, Putkonen et al., 1991, Zhang et al., 2004a). This has placed a 
considerable emphasis on the immunogenic potential of the HIV-1 envelope glycoprotein and its 
capacity to elicit cross-reactive NAbs. It is not the NAbs per se that the field aims to identify, rather the 
cognate epitopes to which they bind. However, the unusual antibody structures and post-translational 
modifications of these antibodies are rarely found in vivo, and attempts to elicit them have so far failed. 
For this reason, the CD4bs specific antibody, VCR01, holds considerable promise because its structure is 
the product of normal V(D)J gene arrangements. Notably, VRC01 has an affinity and neutralizing potency 
that rivals all other HIV-1 specific antibodies, suggesting that induction of potent NAbs by vaccination is 
a realistic possibility. Work is currently underway to use antibodies, such as VCR01, as structural-
scaffolds and selective-agents for the design of relevant immunogens by techniques collectively termed 
reverse-engineering (Kwong et al: presented at HIV Vaccines, Keystone, 2009: X5011)  
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In spite of occasional discoveries of unsually potent NAbs, the majority of HIV-1 infected patients do not 
posses single NAb clones with high levels of neutralizing activity. However, broad and potent 
neutralizing activity can be achieved from many partially-effective antibodies (Scheid et al., 2009). Since 
part of this thesis investigates the role of HIV-1 specific antibody responses that arise under ordinary 
circumstances, the mechanisms that contribute to neutralization in the majority of cases needs further 
discussion. 
1.12 Mechanisms of virus neutralization 
Dimmock makes the distinction between neutralization and virus inactivation (Dimmock, 1984). The 
former involves virus-antibody interactions that lead directly to reductions in infectivity, while the latter 
involves secondary factors such as complement or cells that act in concert with antibodies to eliminate 
virus. Sattentau and Klasse define neutralization as all virus-antibody interactions that result in losses of 
infectivity, but they excluded inhibition by antibodies that bind to receptors on the cell-surface 
(Sattentau and Klasse, 2001). However, this definition is perhaps no longer appropriate since NAb 21c 
has been shown to neutralize by binding gp120 and CD4 simultaneously (Diskin et al.)2010). For the 
purpose of this thesis, neutralization is defined as all antibody-virus interactions that lead to virus 
inhibition. Particular mechanisms cannot be precluded unless they can be empirically confirmed not to 
participate. 
Neutralizing activity has been detected with antibodies that bind to MHC and ICAM-1 receptors 
incorporated within virus particles upon budding from the cell membrane (Arthur et al., 1995, Losier et 
al., 2003). Although ICAM-1 has been implicated in virus attachment, there is no evidence that MHC 
augments virus entry, so why should MHC-specific antibodies neutralize? It is suggested that 
immunoglobulins, which are large molecules approximately 12.5 nm in length, inhibit virus attachment 
through steric hindrance. In a study by Parren et al., half-maximal neutralizing titres of antibodies were 
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shown to match half-maximal binding titres to HIV-1 Env, confirming that functional affinity and 
antibody concentration were critical determinants of neutralization (Parren et al., 1998). This was true 
for all antibodies tested, irrespective of the whether the cognate epitope was a conserved region 
involved in virus entry, such as the receptor binding sites, or a carbohydrate motif. In light of these data 
it has been suggested that sufficient levels of antibody binding to Env is all that is required to inhibit 
infection (Burton et al., 2001). Why then, are some HIV-1 Env-binding antibodies incapable of 
neutralizing?  
An antibody will fail to neutralize if it cannot occupy enough sites on the surface of functional virus 
envelope trimers to prevent virus entry. Thus, neutralization follows a “multi-hit” model, which dictates 
that more than one antibody is required to inhibit entry of a single virion (Della-Porta and Westaway, 
1978). By measuring antibody neutralization of viruses with mixtures of neutralization-sensitive and 
neutralization-resistant envelope glycoproteins, Yang et demonstrated that all trimers need to be bound 
in order to neutralize the virus and that each trimer is inactivated when bound to a single antibody 
(Yang et al., 2005). This was true for nine antibodies with different specificities to epitopes in Env. 
The relationship between epitope occupancy and neutralization is further corroborated by the 
observation that non-neutralizing antibodies that bind to epitopes overlapping the b12 binding site, do 
not interfere with the neutralizing activity of b12 (Herrera et al., 2003). However, the same non-
neutralizing antibodies were shown to have higher binding affinities than b12 for envelope proteins on 
the surface of infected cells, so why do these non-neutralizing antibodies fail to reach the occupancy 
threshold required to neutralize the virus, and why do they not compete with b12 for binding to Env? 
The answer may be that these non-neutralizing antibodies bind to epitopes that are not present on 
functional envelope trimers, but are present on uncleaved gp160 trimers and monomeric gp41/gp120 
envelope proteins. Monomeric, non-functional envelope glycoproteins have been detected on the 
surface of virus particles and infected cells, and it has been suggested that these proteins stimulate the 
production of antibodies that are non-neutralizing (Moore et al., 2006) (Figure 1.6). 
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Figure 1.6 Models of neutralizing and non-neutralizing antibodies  
A. 
B. 
C. 
D. 
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Figure 1.6 Models of neutralizing and non-neutralizing antibodies 
A. Antibodies neutralize HIV-1 by binding to all envelope trimers on the surface of the virus, thus 
blocking attachment to the host-cell receptors. Antibody 2G12 has been shown to bind to high 
mannose carbohydrates. Carbohydrate-specific antibodies are rarely found in vivo. 
B. Antibodies can neutralize virus by binding to epitopes exposed on Env at a post-attachment 
stage of virus entry. 
C. Low affinity antibodies that do not exceed the occupancy threshold required for neutralization 
will not block virus entry. 
D. Antibodies that bind to soluble gp120 or gp41/gp120 monomers on the surface of the virion, but 
not to functional Env trimers, will not neutralize the virus. 
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Antibodies that block the initial adsorption of virus to cells will neutralize. However, this is not the only 
mechanism of neutralization. For instance, antibodies 2F5 and 4E10 do not block HIV-1 attachment, and 
neutralize by blocking later stages of virus fusion (Binley et al., 2003). Additionally, antibodies have been 
shown to alter Env conformation on binding, which can lead to dissociation of gp120 from gp41 
(Poignard et al., 1996), thus lowering the occupancy threshold required for neutralization. There is some 
controversy as to whether an antibody can bind to fusion-competent envelope trimers without 
inhibiting the function of these trimers (Herrera et al., 2003, York et al., 2001). York et al. detected 
binding of non-neutralizing antibodies to envelope glycoproteins from neutralization-resistant primary 
isolates suggesting that different neutralization sensitivities do not relate to levels of antibody binding 
(York et al., 2001). However, this study did not distinguish between antibody interactions with functional 
and non-functional envelopes. The carbohydrate specificity of antibody 2G12 provides additional 
evidence that the precise epitope location may be important in determining levels of neutralization. 
Multiple N-linked glycans contribute to the 2G12 epitope and mutating each of these individually has 
been shown to variably affect levels of neutralization, suggesting that the position of these glycans is 
important in determining whether they mediate neutralization or not (Scanlan et al., 2002). 
Nevertheless, studies have demonstrated that binding-affinity and epitope occupancy, are strong 
determinants of neutralization, in vitro (Yang et al., 2006, Parren et al., 1998). The situation in vivo is 
complicated by the fact that polyclonal responses consist of NAbs with diverse specificities that, 
together, may exceed the occupancy threshold required for neutralization, even if individual low-affinity 
antibody clones cannot, by themselves, neutralize. 
In summary, antibodies will neutralize if they block virus attachment to host cells. Additionally, 
antibodies that bind to Env at post-attachment stages of virus entry can also block virus entry. It is clear 
that antibody affinity and antibody concentration are critical determinants of epitope occupancy, but it 
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is less clear whether these are the only factors that contribute to mechanisms of virus neutralization, in 
vivo. 
1.13 Non-neutralizing roles of antibody in HIV-1 infection 
The constant Fc part of the antibody molecule binds to the Fcγ family of receptors expressed on the 
surface of phagocytes, monocytes, neutrophils, B lymphocytes, natural killer cells (NK), follicular 
dendritic cells (FDCs), and myeloid and plasmacytoid dendritic cells. Antibodies that cross-link virus form 
immune complexes which bind to Fcγ receptors on FDCs. These FDC-bound immune-complexes 
maintain virion infectivity for long periods in vivo and in vitro. Thus, FDCs may cooperate with non-
neutralizing antibodies to enhance virus infection (Smith-Franklin et al., 2002). 
Several classes of Fcγ receptors have been defined. All but one of these have cytoplasmic tails with 
immuno-receptor tyrosine-based activation motifs (ITAM) (Takai, 2002). Interactions between the Fc 
part of neutralizing antibodies and Fcγ receptors has been shown to augment virus-neutralization by 
100 -1000 fold in cultures of monocytes or dendritic cells, possibly by promoting endocytosis and 
degradation of virus in acidic lysosomes (Holl et al., 2006) (Figure 1.7). This mechanism of Fc-dependant 
virus-neutralizing could be important in the acute stages of infection because dendritic cells and 
macrophages are some of the first cells to contact HIV-1 following transmission. Virus particles that are 
endocytosed by antigen-presenting cells (APCs) are processed into peptides then presented to CD4+ T 
cells in complex with MHC class II receptors. This process serves as an important link between humoral 
and cellular immune responses, because CD4+ T cells are required for the development of HIV-1 specific 
NAb responses and CTL responses. Interestingly, antibodies that bind to the CD4bs of gp120 have been 
shown to inhibit MHC class II restricted antigen presentation, possibly by stabilizing gp120 
conformations and inhibiting proteolysis (Tuen et al., 2005).  
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Figure 1.7  Effector functions of antibodies that involve Fcγ receptors and cellular immune responses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: The Fcγ receptors bind to the Fc portion of antibodies.  Fc:Fcγ receptor interactions have 
been shown to enhance neutralization of virus infection of phagocytes such as monocytes and dendritic 
cells, in vitro. HIV-1 Infected CD4+ T cells express viral-envelope glycoproteins. Antibodies that bind to 
Env cross-link Fcγ receptors expressed on NK cells, which stimulates the release of cytoplasmic granule 
toxins (perforin and granzyme) and β-chemokines, leading to mechanism of ADCC and ADCVI, 
respectively.  
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Antibodies that bind to Env expressed on the surface of infected cells cross-link FcγRs expressed on NK 
cells, macrophages, neutrophils and γδ T cells, which leads to targeted cell killing, in vitro. Antibody-
dependant cell-mediated cytoxicity (ADCC) has been shown to correlate with NK cell degranulation 
measured by expression of the CD107a antigen (Chung et al., 2009). Additionally, NK cells may also 
contribute to mechanisms of antibody-dependant cell-mediated virus inhibition (ADCVI), whereby Fcγ 
receptor cross-linking leads to the production of β-chemokines the inhibit HIV-1 replication without 
killing the infected cell (Forthal et al., 2005) (Figure 1.7) 
1.14 Assays of HIV-1 neutralization 
This thesis focuses on neutralizing antibody responses that develop in HIV-1 infected patients. 
Therefore, a suitable neutralization assay was required to measure the neutralizing activity of antibodies 
present in plasma samples derived from patients. Assays that measure neutralization in vitro are tissue 
culture systems consisting of the following components: antibody, target cell, and virus. Additionally, 
each assay requires a suitable end-point measure of virus infection. The choice of neutralizing agent is 
straightforward and depends on the scientific objective. Monoclonal antibodies that bind to known 
epitopes in Env are typically used to characterize neutralization phenotypes of virus isolates. Conversely, 
neutralization assays can be used to characterize the breadth and potency of polyclonal antibodies in 
plasma or sera derived from HIV-infected or vaccinated individuals.  
Differences in target cell phenotype can affect levels of neutralization detected in vitro, as can 
properties of the virus that are unrelated to Env structure. Given the importance of neutralization assays 
to the development of HIV-1 vaccines, standardization and validation is critical if they are to provide 
biologically relevant data. To this end, an international collaboration, named NeutNet, was setup in 
2004 to evaluate different neutralization assays by means of inter-laboratory comparisons using 
standardized reference reagents (Fenyo et al., 2009). The authors concluded the following: 
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“no single assay can be recommended for the measurement of HIV-1 neutralization because the assay 
results vary significantly depending on both the virus and the reagent used” 
Clearly, the choice of neutralization assay is not trivial. The following sections (1.15 and 1.16) discuss 
how the phenotype of the virus and the target cell can influence levels of neutralization detected in 
vitro. 
1.15 Virological factors that affect neutralization in vitro 
Early neutralization assays used viruses that were adapted to grow in immortalized T cell lines (Robert-
Guroff et al., 1985).  Most of these T cell line adapted (TCLA) viruses use the CXCR4 co-receptor. 
Extensive passage of HIV-1 in the absence of NAbs has been shown to select variants that are highly 
sensitive to neutralization. This has been attributed to “open” envelope conformations that expose 
epitopes, particularly in V3, that are usually not exposed on functional-trimeric envelopes of primary 
isolates (Beddows et al., 1998, Moore et al., 1995, Malenbaum et al., 2000). Additionally, TCLA viruses 
are more likely to shed gp120 from functional trimers, thus lowering the site occupancy threshold 
required for neutralization (Poignard et al., 1996). For these reasons, TCLA viruses are poorly 
representative of the majority of field isolates, yet are still used to screen patient sera for low levels of 
neutralizing activity (Seaman et al.,)2010). 
In order to study patient viruses, assays were developed to detect virus neutralization in peripheral 
blood mononuclear cell (PBMC) cultures (Mascola, 1999). By this method, infectious virus is isolated 
from plasma or infected cells by co-culture with mitogen-stimulated PBMCs derived from healthy 
donors. Infection is usually measured from levels of p24 by enzyme-linked immunosorbant assays 
(ELISA). However, levels of p24 in tissue-culture supernatant may not reflect quantities of virus particles, 
because p24-antigen is shed from infected cells. Alternatively, RT activity can be quantified from viral 
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lysates derived from culture supernatants. Unlike p24 antigen, HIV-1 RT activity has been shown to be 
associated with whole-virion production (Fernie et al., 1991).   
Primary isolates are generally less sensitive to neutralization than TCLA strains and are considered to be 
more biologically relevant. However, there are several disadvantages associated with using wild-type 
PBMC-cultured virus. Firstly, the act of culturing virus rapidly selects variants with differing 
neutralization sensitivities (Spira and Ho, 1995, Voronin et al., 2007). Secondly, it is difficult to identify 
genetic correlates of neutralization from diverse molecular quasispecies. Finally, the phenotype of 
PBMCs used to culture the virus may vary between donors and is subject to the conditions of cell 
culture. Since virus phenotype reflects that of the producer-cell membrane, differences in the 
incorporation of host proteins can lead to inconsistencies in virus titre and neutralization sensitivity 
(Hioe et al., 1998, Bounou et al., 2004). These factors limit the reproducibility of neutralization assays 
that use primary HIV-1 isolates, which has led to the development of alternative systems that use 
molecularly cloned viruses expressed in mammalian cell lines. 
Mammalian cell lines transfected with cloned envelope genes, cis-linked to downstream transcription 
promoters, express functional envelope proteins. These proteins are incorporated within virus-like 
particles by co-transfecting a second plasmid, encoding the remaining HIV-1 genes. Transfected 
envelope genes lack LTRs that are required to bind viral integrase (Balakrishnan and Jonsson, 1997). 
Consequently, the envelope gene does not integrate and Env-pseudotyped viruses (pseudoviruses) are 
capable of only a single infectious cycle (Wei et al., 2003). In contrast to the evolving quasispecies of 
primary HIV-1 isolates, clonal envelope plasmids used to construct pseudoviruses are relatively stable. 
For this reason, pseudoviruses constructed with sequenced envelope clones are useful tools for 
mapping epitopes targeted by NAbs (Seaman et al.,)2010).  
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Although pseudoviruses are useful models of wild-type HIV-1, they are structurally distinct in ways that 
can influence virus infectivity and neutralization-susceptibility. Louder et al. demonstrated that a single 
passage of molecularly cloned virus through mitogen-stimulated PBMCs led to a significant reduction in 
sensitivity to NAbs. Interestingly, viruses isolated directly from 293T cells were shown to incorporate 
significantly fewer envelope trimers than PBMC-passaged viruses, which may explain the differences 
observed (Louder et al., 2005). In contrast to these findings, Provine et al. demonstrated that levels of 
Env-incorporation in molecularly cloned virions had minimal impact on the sensitivity to neutralizing 
antibodies (Provine et al., 2009). 
Comparative studies have suggested that pseudovirus assays are generally more sensitive at detecting 
neutralization than assays using replication competent virus, although each type of assay uses different 
cells to measure infection, making it difficult to delineate the true cause for these discrepancies (Fenyo 
et al., 2009, Polonis et al., 2008). To address this problem, Heyndrikx et al. compared the neutralizing 
effects of virus entry inhibitors with Env-pseudotyped viruses and replication competent HIV-1 stocks in 
PBMCs and reported that pseudoviruses were, on the whole, more readily neutralized than wild type 
viruses (Heyndrickx et al., 2008).  
1.16 Target cell factors that affect neutralization in vitro 
Most of the immortalized T cells do not express CCR5 and are limited to investigations of X4-tropic 
variants. In contrast, a wider range of clinical isolates can be assessed using mitogen-stimulated PBMCs 
that more closely resemble the natural targets of HIV-1. The physiological relevance of the PBMC assay 
is demonstrated by its capacity to predict quantities of NAbs that protect macaques from subsequent 
challenge with SHIV (Mascola et al., 2000). Nevertheless, PBMC-based assays are labor intensive and 
require a constant supply of cells from healthy donors. Therefore, reporter-cell lines are required for 
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many applications that require high-throughput neutralization screening or in situations where primary 
HIV-1 isolates are not available.  
The TZM-bl reporter cell line is widely used to assess neutralization of Env-pseudotyped viruses. This cell 
line, also known as JC53BL-13, was derived from a sub-clone of JC-53, which is a CD4+ Hela cell line (HI-J) 
transduced with a retroviral vector encoding CCR5. HeLa cells endogenously express CXCR4, in fact a 
cDNA library derived from HeLa cells was used in the discovery of CXCR4 as a co-factor for HIV-1 entry 
(Feng et al., 1996). Two reporter genes encoding β-galactosidase and luciferase were introduced into JC-
53 cells separately, each under transcriptional control of an HIV-1 LTR (Wei et al., 2002). The LTR 
promoter is transactivated by viral Tat protein, which results in the transcription of both reporter genes, 
thus allowing quantification of virus infection using X-gal or D-luciferin substrates.  
Parent cell lines of TZM-bl were used to determine the contribution of CCR5 cell-surface concentrations 
on rates of HIV-1 entry and neutralization sensitivity. Platt et al. used sub-clones of JC53 that expressed 
different levels of CCR5 to show that co-receptor expression levels are limiting for virus infection (Platt 
et al., 1998a). Subsequently, Reeves et al. showed that high cell-surface concentrations of CCR5 resulted 
in rapid rates of fusion and resistance to the gp41 antagonist, T20 (Reeves et al., 2002). Because T20 
binds to the C-terminal HR domain of gp41 at an intermediary stage of virus entry, it was suggested that 
the surface concentration of CCR5 controlled the time during which the virus was sensitive to 
neutralization (Reeves et al., 2002). In support of this finding, a small molecule antagonist of CCR5, SCH-
351125, has been shown to act synergistically with T-20 by decreasing the availability of the virus co-
receptor, thus slowing rates of fusion and increasing the period that HIV-1 is susceptible to gp41 
antagonism (Tremblay et al., 2002). Chodhury et al. showed that levels of CCR5 expression correlated 
with resistance to monoclonal antibodies that bind to CD4 inducible epitopes (Choudhry et al., 2006). 
Conversely, sensitivity to b12 is not significantly affected by CCR5 surface concentrations. This is 
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unsurprising because b12 blocks attachment to CD4, which occurs prior to CCR5 engagement. From 
these data it is clear that the cell-surface concentration of the co-receptor is a critical determinant of 
virus neutralization for some, but not all, NAbs.  
Expression of CCR5 is approximately 100-fold higher in TZM-bl cells than PBMCs, which may partly 
explain why NAbs such as X5 are more effective in PBMC assays (Choudhry et al., 2006). However, 
disparities in neutralization data obtained with each system are dependent on NAb specificity. For 
example, Binley et al. compared the neutralization phenotypes of 125 primary isolates assayed in PBMCs 
to the corresponding Env-pseudotypes assayed in U87 reporter cells. Overall, discordant neutralization 
sensitivities were observed in 24% of all cases. More neutralizing activity was detected with X5 in the 
PBMC assay, while the opposite was true for antibody 4E10. On the other hand, b12 neutralized similar 
proportions of virus in both systems (Binley et al., 2004). Differences in target cell phenotype may be 
responsible for these inconsistencies, but the authors could not rule out virus-dependant factors 
because different types of virus were used in each assay.  Additionally, it is unlikely that high CCR5 
expression in PBMCs were responsible for the higher levels 4E10 activity because Chodury et al. 
reported that CCR5 expression negatively correlates with 4E10 neutralization (Choudhry et al., 2006). 
Consequently, there are likely to be unknown cellular and viral factors that effect levels of neutralization 
detected in vitro and the results reported by any neutralization assay should be interpreted with 
caution. 
1.17 The natural course of early HIV-1 infection 
The majority of HIV-1 infections are acquired sexually by transmission through the genital tract or rectal 
mucosa. Homogeneity amongst HIV-1 genomes sampled early in infection indicates that most infections 
arise from a single founder virus, while approximately 10-20% of individuals are infected with two to five 
antigenically-distinct virions (Keele et al., 2008). Studies of rhesus macaques intra-vaginally challenged 
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with SIV suggest that productive infection initiates in CD4+ T cells expressing the CCR5 chemokine 
receptor (Li et al., 2009a, Miller et al., 2005). Intraepithelial dendritic cells (DC) and Langerhan cells in 
the lamina propria facilitate dissemination of the transmitted virus to CD4+ T cells by a process known as 
trans-infection (Geijtenbeek et al., 2000). Dendritic cells capture HIV-1 with C-type lectins, such as DC-
SIGN, and deliver virus to CD4+ T cells across a virological synapse (Hubner et al., 2009). It has been 
suggested that direct cell-to-cell transmission of virus may limit the effectiveness NAbs in vivo, however, 
inhibition of trans-infection by NAbs has recently been reported (Martin et al.,)2010). 
Replication of HIV-1 remains localized to the mucosa and draining lymph nodes for approximately 10 
days, a period known as the eclipse phase because viral RNA is not detectable by conventional clinical 
assays (Busch and Satten, 1997, Keele et al., 2008). Limiting numbers of CD4+ T lymphocytes initially 
restricts viral replication, but these foci of infection are subsequently expanded, in part, by chemokine-
secreting plasmacytoid dendritic cells that recruit additional CD4+ T cells to the mucosa. Li et al. 
demonstrate that SIV infection can be prevented by blocking recruitment of CD4+ T lymphocytes to the 
endocervical mucosa with anti-inflammatory agents that inhibits the production of chemokines, such as 
MIP-3α (Li et al., 2009a). These encouraging findings suggest that HIV-1 is vulnerable to elimination 
during the early stages of infection. The challenge to vaccine research is to prime immune responses 
capable of developing into secondary immune responses within the first few weeks of HIV-1 infection. 
Therefore, understanding the factors that control early antibody responses to HIV-1 is of central 
importance to vaccine research and will be the subject of chapter 5. 
At the end the eclipse phase the virus disseminates through the lymphatic system. Dendritic cells and 
macrophages facilitate this process by transporting the virus between the mucosa and lymphoid tissue, 
particularly gut-associated lymphoid tissue (GALT), which is a major source of CD4+CCR5+ T cells and 
bears the brunt of immune destruction during the early stages of infection (Brenchley et al., 2004). 
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Studies of SIV-infected macaques demonstrate that as VL reaches peak levels 30%-60% of all memory 
CD4+ T cells become infected and die by immune-mediated cell killing or viral cytolysis (Mattapallil et al., 
2005). Concomitant with increasing viraemia, a systemic immune response ensues, partly due to 
translocation of commensal bacteria and LPS through compromised GALT tissue in the gut lumen. 
Leukocytes of myeloid and lymphoid lineage respond to high levels of viraemia by producing type I 
interferons (IFN), tumour necrosis factor alpha (TNF-α) and interleukins (IL)-1, IL-15, IL-18 and IL-22 
(Stacey et al., 2009). Although several of these soluble factors have antiviral activity (IFN-α and IFN-β for 
example), this “cytokine storm” enhances viral replication and contributes to CD4+ T cell apoptosis 
(Brule et al., 2007, Lapenta et al., 1999).  
During PHI there is a 50% loss of B cell germinal-centers from the GALT (Levesque et al., 2009). 
Additionally, HIV-1 infected patients have unusually high numbers of B-cell subsets characterized as 
immature cells, exhausted cells and antibody-producing plasmablasts. Most of these features are 
attributed to the high levels of viraemia, either directly through virus-antibody interactions with the 
CD21 complement receptor, or through indirect bystander effects mediated by cytokines and cellular 
interactions. High-level viraemia leads to B cell hyperactivity, hypergammaglobulinaemia, B cell 
proliferation, expression of apoptosis-signaling molecules, and high incidences of B cell malignancies 
(reviewed in (Moir and Fauci, 2009b)) (Titanji et al., 2005, Ho et al., 2006), additionally, low levels of 
memory B cells have been reported at all stages of infection and this is not associated with levels of 
vireamia.  
Peak levels of viraemia, frequently exceeding 106 RNA copies per ml, coincide with the detection of HIV-
1 specific antibodies and an associated seroconversion illness (Fiebig et al., 2003, Little et al., 1999). The 
most common symptoms are fever, myalgia, arthralgia, rash and night sweats (Daar et al., 2001). The 
severity of seroconversion-illness and the extent and duration of vireamia are associated with rates of 
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disease progression (Mellors et al., 1995). In a study of 2176 acutely infected individuals, a small 
proportion (7%) spontaneously controlled VL below 400-500 RNA copies per ml and exhibited slower 
CD4 declines (Madec et al., 2005b).  
In the absence of ART, VL declines to a stable set-point by 12-20 weeks (Rodriguez et al., 2006). Immune 
hyperactivation persists into the chronic phase of disease and this continues to contribute to T cell loss. 
Viral load set-point is minimally predictive of progression to AIDS in chronic infection, whereas markers 
of T cell activation, including CD38 and HLA-DR, have been shown to be strong positive correlates of HIV-
1 disease progression (Rodriguez et al., 2006, Deeks et al., 2004, Giorgi et al., 1999) .  
Mathematical models based on rates of VL decrease following intervention with ART indicate the 
average half life of an infected CD4+ T cell is approximately 0.7 days (Markowitz et al., 2003). Despite 
this, relatively steady CD4 counts and VLs are maintained by rates of cell proliferation that exceed 109 
cells per day and daily viral turnovers exceeded 1010 virions (Ho et al., 1995, Perelson et al., 1996). 
However, continuous high-level replication of HIV-1 leads to a progressive CD4 T cell loss at a rate of 30-
90 cells /mm3 per year (Stein et al., 1992). Eventually, this leads to severe immunosuppression and 
patients become susceptible to AIDS-defining illnesses. The median CD4 count associated with the 
development of an AIDS-defining illness was shown to be 67 cells/mm3, with 10% of patients developing 
an illness with CD4 counts <200 cells/mm3 (Taylor et al., 1995).  
1.18 The role of cellular immune responses in the control of HIV-1 
There is substantial evidence to suggest that CD8+ cytotoxic T cell (CTL) responses contribute to the 
initial decline of VL and to durable control of VL set-points. The initial decline in VL coincides with the 
appearance of HIV-1 specific CTLs (Borrow et al., 1994). Additionally, macaques depleted of CD8+ CTLs 
prior to challenge with SIV sustain high VLs, strongly inferring an important role for this subset in the 
early control of viraemia (Schmitz et al., 1999).  Additionally, a subset of HIV-1 infected patients who 
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control viraemia in the absence of ART have been variably shown to exhibit strong T cell responses. 
Patients with VLs below 2000 copies/ml are termed viraemic controllers (VC) and tend to progress more 
slowly to AIDS.  Approximately 1 in 300 patients maintain levels of viraemia below detectable limits of 
ultrasensitive assays and are known as elite controllers (EC) (Deeks and Walker, 2007). Pereya et al. 
detected higher levels of CD8+ CTLs and CD4+ T helper cells in 124 ECs and VCs compared to 30 subjects 
with progressive disease. Factors associated with T cell mediated viral control included high levels of 
expression of IL-2 and IFN-α, and specificity to MHC-restricted epitopes in Gag (Pereyra et al., 2008a). 
The mechanism by which CTLs control HIV-1 replication was thought to be through direct-cytolysis of 
infected T cell, but this mechanism has recently been questioned by macaque studies that failed to 
identify changes in rates of CD4+ T cell killing following CD8 + cell depletion. Therefore, other 
mechanisms, such as the antiviral effects of cytokines, may be more important (Klatt et al., Wong et al.).  
Genetic-linkage studies have shown that HLA-B57, HLA-B27 and HLA-B51 alleles are associated with 
better prognoses (Carrington and O'Brien, 2003). These genes encode MHC class I molecules involved in 
antigen-presentation to CD8+ CTLs. Individuals that carry these alleles have been shown to develop 
potent CD8+ T cell responses directed at epitopes in HIV Gag, which concurs with the bias for Gag-
specific CTL responses in ECs (Crawford et al., 2007). Population wide analyses of these genetic 
polymorphisms provide convincing evidence for a protective role of CD8+ T cell responses (Fellay et al., 
2007), but on an individual basis they are not always predictive of better clinical outcomes. For example, 
in a HIV transmission pair (ie two patients infected with an antigenically similar virus), rapid disease 
progression was observed in the transmitter, while the recipient controlled VL to undetectable levels, 
despite both patients carrying the HLA-B*57 allele (Bailey et al., 2008). Overall, these findings support a 
protective role for CD8+ T cell reponses in vivo, but suggest that other factors may also be important.   
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1.19 The role of neutralizing antibodies in the control of viral load. 
The role of neutralizing antibodies in the control of VL is unclear. Anti-HIV-1 IgM has been detected 
within 3 days after the onset of symptoms (Cooper et al., 1987). However, standard clinical assays 
generally detect antibodies targeting p24 core antigen within 4 to 10 weeks after transmission. The first 
antibodies targeting Env may be gp41-specific. Tomaras et al. detected gp41-specific IgM within virion-
antibody immune complexes 8 days after VL was first detected. Antibody-dependent complement-
mediated HIV-1 inactivation is observed ex vivo with plasma from acutely infected individuals (Aasa-
Chapman et al., 2005), and there are conflicting reports as to whether this contributes to early viraemia 
control (Huber et al., 2006, Tomaras et al., 2008).  
Mature IgG responses capable of neutralizing autologous virus have been detected within 4 weeks after 
the onset of symptoms. However, most NAb responses are first detected after 12 weeks or more 
following transmission, after the initial decline in VL (Gray et al., 2007, Wei et al., 2003),Aasa-Chapman 
et al., 2004). Therefore, it is unlikely that NAbs control viraemia during the early stage of PHI. However, 
it is less clear whether NAbs contribute to the durable control VL set-point at later stages of infection.  
Passive infusions of b12 exerted minimal control on established HIV-1 infection in a SCID-humanized  
mouse model of HIV-1 infection, although transient suppression of VL was observed in mice 
administered cocktails of b12, 2G12 and 2F5 (Poignard et al., 1999). Neutralization sensitive viruses 
were isolated from b12 treated mice, indicating that neutralizing titres of antibody were ineffective at 
inhibiting the replication of HIV-1 in vivo. However, in these experiments proviruses were isolated from 
cells of spleen and lymph node biopsies, which may not reflect actively replicating virus (Nickle et al., 
2003, Ruff et al., 2002). In fact, the majority of virus isolates were neutralization resistant and escape 
mutants were detected 7 days after b12 transfusion, suggesting that escape occurred rapidly. Rapid 
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selection of NAb-escape mutants does not imply ineffective neutralization; it indicates that 
neutralization-sensitive viruses can be eliminated by neutralizing antibodies.  
In humans, antibody escape mutants have been detected as early as 12 weeks post infection 
(Goonetilleke et al., 2009). Goonetillike et al. identified replacement of wild-type founder sequences 
with viruses carrying envelope mutations at known neutralizing epitopes. Complete loss of founder virus 
sequences implies that NAbs effectively eliminated the quasi-species majority, which confirms that NAbs 
exherts some control on viral replication. However, the authors did not confirm the neutralization-
sensitivities of the wild-type and mutant viruses. Although these mutations were previously shown to 
confer neutralization resistance in other studies, there is no guarantee that these mutations transfer 
similar phenotypes to antigenically-distinct viruses. Nevertheless, if these findings can be confirmed, it 
seems likely that NAbs may inhibit viral replication early in infection. 
Transient selection of neutralization escape mutants does not imply durable control of VL. However, 
several studies conducted in the late 1980’s and 1990’s claimed that NAb responses correlated with 
slower rates of disease progression. Cross-sectional and longitudinal studies showed higher levels of 
neutralization in long-term non-progressors (LTNPs) compared with rapid progressors (Karpas et al., 
1988, Cao et al., 1995, Pilgrim et al., 1997, Scarlatti et al., 1996, Zhang et al., 1997). However, in none of 
the studies was it possible to decipher the clinical impact of NAbs from other confounding factors. 
Cecilia et al. attempted to resolve this issue by studying NAb responses in pairs of LTNPs and rapid 
progressors matched according to age, sex, race, and number of circulating CD4+ lymphocytes (Cecilia et 
al., 1999). Neutralizing responses were shown to be significantly lower in the rapid progressors when 
they had developed AIDS, but prior levels of neutralization were not predictive of these differing rates of 
disease progression. Thus, it was not clear whether low-level neutralizing activity was cause or effect of 
AIDS pathogenesis. Notably, a case study of heterozygotic perinatally-infected twins reported lower 
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levels of NAbs and antibody-dependent cellular cytotoxicity in the child that rapidly progressed to AIDS 
(Hutto et al., 1996). Lambotte et al. also observed higher levels of antibody-dependant cell mediated 
cytotoxicity in ECs compared with normal chronic progressors (Lambotte et al., 2009). Therefore, it is 
possible that non-neutralizing effector functions of antibodies may be important correlates of disease 
control. 
Studies conducted more recently suggest that NAb responses are not associated with better clinical 
outcomes and may positively correlate with VL. In a study by Li et al, fewer elite controllers had broad 
neutralizing activity than viraemic patients (Li et al., 2007). Furthermore, Doria-Rose et al. investigated 
24 ECs, 37 patients with low viraemia and 52 chronic progressors and demonstrated that only 25% of 
the ECs had broad NAb activity compared to 42% in the other two groups (Doria-Rose et al., 2009). 
Mahalanabis et al. reported variable levels of neutralization against autologous viruses derived from 
viraemic controllers, although neutralizing-serum titres varied according to the autologous HIV clone 
used in the neutralization assay. Interestingly, NAb-sensitivity did not vary amongst HIV-clones derived 
from one of two patients with elite control of viraemia, which may indicate that NAb responses 
effectively limited viral diversity in this individual (Mahalanabis et al., 2009b). Bailey et al. also 
demonstrated low levels of Env diversity in ECs and equivalent levels of neutralizing titres to chronic 
disease progressors (Bailey et al., 2006). 
A possible reason for the discrepant results reported by investigation of NAb responses in vivo, relates 
to differences in study design. The early studies grouped patients according to CD4 count, while more 
recent studies have tended to group patients according to VL (Table 1.2A vs. Table 1.2B). Additionally, 
the early studies compared LTNPs, who had been infected for several years, with rapid progressors, who 
had been infected for shorter periods. This is problematic because broad and potent neutralizing  
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Study Year Group*
General NAb 
trend
n
VL RNA 
copies/ml
CD4 count 
cells/mm3
Notable 
exceptions
Neutralization 
Assay
Virus
LTNP Similar 10  <50- 302,000 >500 for >10  years
CP 7 - na
ES Similar 9 <50 -
CP 7 >10,000 -
EC 17 <50 -
VC 17 50-2,000 -
CP 20 >10,000 -
LTNP 24 mean <50 -
SP 37 mean 1,665 -
CP 52 mean 1,8531 -
LTNP 18 <1,000 >500
SP 8 1,000-12,000 -
CP 6 2,500 -250,000 <500
VC 13 <400 -
CP 75 4,000-2,7127 -
VC 8 <2,000 -
CP 19 500-1,000 -
EC 2 <75 -
CP 11 <2,000 -
Study Year Group*
General NAb 
trend
n VL CD4 count
Notable 
exceptions
Neutralization 
Assay
Virus
LTNP 15 70,000 >600 for >7 yrs
CP 18 >1,000,000  200-600
LTNP 10 -  >500
CP 4 - -
LTNP 6 - >600 for >10 yrs
STNP 6 - >600 for 2-7 yrs
CP 5 - 10-371
LTNP 12 -  >600 for >7 yrs
CP 13 -  <20-800
LTNP 14 - >316 for 7 yrs
RP 14 - decline >53 cells per qtr
Aut & Het
Aut & Het
Pseudovirus
Pseudovirus
Pseudovirus
Harrer et al
Bailey et al
Pereya et al
Doria-Rose et al
Li et al
Lambotte et al
Deeks et al
Mahalanabis et al
PBMC & TCLA
GHOST (GFP)
Het
Het
Het
Het
Aut & Het
Aut
Pseudovirus
Pseudovirus
Pseudovirus
TCLA
PBMC
PBMC & TCLA
Het
Het
Aut & Het
Aut & Het
Het
Table 1.1 A: Studies that suggest a positive correlation or no correlation between NAb potency and viral load
Table 1.1 B: Studies that suggest NAb responses are associated with slower rates of disease progression
ECs had Variable 
NAb response
25% ECs had 
broad NAb 
response
ECs had higher 
levels of ADCC
Variable NAb 
responses 
PBMC
Pseudovirus &     
TCLA
1996
2006
2008
2009
2007
2009
2006
1998
2009
Pantaleo et al
Cao et al
Harrer et al
Montefiori et al
Cecilia et al
1995
1995
1996
1996
.2  
2  
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Table 1.2A: Studies that suggest a positive correlation or no correlation between NAb potency and VL 
Two studies reporting similar levels of neutralizing activity between patients grouped according to VL 
are shown along with eight studies reporting lower levels of neutralizing activity in patients with low VLs 
compared to patients with high VLs. The patient groups (Long-term non-progressors (LTNP), elite 
controllers (EC), chronic progressors (CP) and viraemic controllers (VC)) are shown in the third column 
and correspond to the definitions given in each study. For these studies, VLs were used to assign 
patients to each group. Note that the criteria for each group differ between the studies (column 6). The 
assays used by each study are shown in the far right columns. Three studies assayed neutralization with 
autologous (Aut) and heterologous (Het) viruses, while five studies assayed responses with heterologous 
viruses only. 
 
Table 1.2B: Studies that suggest NAb responses are associated with slower rates of disease 
progression 
Five studies are shown that report higher levels of neutralizing activity in LTNPs compared to CPs, short 
term non-progressors (STNPs), and rapid progressors (RPs). These studies grouped patients according to 
their CD4+ T cell counts and durations of infections. GHOST cells are human osteogenic sarcoma (HOS) 
cells that stably express the virus entry receptors along with a green fluorescence protein (GFP) reporter 
gene which is used to detect HIV-1 infection. 
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responses develop in response to sustained levels of viraemia (Sather et al., 2009). This supports the 
view that sustained levels of antigen are required to stimulate B cell responses, as demonstrated by 
observations that antibodies to HIV-1 occasionally become undetectable in patients receiving ART (Hare 
et al., 2006). Therefore, NAbs may accumulate and mature in viraemic LTNPs, while elite controllers may 
lack sufficient levels of viraemia to stimulate antibody production.  
1.20 The impact of ART on the control of HIV-1 infection 
Since HIV-1 was first discovered as the causative agent of AIDS, there has been considerable progress in 
the development of ART. The first drug to be licensed was Zidovudine in 1987, which was shown to 
decrease mortality and the risk of opportunistic infections in a randomized placebo-controlled trial of 
patients with AIDS defining illnesses (Fischl et al., 1987). This drug falls into the class of nucleoside 
reverse transcriptase inhibitors (NRTIs) which are metabolized by cellular kinases to form nucleotide 
analogues that lack 3’ hydroxyl groups required during RT-dependent cDNA synthesis (Horwitz J.P., 
1964). Four additional mechanistic classes of ART have since been licensed for the treatment of HIV-1, 
namely, non-nucleoside RT inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors and viral-
entry inhibitors. Current British guidelines for the treatment of HIV-1 recommend initiation of 
combination ART consisting of dual NRTI with either a PI or NNRTI (Gazzard et al., 2008).  
An editorial published in the New England Journal of Medicine in 1996, entitled “Time to hit HIV, early 
and hard” advocated the early initiation of combination therapy and it was common practice to initiate 
therapy in patients with CD4 counts less than 500 cells/mm3 (Ho, 1995). However, an international 
collaborative study of 62,760 participants demonstrated that although ART reduced the overall risk of 
death by approximately 50%, the survival benefit was only 1% for patients with CD4 counts more than 
500 cells/mm3 (Hogg et al., 2001). Observations of virologic failure and drug resistance are major 
arguments against early therapy, because treatment efficacy needs to be sustained throughout the 
course of the disease. Drug toxicities and complicated dosing regimens lead to poor drug adherence 
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rates, which in turn leads to the development of drug resistant virus (reviewed in (Rowland-Jones and 
de Silva, 2008)). For this reason current UK, US, and WHO guidelines recommend commencing 
treatment when CD4+ counts reach 350 cells/mm3 (Office of AIDS Research Advisory Council ((OARAC), 
December 2009) (Gazzard et al., 2008).  
There is some evidence supporting the use of ART-initiation at thresholds greater than 350 cell/mm3. 
Notably the NA-ACCORD and UK CHIC studies reported lower rates of mortality and morbidity in 
patients who initiated therapy with CD4 counts greater than 350 cell/mm3 (Kitahata et al., 2009, Phillips 
et al., 2007). However, NA-ACCORD was not randomized and was limited by large numbers of patient 
exclusions. Although UK-CHIC analysed larger numbers of patients (17,609), insufficient data was 
collected on causes of morbidity and mortality to ascertain net-benefit to risk ratios associated with 
commencing ART in the presence of high CD4 counts. Randomized trials are therefore needed to 
definitively address the optimal timing for initiating ART with respect to CD4 count. 
1.21 Rationale for administering ART in early infection 
There is now a strong case for early treatment regimes aimed at limiting immune destruction in PHI. 
Firstly, lower levels of VL are associated with less viral diversity, which may limit escape from adaptive 
immunological responses (Altfeld et al., 2001). Secondly, early treatment has been associated with 
restoration of B and T lymphocyte number and function, which has been associated with improved 
antiviral responses (Hoen et al., 2007, Titanji et al., 2005). Thirdly, some preliminary reports show long-
lasting virus suppression and sustained levels of CD4+ T cell counts after termination of early therapy; 
ultimately, this may prolong the duration of symptom-free disease and reduce the demand for ART in 
the long-term (Steingrover et al., Hecht et al., 2006). Finally, lower VLs in primary infection are 
associated with reduced rates of transmission (Wawer et al., 2005, Attia et al., 2009) 
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Early initiation of ART has been shown to lead to a more robust immunological recovery following PHI. A 
study by Streeck et al. monitored HIV-1 specific CD8+ T cell responses in 20 acutely infected individuals 
by IFN-γ enzyme-linked immunospot assay (ELISpot) and flow cytometry. The 12 patients who opted to 
initiate early ART for 24 weeks had HIV-specific CD8+ T cells that showed enhanced differentiation from 
an effector memory to an IFN-γ+ phenotype. Six months after treatment ended, patients had higher 
levels of CD8+ T cell activation and preserved CD4+ T cell numbers compared to untreated patients, 
despite similar levels of VL to treatment naïve patients (Streeck et al., 2008). This suggests that short 
courses of ART in PHI may have long-term benefits. Early initiation of ART may also result in the 
restoration of HIV-specific CD4+ T helper cell responses, which has been associated with transient 
control of viraemia following treatment interruption (Malhotra et al., 2000, Ferrantelli et al., 2004). 
Studies have shown that ART administered in acute infection can preserve B cell function. Morris et al. 
demonstrated that B cell hyperactivity and hypergammaglobulinaemia resolve in response to ART 
administered during acute and chronic stages of infection (Morris et al., 1998). Additionally, early 
initiation of ART has been associated with reduced rates of B cell apoptosis, and partial restoration of 
memory B cell pools (Titanji et al., 2005). Preservation of B cell responses was recently reported 
following early initiation of ART in HIV-1 infected infants (Pensieroso et al., 2009). However, B cell 
memory cells were not restored by ART in chronic infection, suggesting that early intervention may be 
required to prevent permanent B cell depletion (Hart et al., 2007). Limiting B cell and CD4+ T cell 
dysfunction with short courses of ART in PHI could potentiate NAb responses, which may contribute to 
the control of viraemia after treatment cessation.  
Although several studies have demonstrated clinical benefits following early-ART intervention, it is 
unclear whether these protective effects are limited to the duration of therapy. Currently, decisions 
regarding early treatment are not evidence based and are left to the discretions of the clinician and 
patient. In order to determine the long-term impact of early treatment more data are needed from 
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suitably-powered randomized-controlled trials, such as the Short Pulse Antiretroviral Therapy at 
seroConversion (SPARTAC) study. This trial is ongoing and has recruited 366 eligible participants from 
genitourinary medicine clinics in the UK, Australia, Italy, Uganda, South Africa, Spain and Brazil. Upon 
confirmation of PHI, each patient is randomized to receive either 12 weeks or 48 weeks ART, or no 
therapy. The primary outcome measure is the time taken for CD4 counts to decrease below 350 cells 
per/mm3 on two consecutive occasions, assessed one month apart. All patients are to be followed until 
130 primary end-point events are detected. The primary objective of SPARTAC is to determine whether 
administering ART for a limited period during PHI can slow rates of CD4+ T cell loss after treatment ends 
(Babiker and Gibb, 2006). The decision to treat patients for a minimum period of three months was 
informed by a pilot study of 90 patients (Fidler et al., 2002) that showed this intervention was well 
tolerated and did not induce ART resistance. The 48 week treatment arm was included to assess 
whether longer treatment regimes improved the clinical outcome further, although SPARTAC is not 
specifically-powered to detect a difference between the 12 and 48 week trial arms.  
Clinical specimens are collected from patients enrolled into SPARTAC at 4 to 12 week intervals and used 
to assess the impact of early ART on humoral and cellular immune responses. Work in our own lab has 
focused on neutralizing responses that develop after patients discontinue therapy. Because 
investigators are blinded to the treatment arm of the patient, it is currently not possible to compare 
patients who received early ART with those who did not. However, neutralizing responses can be 
assessed in individuals randomized into the two ART treatment arms.  
1.22 Outline of this thesis 
The SPARTAC study provided a useful platform with which to study changes in neutralizing antibody 
activity that develop after patients discontinue ART. We hypothesized that rebounding VLs stimulate the 
production of neutralizing antibodies after ART cessation, resulting in an association between quantities 
of circulating virus and subsequent levels of neutralizing activity. Furthermore, NAb reponses were 
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predicted to inhibit the replication of neutralization-sensitive quasispecies and select NAb-resistant 
virus. In order to determine whether antibody selection contributed to the control of viral load, 
sequencing analysis of HIV-1 env was undertaken in one patient with a clinical history that was 
suggestive of antibody-mediated control of VL. The patient, who was enrolled into the SPARTAC pilot 
study, was diagnosed with a lymphoplasmacytic B cell lymphoma. He had also been diagnosed with an 
acute hepatitis B virus (HBV) infection two years prior to HIV-1 seroconversion. Following a three-month 
course of early ART the patient developed a VL set point of 105 RNA copies per ml. Three years later the 
patient became unwell and his lymphoma required treatment with a monoclonal antibody (rituximab) 
that targets and depletes CD20+ B cells. Surprisingly, this led to a transient 1.7 log10 increase in HIV-1 VL. 
The patients HBV infection also reactivated following rituximab therapy. The clinical details of this case 
led us to hypothesize that NAbs were important in controlling the patient’s HIV-1 VL. In order to 
investigate this possibility, several techniques were employed to characterize the patient’s virus and 
NAb response before and after B cell depletion. The results of this unique case study will be presented in 
chapter 4.  
This thesis examines three aspects of HIV-1 antibody research. Firstly, the development and validation 
of an HIV Env-pseudotype neutralization assay will be reported, along with novel techniques that 
improve the sensitivity and specificity of this type of assay. Secondly, we examine the role of NAbs in 
natural infection. We report the only documented case of B-cell depletion in an HIV-1 infected human 
and present compelling evidence that NAbs contributed to HIV-1 control in this individual. The relevance 
of this case to the wider field will be discussed. The final chapter examines how levels of viraemia during 
the early stages of HIV-1 infection control the development of neutralizing antibody responses. This 
investigation focuses on patients enrolled into the SPARTAC trial who received early, short-courses of 
ART. This allowed us to examine the temporal association between developing NAb responses and VL 
rebound after ART-cessation.  
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Materials and Methods 
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2.1 Mammalian cell lines and tissue culture maintenance 
The human epithelial kidney cell line 293T clone 17 (293T/17) is a derivative of the 293tsA1609neo cell, 
which constitutively expresses the simian virus 40 (SV40) large T-antigen (DuBridge et al., 1987). Clone 
17 has been specifically selected for its high transfectability and its capacity to produce high titres of 
infectious retrovirus (American Type Culture Collection (ATCC), CRL-11286). The indicator cell line, TZM-
bl was used to quantify infectious pseudovirus particles (described in section 1.16) (National institute for 
health (NIH) AIDS Research and Reference Reagent Program) (Wei et al., 2002). Both cell lines were 
cultured in complete Dulbecco’s modified eagle’s medium (complete DMEM), containing 4.5 g/l glucose, 
L-glutamine, 10 % (v/v) fetal-calf serum (FCS) (heat inactivated at 56°C for 1 hour), 100 U/ml penicillin G 
and 100 μg/ml streptomycin (Invitrogen Life Technologies, UK). 
Cells were passaged when 80-90% confluent. Adherent-cell monolayers were washed once with Trypsin-
ethylenediaminetetraacetic acid (Trypsin-EDTA) (Invitrogen) and incubated with Trypsin-EDTA at 37°C 
for 2-5 min. Cells were resuspended in 10 ml of complete-DMEM and centrifuged at 400 g for 5 min. Cell 
pellets was resuspended in complete-DMEM and one twentieth of the volume was transferred to a 
tissue culture flask in 5-6.25 ml of complete DMEM per cm2 of the flasks surface area.  
2.2 DNA vectors used for cloning, sequencing and pseudovirus construction 
Plasmid pcDNA3.1(+) and phagemids KS Bluescript II and SK Bluescript II (Stratagene) were used to clone 
HIV-1 envelope genes (Figure 2.1). Expression vector pMD-G encodes vesicular stomatitis virus G-protein 
(VSV-G) from a CMV promoter (Naldini et al., 1996). Expression vector pHXB2-env contains the HIV-1 
envelope gene expressed from an SV40 promoter.  The HIV-1 backbone pNL4-3∆env is derived from a 
full-length HIV-1 chimera (pNL4-3) consisting of the 3’ half of HIVLAV and the 5’ half of HIVNY5. The blunt-
ended proviral DNA genome was cloned into the multiple cloning site (MCS) of pUC18 (Adachi et al., 
1986). The LAV envelope gene was made defective by mutating at the start codon and at a unique KpnI 
restriction site (Dorfman et al., 2002) (Figure 2.2). 
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Figure 2.1 DNA vectors used for HIV-1 envelope cloning 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 A: PCR amplified HIV-I env was cloned in plasmid pcDNA3.1 using 5’XhoI-3’ApaI or 5’NotI-
3’ApaI restriction sites downstream of the CMV promoter (P CMV) and upstream of the bovine growth 
hormone polyadenylation sequence (BGH). The neomycin resistance gene (neomycin) is expressed with 
an SV40 early promoter and origin (SV40 ori) and SV40 polyadenylation sequence (SV40 pA) (neomycin 
selection was not used). The pUC origin of replication (pUC ori) initiates plasmid replication in E.coli. The 
F1 origin (F1 ori) initiates plasmid replication in phage and was not used. Figure 2.1B: Envelope genes 
from pcDNA.env were subcloned into phagemids KS pBluescript II and SK pBluescript II. Both phagemids 
are identical except for oppositely orientated MCS which intersperse a lacZ gene and lac promoter. The 
pMB1 origin of replication (pMB1ori) replicates plasmids in E.coli. The ampicillin resistance gene (Amp R) 
confers antibiotic resistance. 
A 
B 
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Figure 2.2 DNA vectors used for pseudovirus construction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 A: The full-length HIV-I backbone, NL4-3Δenv, is a chimera of the HIV-1 strains, HIVNY5 and 
HIVLAV. The native 5’ LTR of HIVNY5 serves as a promoter for transcription. The HIVLAV env gene is non-
functional owing to frame-shift mutations at the start codon and at a unique KpnI restriction site (red 
crosses).  
Figure 2.2 B: pHXB2-env encodes full length HIVHXB2
 envelope under transcriptional control of an SV40 
promoter (SV40 pr).  
Figure 2.2 C:  Plasmid pMD-G consists of a vsv-g gene flanked by a 5’ intervening sequence 2 (IVS2) and 
polyadenylation sequence from a human β-globin gene. The vsv-g gene is transcribed from a CMV-
immediate-early promoter (CMV). Plasmids pNL4-3Δenv, pHXB2-env and pMD-G encode an ampicillin 
resistance gene for antibiotic selection in E.coli. 
A 
B C 
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Dr Massimo Pizzato kindly provided pHXB2-env, pMDG and pNL4-3∆env. Plasmids encoding HIV-1 clade 
B and clade C reference envelopes were obtained from the NIH AIDS Research and Reference Reagent 
Program (Li et al., 2005, Bailey et al., 2006). 
2.3 Antibodies, plasma and recombinant proteins. 
Pooled plasma derived from HIV-uninfected donors was obtained from Autogen Bioclear. Neutralizing 
monoclonal antibodies 447-52D and 2G12 were obtained from the National Institute for Biological 
Standards and Control (NIBSC, Potters Bar, UK). Antibodies b12 and 4.8d were gifts from Professor 
Dennis Burton (Scripps Research Institute, La Jolla, US). The CD4 peptide mimic, M33, is a 27 amino-acid 
peptide mimicking the gp120 binding site of CD4 and was provided by Professor Quentin Sattentau 
(William Dunn School of Pathology, Oxford University, UK) (Martin et al., 2003). Recombinant gp120 
derived from clade B HIV-I strain BaL, expressed in Chinese hamster ovary (CHO-K1) cells, was provided 
by Dr Simon Jeffs (Jefferiss Trust Laboratories, Imperial College, UK). 
2.4 Clinical assays of HIV-1 viral load 
The PCR-based Amplicor HIV-1 Monitor v1.5 Assay (Roche) quantifies HIV-I RNA from plasma samples 
mixed with known concentrations of a synthetic protein-coated RNA construct which serves as an 
internal quantitation standard (QS). The RNA is RT-PCR amplified using gag specific primers and Thermus 
thermophilus DNA polymerase (rTth pol), which has RT and DNA polymerase activity. Biotin labeled 
oligonucleotide probes are hybridized to amplified DNA products to allow quantification of the QS and 
viral RNA with avidin-horseradish peroxidase (HRP) conjugates. The amount of bound amplicon is 
determined using an ELISA plate reader after the addition of an HRP-specific colorimetric substrate.  
 The Chiron v3.0 or Versant branched DNA (bDNA) HIV-RNA v3.0 assay (Bayer, NY, US) uses bDNA 
nucleic acid hydribization to quantify VL without amplifying the RNA target.  Oligonucleotides are used 
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to capture viral RNA to the base of a microtitre well, while a second set of oligonucleotides amplifies a 
chemiluminescent signal. 
2.5 Clinical assays for the quantification of antibodies. 
Quantification of total IgG, IgM and IgA was performed using an automated immunonephelometric 
Beckman Immage system (Beckman-Coulter Diagnostics, USA). The technique measures the light-
scattering properties of antibody/latex-particle immune complexes (Denham et al., 2007). Anti-hepatitis 
B surface antigen (HBsAb) was quantified by ELISA using the Axsym Abbott system (Abbott Diagnostics, 
Wiesbaden, Germany). Both assays are validated for diagnostic purposes and were performed at the 
Clinical Biochemistry Laboratory at St Mary’s Hospital, Paddington. 
2.6 Extraction of viral RNA from human plasma for RT-PCR amplification env 
Viral RNA was extracted from cryo-preserved, EDTA or acid-citrate-dextrose (ACD) plasma, for RT-PCR 
amplification of HIV-1 env. Where stated, virus was concentrated from 3 ml of plasma mixed with 9 ml 
of phosphate buffer saline (PBS) (Sigma Aldrich), by ultracentrifugation at 60,000 g for 2 hr at 4°C 
(Sorvall Combi AH-629 rotor). Supernatants were decanted and viral pellets were resuspended in 140 μl 
of PBS. Concentrated virus, or 140 μl of unconcentrated plasma were processed using a QIAamp viral 
RNA extraction kit (QIAGEN, UK). Virus was lysed with 540 μl of buffer AVL (supplied) containing 10 
ng/μl poly-A carrier RNA. After 10 min incubation at room temperature (18-22°C), samples were diluted 
twofold with ethanol, vortexed for 15 sec and passed through a silca-resin centrifuge column at 16,000 g 
for 1 min. Adsorbed RNA was washed with 500 μl each of buffers AW1 and AW2 (supplied) by successive 
centrifugations at 16,000 g for 1 min. The column was dried by a further 2 min centrifugation at 16,000 g 
and viral RNA was eluted with 30-60 μl of buffer AVE (supplied).  
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2.7 Reverse transcription of viral RNA 
Viral RNA was reverse transcribed to cDNA using the nef-specific primer, EnvN (Table 2.1). First, 10-30 μl 
of viral RNA was annealed to 2 pmol of EnvN and 10 nmol of each of the deoxyribonucleotide 
triphosphates (dNTPs) (deoxyribo-adenosine triphosphate (dATP), deoxyribo-thymidine triphosphate 
(dTTP), deoxyribo-cytidine triphosphate (dCTP), and deoxyribo-guanosine triphosphate (dGTP)), by 
heating to 65°C for 5 min in a GeneAmp PCR System 9700 thermocycler, then incubating on ice for 1 
min. Two-hundred units (U) of recombinant Moloney murine leukemia virus RT (Superscript III, 
Invitrogen) was added to each reaction in the manufacturers supplied buffer to yield final 
concentrations of 5 mM 1,4-dithiothreitol, 50 mM Tris-HCl (pH 8.3), 75 mM potassium chloride (KCL), 3 
mM magnesium chloride (MgCl2), 500 μM dNTP and 100 nM EnvN. Reverse transcription was performed 
at 25°C for 15 min, then at 55°C for 2 hr. The reaction was terminated by denaturing Superscript III RT at 
70°C for 15 mins. 
2.8 PCR amplification of full-length HIV-1 envelope for construction of expression plasmids. 
Full length HIV-I env was amplified from cDNA by nested-PCR with Easy-A high fidelity PCR cloning 
enzyme (Stratagene, UK). This enzyme is a fusion of 5 U/μl Thermus aquaticus (Taq) DNA polymerase (5 
U/μl), 4 U/μl recombinant Pyrococcus furiousus (Pfu) DNA polymerase, and 40 ng/μl recombinant Pfu 
polymerase enhancing factor (P45). Viral cDNA was added to the supplied enzyme-reaction buffer 
supplemented with 200 μM dNTPs, 100 nM outer-sense primer EnvA, and 100 nM outer-antisense 
primer, EnvN, made-up to a final volume of 50 μl with nuclease-free water (Sigma). First-round products 
were amplified using a thermo-cycler programmed as follows: 2 min denaturation at 95°C followed by 
10 cycles consisting of denaturation (95°C for 40 s), annealing (50°C for 30 s) and extension (72°C for 3 
min 30 s) followed by a further 25 cycles of denaturation (95°C for 40 s), annealing (55°C for 30 s) and 
extension (72°C for 3 min 30 s). Thermo-cycling was followed by a final incubation at 72°C for 5 min. One 
microlitre of each reaction was used as the template for second-round amplifications with 100 nM inner 
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Table 2.1 Primers used for PCR amplification, sequencing, mutagenesis and quantitative-RT PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1 The oligonucleotides shown in this table were used for RT-PCR amplification of HIV-1 env 
(section 2.7-2.8), mutagenesis of Rit.336d.c3 env (section 2.24), sequencing (section 2.27), and the SYBR-
Green II product enhanced reverse transcriptase assay (SG-PERT) described in section 2.25. Primers 
designed by the candidate are indicated. Equal amounts of primers EnvF2 and EnvF3 were mixed prior 
to use in PCR amplifications of full length HIV-1 env, as were primers EnvR2 and EnvR3 (*). Restriction 
sites used for cloning and mutagenesis are underlined. Primers indicated by the following references 
have been described in previous studies: 1 (Derdeyn et al., 2004), 2 (Oelrichs et al., 2000), 3 
(Voulgaropoulou et al., 1999) and 4 (Silver et al., 1993). All primers were synthesized by Eurogentec, UK. 
Application Primer Orientation Sequence (5'→3')
HXB2 
numbering
Restriction 
site
Ref
Reverse 
transcription     
HIV-1 env
EnvN anti-sense CTG TCA ATC AGG GAA GTA GCC TTG TGT 5954←5982 1
EnvA outer sense GGC TTA GGC ATC TCC TAT GGC AGG AAG AA 9145→9171 1
EnvN outer anti-sense CTG TCA ATC AGG GAA GTA GCC TTG TGT 5954←5982 1
EnvF2 inner sense* GGG CTC GAG GCG GCC GCG AGC AGA AGA CAG TGG CAA TG 6207→6227 XhoI-NotI this study
EnvF3 inner sense* GGG CTC GAG GCG GCC GCG AGC AGA AGA CAG TGG CAA TGA 6207→6228 XhoI-NotI this study
EnvR2 inner anti-sense* AAA TCT AGA GGG CCC CCA CTT GCC ACC CAT RTT A 8793←8811 XbaI-ApaI this study
EnvR3 inner anti-sense* AAA TCT AGA GGG CCC CCA CTT GCC ACC CAT RTT ATA GC 8789←8811 XbaI-ApaI this study
Env10F outer sense CTA TGG CAG GAA GAA GCG GAG AC 5968→5990 2
Env13R outer anti-sense CTA TCT GTC CCC TCA GCT ACT GC 8707←8685 2
Env11F inner sense GCA TGA GGA TAT AAT CAG TTT ATG GG 6536→6561 2
Env12R inner anti-sense CAA ATG AG TTT TCC AGA GCA ACC C 8035←8012 2
JAE1 sense CACAGTACAATGTACACATG 6953→6972 3
JAE4 anti-sense ACAATTTCTGGGTCCCCTCC 7320←7339 3
R339E/F sense ATT GTA ACA TTT CTA GAG TAG AAT GGG AAG ACA CCT TAA 7213→7251 XbaI this study
R339E/R anti-sense TTA AGG TGT CTT CCC ATT CTA CTC TAG AAA TGT TAC AAT 7213←7251 XbaI this study
R339N/F sense ATT GTA ACA TTT CTC GAG TAG AAT GGA ATG ACA CCT TAA 7213→7251 XhoI this study
R339N/R anti-sense TTA AGG TGT CAT TCC ATT CTA CTC GAG AAA TGT TAC AAT 7213←7251 XhoI this study
Q363R/F sense TAA AAC AAT AAT CTT TAA TCG ATC CTC AGG A 7292→7322 ClaI this study
Q363R/R anti-sense TCC TGA GGA TCG ATT AAA GAT TAT TGT TTT A 7292←7322 ClaI this study
ENV12F sense AGG AGG GGA CCC AGA AAT TG 7319→7338 1
ENV11R anti-sense TGG GAG GGG CAT ACA TTG C 7521←7539 1
Env11F sense GCA TGA GGA TAT AAT CAG TTT ATG GG 6536→6561 1
Env12R anti-sense CAA ATG AGT TTT CCA GAG CAA CCC 8035←8012 1
BMV129 sense GGT CTC TTT TAG AGA TTT ACA GTG 4
BMV131 anti-sense CGT GGT TGA CAC GCA GAC CTC TTA C 4
BMVF1 sense TTG TCG GCT TTA CCT GCT TT this study
BMVR1 anti-sense TAG TTG TTG GGC TTC GCT TT this study
Mutagenesis                       
HIV-1 env
SG-PERT                                 
BMV
Sequencing                      
HIV-1 env
PCR amplification         
HIV-1 env
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sense primer, EnvF2/F3, and 100 nM inner-antisense primer, EnvR2/R3 (Table 2.1), using the same 
buffer conditions as the first-round reaction. The inner primers contained degenerate nucleotide bases 
to account for common variations in the primer binding sites identified in the Los Alamos sequence 
database. Thermo-cycling conditions were the same as for the first-round amplification, except for a 
shorter extension time of 2 min 45 sec. Five microlitres of each second-round PCR product were mixed 
with 1 μl of DNA loading dye (Promega) and analysed by electrophoresis through 1% agarose gel (1% 
(w/v) agarose, Tris-acetate-EDTA (TAE) electrophoresis buffer (40mM Tris acetate, 1 mM EDTA) and 0.5 
μg/ml ethidium bromide). After 40 min electrophoresis at 120 Volts, separated DNA was visualized 
under ultraviolet (UV) light with a transilluminator (Gel-Doc). 
2.9 Purification of PCR amplified DNA 
Amplified envelope genes were purified using Genejet spin columns (Fermentas) using the buffers 
supplied by the manufacturer. Each PCR product was mixed with 2 volumes of binding buffer, which 
contains the chaotropic salt, guanidine thiocyante, to precipitate proteins and to provide the high-salt 
conditions necessary to adsorb DNA to the silica-resin of the Genejet spin column. The DNA solution was 
passed through the column by centrifugation and the absorbed DNA was washed twice with an ethanol-
based wash solution and dried by centrifugation at 16,000 g for 1 min. Purified DNA was eluted under 
low salt conditions with 2 x 40 μl volumes of Tris EDTA (TE) buffer (10 mM Tris, pH 8.0, 1 mM EDTA).   
2.10 DNA digestion 
2.10.1 DNA digestion for plasmid construction 
Purified env PCR product or 5 μg of plasmid DNA was digested with 40-80 U of restriction enzyme in the 
supplied reaction buffer made up to a 100 μl with MilliQ purified water. Typically, PCR amplified env 
DNA was digested with 40 U each of ApaI and XhoI restriction enzymes at 37°C for 6 hr.  
79 
 
2.10.2 Analytical restriction digest 
For restriction analysis of plasmid DNA, 500 ng of plasmid was incubated with 20 U of restriction enzyme 
in the supplied reaction buffer, made up to 20 μl with Milli-Q purified water. Reactions were incubated 
at 37°C for 1 h. Digested DNA products (10 μl) were analysed by electrophoresis through 1% (w/v) 
agarose gel. 
2.11 Gel Extraction  
Products of DNA digestion intended for cloning were separated by electrophoresis through 0.8% (w/v) 
agarose gel. A GeneJet gel extraction kit (Fermentas) was used to purify separated DNA from agarose-
gel slices. Each gel piece was mixed with equal weights of binding buffer and incubated at 50 °C until the 
agarose had dissolved. Solubilised agarose solution was passed through a GeneJet purification column 
by centrifugation at 16,000 g for 1 min. The absorbed DNA was washed once with binding buffer and 
twice with an ethanol-based wash solution. Columns were dried by centrifugation and DNA was eluted 
with 2 x 50 μl volumes of TE buffer.  
Eluted DNA was concentrated by ethanol precipitation prior to ligation or nucleotide sequencing. DNA 
samples destined for ligation were mixed with 2.5 M ammonium acetate, while samples prepared for 
sequencing were mixed with 300 mM sodium acetate. Salt-adjusted DNA samples were mixed with two 
volumes of ice-cold ethanol and incubated on ice for 1 hr. Precipitated DNA was centrifuged at 16,000 g 
for 1 hr at 4 °C. Supernatants were discarded and DNA pellets were washed with 70% ethanol by 
centrifugation at 16,000 g for a further 20 min. Decanted supernatants were discarded and the DNA 
pellets were left to dry before each was dissolved in 15 μl of nuclease-free water (Sigma Aldrich). A 
microvolume spectrophotometer (NanoDrop ND-1000, Thermofisher scientific) was used to assess 
nucleotide purity and measure DNA concentration. 
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2.12 DNA ligation 
Restriction-digested env amplicons and pcDNA3.1 were ligated with T4 ligase (NEB), which catalyses the 
formation of phosphodiester bonds between juxtaposed 5’ and 3’ hydroxyl termini of cohesive or blunt 
ended DNA. Purified, restriction-digested insert and vector were combined at a molar ratio of 1:6, 
yielding a final molar concentration of 100 nM in a reaction buffer composed of 50 mM Tris-HCl (pH7.5), 
10 mM MgCl2, 1mM ATP, 10 mM dithiothreitol (DTT), and 2,000 units of T4 ligase. The final reaction 
volume was made up to 15 μl with nuclease-free water. Ligation reactions were incubated overnight at 
16°C. 
2.13 Production of competent bacteria 
 
Strains of Escherichia coli (E.coli) DH5-α, XL1-blue and MACH1 (Stratagene) were made chemically-
competent for transformation with plasmid DNA using the Inoue method (Inoue et al., 1990).  Briefly, 
non-competent bacteria were streaked onto Petri dishes containing LB-agar (1.5% (w/v) agar dissolved 
in lysogeny broth (LB) (10 g/l Bacto-tryptone, 5 g/l yeast extract, 171 mM sodium chloride (NaCl), pH 
7.4)). Plates were inverted and left to grow overnight at 37°C. A single colony was used to inoculate 25 
ml of super-optimal broth (SOB) (2% Bacto-tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCL, 10 
mM MgCl2 and 10 mM magnesium sulphate (MgSO4)), which was incubated at 37°C in an orbital shaker. 
After 6 hours, 4 ml of cultured bacteria was transferred to an Erlenmeyer flask containing 250 ml of 
super-optimal broth (SOB) and this was incubated for a further 8-16 hr in an orbital shaker at 18°C. 
Bacterial growth was monitored by spectrophotometry and when light absorbance at wavelength of 
λ=600nm (A600) reached 0.5 – 0.8, the flask was transferred to an ice-water bath. Chilled bacteria were 
harvested by centrifugation at 2500 g and resuspended in ice-cold transformation buffer (TB) (10mM 
piperazine-N,N′-bis (2-ethanesulfonic acid) (PIPES), pH 6.5, 55 mM manganese chloride (MnCl2), 15 mM 
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calcium chloride (CaCl2), 250 mM KCL). Bacteria were centrifuged again and resuspended in 20 ml of TB 
supplemented with 7% (v/v) dimethyl-sulfoxide (DMSO). After 10 min incubation on ice, 100 μl aliquots 
of competent bacteria were snap-frozen in liquid nitrogen and stored at -80°C. The OneShot TOP10 
strain of E.coli was purchased from Invitrogen in a transformation-competent state. 
2.14 Transformation of competent E.coli 
For bacteria transformation, 4 μl of DNA-ligation reaction or 100 ng of purified-plasmid DNA were added 
to a partially-thawed aliquot of competent E.coli and incubated on ice for 30 min. Transformation 
reactions were “heat-shocked” for 1 minute in a water bath set to 42°C, then incubated with 500 μl of 
super-optimal broth with catabolite repression (SOC) (SOB with 20 mM Glucose) in an orbital shaker at 
37°C. After 1 hr incubation, 100 μl of the transformed bacteria were spread onto LB-agar containing 120 
μg/ml ampicillin. Plates were inverted and incubated at 37°C overnight.  
2.15 Screening bacterial clones for the intended plasmid construct 
Ampicillin-resistant bacteria colonies were screened for the presence of correctly-sized expression 
vectors by electrophoresis of bacteria-colony lysates. This method was developed for high-throughput 
screening of 96 colonies per run (Figure 2.3). Colonies were harvested with sterile 20 μl pipette tips, 
which were transferred to a 96-well pipette-tip holder.  Once filled with bacteria-coated pipette tips, the 
pipette tip holder was used to inoculate all wells of a 96-well plate containing 100 μl of LB with 120 
μg/ml ampicillin. Pipette tips were removed and the inoculated cultures incubated at 37°C for 4 hrs. 
Residual bacteria, still attached to the 96 pipette tips, were transferred to microtitre wells containing 15 
μl of lysis buffer (50 mM Tris HCl, pH 8.0, 10 mM EDTA, 10 μg/ml RNAase A, 50 μg/ml chicken-egg-white 
lysozyme, 0.05% (w/v) 3,3’,5,5’-tetrabromophenolsulfonphthalein (Bromophenol Blue), 10% glycerol). 
After 5 min incubation at room temperature, the pipette tip holder was removed and 2 μl of  
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Figure 2.3 High throughput colony screening method for the identification of pcDNA.env constructs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 shows the high throughput screening method used to identify correctly sized HIV-1 envelope 
constructs by colony lysis. Colonies were selected with sterile pipette tips and transferred to a 96-well 
pipette-tip holder. The pipette tips were transferred to a microtitre plate containing LB/ampicillin, then 
to a second plate containing bacteria lysis buffer. Samples were processed in bulk as described in section 
2.15, then analyzed by electrophoresis through 1 % agarose. Positive colonies were identified from the 
migration rates of super-coiled DNA plasmids and the corresponding wells of the LB/ampicillin plate 
were used to set-up small scale bacteria cultures for alkaline lysis minipreperation.  
83 
 
phenol:choloform:isoamyl alcohol (25:24:1) were added to each well. Microtitre plates were sealed with 
adhesive plastic covers and vortexed to emulsify the contents. Plates were centrifuged at 2,000 g for 2 
min then vortexed and centrifuged once more at 2,000 g for 5 min. Supercoiled-plasmid DNA contained 
within the aqueous phase of each well was separated by electrophoresis through 1% agarose. Separate 
bacteria lysates containing pcDNA3.1 or pcDNA.env (previously confirmed to be correct by nucleotide 
sequencing) were added to the agarose gel as negative and positive controls, respectively. Correctly 
sized DNA plasmids were identified as those that migrated through agarose at the same rate as the 
pcDNA.env control. Positive transformants from the bacteria-culture plate were used to inoculate 5 ml 
of LB/ampicillin (100 μg/ml) which was incubated at 37°C in an orbital shaker for 12-16 hr. Bacteria were 
harvested by centrifugation at 4,000 g for 10 mins and the bacteria pellets were processed by alkaline-
lysis mini-preparation or stored at -80°C until needed. 
2.16 Monitoring growth of pcDNA.env transformed E.coli 
Growth of bacteria, transformed with pcDNA.env plasmids, was monitored by spectrophotometry at 
hourly intervals. Once light absorption values (A600) reached 0.4, an aliquot of each culture was diluted 
1:106 in LB and 100 μl was spread onto LB agar plates with or without ampicillin. After 12 hr incubation 
at 37°C, colonies were counted on each plate and used to determine the relative proportion of 
transformed and non-transformed E.coli. 
2.17 Alkaline-lysis mini-preparation of plasmid DNA. 
DNA plasmids were purified from bacteria by alkaline-lysis using a GeneJet miniprep kit (Fermentas).  
Bacteria were resuspended in 250 μl of resuspension buffer (containing RNAase A) and lysed with 250 μl 
of lysis solution containing sodium dodecyl-sulphate (SDS) and sodium hydroxide, which denatures 
bacterial protein and DNA, respectively. After 5 min, lysis reactions were terminated with 350 μl of 
neutralization buffer containing potassium acetate. Precipitated bacterial proteins and chromosomal 
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DNA were pelleted by centrifugation at 16,000 g for 5 min. Supernatants, containing the plasmid DNA, 
were passed through a silica-membrane spin column by centrifugation (16,000 g for 1 min) and the flow-
through was discarded. Columns were washed twice with an ethanol-based wash solution (16,000 g for 
1 min) and residual wash buffer was removed by centrifuging the empty column (16,000 g for 2 min). 
DNA was eluted into 50 μl of elution buffer (10 mM Tris-HCl, pH 8.5) that was passed through the 
column by centrifugation at 16,000 g for 1 min. 
2.18 Large-scale alkaline-lysis maxi-preparation of DNA plasmids with high copy number. 
One-hundred ml of LB containing 120 μg/ml ampicillin were inoculated with single colonies of MACH1 
E.coli, transformed with high-copy number plasmids, pHXB2-env or plasmids from the clade B or clade C 
HIV-1 envelope reference panels. Bacteria were incubated at 37 °C for 16-18 hr in an orbital shaker 
before harvesting by centrifugation at 4,000 g for 15 min. In order to grow MACH1 E.coli, transformed 
with the low-copy number plasmids, pNL4-3Δenv or pMD-G, 20 ml of LB containing 120 μg/ml 
ampicillin, was inoculated with a single transformed colony and incubated at 37°C in an orbital shaker 
for 8 hours. Four milliliters of this culture were added to 200 ml of LB with ampicillin and incubated at 37 
°C. After 5 hours, light absorbance was monitored at hourly intervals by spectrophotometry. When A600 
reached 0.8 the bacteriostatic antibiotic, chloramphenicol, was added to a final concentration of 170 
μg/ml and bacteria were incubated for a further 12 hr before harvesting by centrifugation at 4,000 g for 
15 min.  
A QiaFilter maxi-preparation kit (Qiagen) was used to purify DNA plasmids from bacterial pellets. 
Bacteria were resuspended in 10 ml of resuspension buffer (Buffer P1) ( 50 mM Tris HCl,  pH 8.0,  10 mM 
EDTA, 10 μg/ml RNASE A), then mixed with 10 ml lysis buffer (P2) (200 mM sodium hydroxide, 1% (w/v) 
SDS). After 5 min, lysis reactions were stopped with 10 ml of chilled neutralization buffer P3 (3.0 M 
potassium acetate, pH5.5). The resulting solution was decanted into the barrel of a QIAfilter cartridge 
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and incubated at room temperature for 10 min to allow a precipitate to float to the surface. Bacterial 
lysates was passed through the QIAfilter into a QIAGEN-tip 500 column, pre-equilibrated with 10 ml of 
buffer QBT (750 mM NaCl, 50 mM MOPS, pH 7.0, 15% (v/v) isopropanol; 0.15% (v/v) Triton® X-100). 
Once all the sample had passed through the anion-exchange resin, the column was washed twice with 
30 ml of buffer QC (1 M NaCl, 50 mM MOPS, pH 7.0, 15% (v/v) isopropanol), and DNA was eluted with 
15 ml of buffer QF (1.25 M NaCl, 50 mM Tris-Cl, pH 8.5, 15% (v/v) isopropanol). The eluent was mixed 
with 0.7 volumes of room-temperature isopropanol to precipitate DNA, which was harvested by 
centrifugation at 4,000 g for 1 hr at 4°C. The supernatant was discarded and the DNA pellet was washed 
with 5 ml of 70 % ethanol (v/v). After a further 30 min centrifugation at 4,000 g the DNA pellet was air-
dried then re-dissolved in 500 μl of TE buffer. The DNA concentration was measured using a NanoDrop 
ND-1000 and the sample was stored at -20°C. 
2.19 Construction of HIV-1 Env-pseudotyped viruses 
2.19.1 Transfection of 293T/17 cells with linear polyethyleneimine 
Envelope-pseudotyped viruses were constructed by co-transfection of 293T/17 cells with pcDNA.env 
and pNL4-3env using linear polyethyleneimine (PEI; 25 kDa) (Polysciences Inc, Warrington, PA, US) 
(Kirschner et al., 2006). Stocks of PEI were prepared in nuclease-free water to a concentration of 1 
mg/ml and adjusted to pH 7 with 5M HCl. Solutions were filter-sterilized and stored at -80°C. The 
following method was used to transfect cells in polylysin-coated 24-well plates. Quantities of PEI and 
DNA used to transfect 293T/17 cells in larger receptacles (T25 tissue culture flasks and 10 cm diameter 
Petri dishes) were scaled-up according to the surface area of the cell monolayer. 
One day prior to transfection, 293T/17 cells were seeded at a density of 2x105 cells per well. When cells 
reached 80-90% confluence, tissue culture medium was replaced with 500 μl of DMEM containing 10% 
(v/v) FCS without antibiotics. Transfection mixtures were prepared by mixing 533 μg of pNL4-3env 
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with 267 μg of pcDNA.env in 250 μl of serum-free Optimem medium. Solutions of DNA were mixed with 
250 μl of Optimem containing 2.4 μg of PEI and incubated at room temperature for 30 min to allow 
DNA-PEI complexes to form. Transfecting-DNA mixtures were mixed with the 293T cell supernatants and 
the 24-well plate was incubated at 37°C in a humidified, 5% CO2-gassed incubator. After 4 hours, tissue-
culture medium was replaced with complete DMEM (with antibiotics). Supernatants, which contained 
pseudovirus particles, were harvested 48 hr and 72 hr post-transfection and clarified by centrifugation 
at 800 g for 30 min. Transfected-cell supernatants harvested from larger tissue-culture receptacles were 
passed through a 45 μm Luer-lock syringe filters and stored at -80°C prior to virus titration and 
neutralization experiments. 
Virus pseudotyped with VSV-G, and non-enveloped virus-like particles, were constructed for use as 
experimental controls in virus titration and neutralization assays.   Both types of control virus were 
produced in 293T/17 cells, pre-seeded in T25 tissue culture flasks. Envelope-deficient virus was 
constructed by transfecting 9.6 μg pNL4-3env with 22.5 μg of PEI, while VSV-G pseudotyped virus was 
constructed by transfecting 9.6 μg of pNL4-3env and 3.2 μg pMD-G plasmid DNA with 22.5 μg of PEI.  
2.19.2 Transfections with lipofectamine 2000 
Where stated, 2 μl of the cationic-lipid, Lipofectamine 2000 (Invitrogen Life Science, UK), were used in 
place of 2.4 μg of PEI for the construction of Env-pseudotyped viruses by transfections in 24-well tissue-
culture plates. The methods for transfection were the same as for PEI transfections (section 2.19.1).  
2.20 Infectivity screening of HIV-1 Env-pseudotyped virus. 
The TZM-bl reporter cell line (section 2.1) was used to detect infectious pseudoviruses in supernatants 
harvested from small scale (24-well plate) 293T/17 cell transfections. Ninety-six well white-opaque 
microtitre plates (Costar, product code: 3917) were pre-seeded with 1.5x104 TZM-bl cells in 100 μl of 
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complete-DMEM. Plates were left at room temperature for 2 hr to allow cells to distribute evenly before 
transferring to a 37°C incubator containing 5% CO2. After 24 hours, cell supernatants were aspirated and 
replaced with 200 μl of pseudovirus supplemented with 10 μg/ml diethylaminoethyl-dextran (DEAE-
Dextran). Each pseudovirus was added to quadruplicate wells. 
After 48 hr incubation, infected-cell monolayers were fixed with 0.2% gluteraldehyde and 
histochemically stained with bromo-chloro-indolyl-galactopyranoside (X-gal) staining solution (2 mM 
MgCl2, 5mM potassium ferrocyanide (K4Fe(CN)6), 5mM potassium ferricyanide (K3Fe(CN)6), 137 mM 
NaCl, 2.7 mM KCl, 10 mM disodium phosphate (Na2HPO4), 1.76 mM monopotassium phosphate 
(KH2PO4), pH 7.4 and 1 mg/ml of X-gal stock solution dissolved in N,N-dimethylformamide). Infected 
cells, expressing β-galactosidase, produced “blue” focus forming units (FFU) after 6 hr incubation at 
37°C. Cell monolayers were washed twice with tap water and then left to air dry.  
An ELISPOT reader (AID, model no. ELR06) was calibrated to count the number of FFU in each well. The 
AID EliSpot software (v3.0) collected images in each well, across a surface area of 24 mm2, which is 75% 
of the total surface area. Image correction parameters were optimized to achieve a high-contrast 
between FFU and background artifact produced from dense clusters of uninfected cells. The camera 
shutter speed was set to 1/2046 sec and the video processing amplification parameters were set to the 
following values: Brightness 122, gain 0, hue 158, colour saturation 1, sharpness 255 (max), gamma 129, 
white balance (red) 138, white balance (blue) 160. All FFU that produced an image-intensity greater than 
12 were counted. Pseudoviruses producing more than 200 FFU per well were scaled-up by large-scale 
transfections in T25 tissue cultures flasks or 10cm diameter Petri dishes for virus titrations and 
neutralization experiments. 
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2.21 Titration of HIV-1 Env and VSV-G-pseudotyped virus. 
White-opaque microtitre plates were seeded with 1.5x104 TZM-bl cells in 100 μl of complete-DMEM, 24 
hr prior to pseudovirus titrations (section 2.20). Frozen aliquots of supernatant, containing filter-purified 
pseudovirus, were thawed at room temperature and serially diluted fivefold in complete DMEM (six 
dilutions ranging from 1:1 to 1:3125). Each dilution was mixed with equal volumes of complete-DMEM 
supplemented with 20 μg/ml DEAE-dextran (10 μg/ml final concentration). Supernatants from the pre-
seeded microtitre plate were removed and 200 μl of each pseudovirus dilution were added to triplicate 
wells. Plates were incubated for 48 hr at 37 °C, fixed with 0.2% gluteraldehyde and stained with X-gal 
(section 2.20). Focus forming units were counted using an ELISpot plate reader (AID) and infectious titres 
were calculated from virus dilutions that produced FFU within a linear range of 10 – 800 FFU per image. 
Pseudovirus titres are given as infectious units (IU) per ml, however, these titres are only applicable to 
microtitre wells (0.32 cm2) containing 200 μl of supernatant. 
2.22 Assessing antibody-mediated neutralization of HIV-1 Env-pseudotyped virus 
Neutralization of Env-pseudotyped viruses was assessed with patient-derived plasma and NAbs using a 
modified version of the standardized luciferase assay (Montefiori, 2009). This assay was adapted to 
incorporate automated cell counting of β-galactosidase expressing TZM-bl cells. Plasma was heat-
inactivated at 56°C for 1 hour, then serially diluted 3-fold from 1:10 to 1:2430. Each plasma dilution was 
mixed with an equal volume of pseudovirus, supplemented with DEAE-dextran (20 μg/ml), yielding 6000 
IU/ml of pseudovirus, 10 μg/ml DEAE-dextran and dilutions of plasma ranging from 1:20 to 1:4860. 
Where stated, plasma was substituted for NAbs, b12 or 2G12, at final concentrations ranging from 
0.0781 μg/ml to 20 μg/ml. Pseudovirus was incubated with plasma or NAb for exactly 1 hr at room 
temperature, then 200 μl of each mixture was added to triplicate microtitre wells containing TZM-bl cell 
monolayers, pre-seeded 24 hr previously (see section 2.20). Virus-only controls consisted of well 
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containing 200 μl of supernatant containing 6000 IU/ml of pseudovirus and 10 μg/ml of DEAE-dextran. 
In order to confirm that heat-inactivated virus did not contain infectious virus particles, plasma diluted 
1:20 in complete-DMEM was added to microtitre wells in the absence of virus. Plates were incubated at 
37°C in a humidified, 5% CO2-gassed incubator. After 48 hours, cell monolayers were washed twice with 
PBS, fixed with 0.2% gluteraldehyde, and stained with X-gal. After two more washes with water, plates 
were dried at room temperature and FFU were counted using an ELISpot plate reader (AID) (see section 
2.20). Neutralization was calculated as the percentage reduction of FFU mediated by each plasma 
dilution relative to the virus-only controls. Percentage neutralization was plotted against log plasma 
dilutions (or log NAb concentration) and curves were fitted to the data points using XLfit curve fitting 
software (IDBS, UK). Half-maximal neutralizing titres (IC50) were interpolated from neutralization curves 
and are presented as reciprocal dilutions of plasma or concentrations of NAb. 
2.23 Quantification of pseudovirus infection by luciferase detection 
Where stated, pseudovirus infected TZM-bl cells were quantified by luminometry using D-luciferin 
(BriteLite Plus, PerkinElmer), which is metabolized by luciferase to produce oxyluciferin in a 
chemiluminescent reaction. Forty-eight hours post-infection, supernatant fluids were aspirated from 
each well and replaced with 100 μl of D-luciferin and 100 μl of fresh DMEM without phenol red (Sigma-
Aldrich). Cells were lysed by vigorous pipetting and after 10 min incubation at room temperature 
relative light units (RLU) were quantified using a luminometer (XS, Harta, UK). Background levels of 
luminescence were recorded from wells that received TZM-bl cells without virus. 
2.24 Site directed mutagenesis 
Plasmids pcDNA.env(E339/R363), pcDNA.env(N339/R363) and pcDNA.env(N339/Q363) were obtained by 
site-directed mutagenesis of pcDNA.env(Rit336d) using the quick-change method (Papworth 1996). The 
R339E and R339R mutations were introduced to pcDNA.env(Rit.336d.c3) prior to the Q363R mutations . 
90 
 
Mutagenesis primers were designed to incorporate restriction sites that encoded synonymous-mutation, 
so that successfully mutated clones could be identified by restriction analysis (Table 2.1). Primers 
R339E/F and R339E/R introduced and R to E mutation at site 399 and an XbaI restriction site, while 
primers R339N/F and R339N/R introduced an R to N mutation at site 339 and an XhoI restriction site 
(Table 2.1). Plasmid pcDNA.env(RitD336) was used as the template for PCR amplification using PfuUltraII 
Fusion HS (Stratagene) in buffer supplied by the manufacturer supplemented with 200 μM dNTPs, 3% 
DMSO and 10 nM of each primer. Each reaction was subjected to the following thermo-cycling 
conditions: Five min denaturation at 95°C followed by 18 amplification-cycles consisting of denaturation 
(95°C for 50 sec), annealing (60°C for 50 sec), and extension (68°C for 9 min). Thermo-cycling ended with 
a final incubation at 68°C for 12 min. The reactions were digested with 10 units of DpnI restriction 
enzyme to remove dam-methylated PCR template, and the products of digestion were used to transform 
competent MACH1 E.coli. Plasmid envelopes, purified from bacteria by alkaline lysis mini-preparation, 
were screened for the intended mutations by analytical restriction digests with XbaI (R339E mutants) 
and XhoI (R339N mutants). Mutant envelope plasmids were mutagenised further using primers Q363R/F 
and Q363R/R, which introduced a Q to R mutation at site 363 and a ClaI restriction site. Double-mutant 
clones were identified by restriction-digestion with ClaI and the final mutants clones were verified by 
sequencing of mini-scale plasmid DNA preparations.  
2.25 Quantification of HIV-1 reverse transcriptase activity. 
Relative concentrations of pseudovirus particles in supernatant fluids were assessed using a product-
enhanced reverse transcriptase (PERT) assay that quantifies cDNA reverse transcribed from an RNA 
template by HIV-1 RT. Quantities of the cDNA product are measured by real time PCR using the 
asymmetric cyanine nucleic acid stain, SYBR Green I (SG), which absorbs blue light (λmax = 488 nm) and 
emits green light (λmax = 522 nm) when bound to double stranded DNA. Purified plant-viral RNA 
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derived from Brome Mosaic virus (BMV) is used as the template because of a lack of sequence homology 
with retroviral and mammalian genomes. Additionally, this virus lacks a DNA phase to its life cycle, thus 
reducing the potential for false-positive results from DNA contaminants. This assay was developed in 
house (Pizzato et al., 2009). The sensitivity of the assay was subsequently improved by redesigning the 
PCR primers to prevent the formation of primers-dimers and eliminate RNA-dependant Taq polymerase 
activity (Table 2.1).  
The modified SG-PERT assay was executed as follows. Supernatants were mixed with equal volumes of 
viral lysis buffer (100 mM Tris-HCl (pH7.5), 50 mM KCl, 0.2 mM DTT, 0.25 % (v/v) Triton X-100, 50 % (v/v) 
glycerol and 0.4 U/μl RNase inhibitor (Fermentas)) and incubated at room temperature for 5 min. Viral 
lysates were diluted ten-fold in dilution buffer (20 mM Tris-HCl, 20 mM KCl and 5 mM ammonium 
sulphate (NH4)2SO4, pH8.3), then 10 μl of each sample was added to a LightCycler capillary (Roche) with 
10 μl of reaction buffer (20 mM Tris-HCl, 20 mM KCl, 5 mM (NH4)2SO4, 200 μM dNTPs, 0.5 μM sense 
primer BMVF1, 0.5 μM antisense primer BMVF2, BSA 0.1 μg/ml, 1/20000 SYBR green I, 12 ng BMV 
template RNA and 0.2 U Hotstart Taq (MBI Fermentas)). Capillaries were placed in a LightCycler 2.0 
(Roche) instrument and incubated at 37°C for 30 min. The reverse transcribed BMV cDNA product was 
amplified using the following program: 5 min Taq polymerase activation at 95°C followed by 45 
amplification cycles of denaturation (5 sec at 95°C), annealing (5 sec at 55°C), extension ( 15 sec at 72°C) 
and data acquisition (7 sec at 83°C).  Amplification curves were generated by the LightCycler software 
(v4) from log fluorescence (λ = 530mn) measured during the acquisition step. For each amplification 
curve the software calculated a crossing point, defined as the cycle number at which the real-time 
fluorescence rises above background fluorescence recorded prior to PCR amplification. After the final 
amplification cycle, melting temperatures of the DNA products were determined by cooling the samples 
to 55 °C then heating to 95°C at a rate of 0.1°C per second, while constantly monitoring the decline in 
fluorescent signal. 
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2.26 Competitive binding assays 
Antibody specificity was mapped using a competitive-binding enzyme-linked immunosorbent assay 
(ELISA).  High-binding ELISA plates (Greiner) were coated with 1 mg/ml of recombinant BaL-strain gp120 
and incubated at 4°C overnight. Plates were washed three times with wash buffer (PBS, pH 7.4, 0.05% 
Tween-20) using an automated microtitre-plate washer (M96, MTX LabSystems), and blocked with 200 
μl of blocking buffer (PBS, pH 7.4, 0.05% tween-20, 2% milk powder) to limit non-specific antibody 
binding.  After 1 hr incubation at room temperature, plates were washed three times and each well 
received either 50 μl of sample buffer (PBS 0.05% Tween-20, 1% BSA), or 50 μl of sample buffer 
containing 5 μg/ml of M33. Plates were incubated for a further hour, during which time plasma samples 
were diluted three-fold in sample buffer, yielding dilutions ranging from 1:10 to 1:2190. Without 
washing the plate, 50 μl of each plasma dilution were added to duplicate wells and after 1 hr incubation, 
plasma dilutions were mixed with 100 μl of biotinylated-NAb to yield 50% saturating titres (4.6 μg/ml 
b12, 0.36 μg/ml 2G12 or 0.8 μg/ml 447-D). Biotinylated NAb 4.8d (2.4 μg/ml) was added to wells that 
previously received M33 peptide. After one hr incubation, plates were washed three times and bound 
NAb was detected with 1.25 μg/ml of streptavidin-HRP conjugate and 3,3’,5,5’-tetramethylbenzidine 
(TMB) colorimetric substrate (Thermofisher). After 20 min incubation the reaction was stopped with 
0.08 M sulfuric acid and light absorbance at λ=450nm (A450) was measured with a spectrophotometer 
plate reader (BioRad, model 3550). Plasma-mediated inhibition of NAb-binding was determined as the 
percentage reduction in A450 relative to wells that received sample buffer instead of plasma. 
2.27 Evolutionary analyses of HIV-1 envelope genes 
2.27.1 PCR  amplification of HIV-1 envelope for sequencing reactions. 
For clonal sequencing analysis of the C1-C3 region of HIV-1 envelope (bases 6536-9797, HXB2 
referencing), reverse-transcribed viral RNA (cDNA) was amplified by nested PCR using outer primers 
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Env10F/Env13R and inner primers Env11F/Env12R. Reaction mixtures contained 2 μl cDNA (or 1 μl of 
first round product), 200nM dNTP, 1 U platinum Taq polymerase (Invitrogen Life Sciences, UK), 2mM 
MgCl2, 200 nM of each  primer, made up to 50 μl in the 1X reaction buffer supplied by the manufacturer. 
Thermo-cycling parameters were as follows:  2 min denaturation at 94°C, followed by 35 cycles 
consisting of denaturation (95°C for 30 sec), annealing (55 °C for 30 sec) and extension (72 °C for 3 min 
30 sec). Thermo-cycling was followed by a final incubation at 72°C for 5 min. 
2.27.2    TOPO TA cloning of HIV-1 envelope genes for sequencing analyses 
Amplification products were cloned using a TOPO TA Cloning Kit according to the manufacturer’s 
instructions (Invitrogen Life Sciences). Briefly, 4 μl of agarose-gel purified PCR product were mixed with 
1 μl of reaction mix containing Vaccinia virus Topoisomerase I which ligates overhanging 3’ 
desoxyadenosines (added by Taq polymerase) to the recessed 5’ terminus of the linearized pCR2.1 
vector. After 30 min incubation at room temperature, 1 μl of ligated DNA was used to transform TOP10 
E.coli. Bacteria colonies were grown on LB-agar with 120 μg/ml ampicillin and individual clones were 
expanded for DNA purification by alkaline-lysis mini-preparation (section 2.17). Sequencing reactions 
were prepared in Big Dye Terminator v3 reaction mixtures (Applied Biosystems, UK) containing of 3.7μL 
H20, 1.5μL BigDye buffer, 625 nM  of primers ENV11F/ENV11R or ENV12F/ENV11R, 0.8μL BigDye 
Terminator v3 reaction buffer and 2μL of TOPO TA cloned envelope plasmid. Alternatively, the C2-V3 
region was amplified from pcDNA.env clones using outer primers CV1/CV4 and inner primers JAE1/JAE4. 
The PCR reaction was performed on a Peltier Thermal-cycler (PTC-200, MJ Research, UK) using the 
following conditions: 30 cycles of denaturation (96° for 10 sec), annealing (50° for 5 sec) and elongation 
(60° for 2 min). Amplified products were purified by ethanol precipitation with 300 mM sodium acetate 
(section 2.11), then sequenced using an ABI 3700 DNA analyzer (Applied Biosystems, UK). 
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2.27.3 Phylogenetic analyses  
Evolutionary studies of HIV-1 envelopes genes were conducted by Dr Gary Huang and colleagues at the 
Peter Medawar Institute (University of Oxford, UK). Sequences were aligned manually using X11, 
Sequencher (version 4.8, Gene Codes Corporation) and Se-Al (v2.0a11) software. Alignments were used 
to construct rooted phylogenetic trees using a Markov chain Monte Carlo (MCMC) algorithm that 
estimates sequence diversity and evolutionary divergence time. The MCMC algorithm was implemented 
using BEAST software which uses a relaxed molecular clock to estimate rates of evolution. BEAST 
software was also used to calculate effective population sizes for Bayesian skyline plots. For all analyses 
a general time-reversible model of nucleotide substitution was used, which has the following 
assumptions i) for any given site the rate of change from one base to another is independent of the base 
that occupied it previously (Markov property) ii) nucleotide substitution rates are constant iii)  the 
relative frequencies of each base are at equilibrium. The GTR model used a specific nucleotide 
substitution matrix (Q) derived from priors calculated using BEAST software. In order to identify sites 
under positive selection, maximum likelihood (ML) phylogenetic trees were converted to parenthetical 
notation and used as input files for the CODEML algorithm implemented by PAML software. The 
CODEML algorithm applies models of non-synonymous (N) and synonymous (S) substitution rates 
(dN/dS; the ω parameter) and tests the likelihood that the observed data fits each model using 
empirical Bayes and Χ2 tests.  
2.28 HLA typing  
Where stated the patients HLA type was determined to the oligo-allelic level using Dynal RELITM reverse 
sequence-specific oligonucleotide kits for the HLA-A and HLA-B, loci (Dynal Biotech). To obtain four-digit 
typing, Dynal Biotech sequence-specific priming kits were used, in conjunction with the Sequence-
Specific Oligonucleotide type (Duda et al., 2009).  
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2.29 IFN‐γ ELISPOT assays. 
Cytotoxic T cell function was assessed by IFN‐γ ELISPOT by Dr John Frater and colleagues (Oxford 
University). Polyvinylidene microtitre plates (Millipore) were pre-coated with 0.5 μg/ml anti–human 
IFN‐γ monoclonal antibody (Mabtech). A total of 105 freshly isolated PBMCs were added per well in a 
volume of 100 μL of R10 medium (RPMI 1640 supplemented with 10% FCS , 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 2 mM L‐glutamine, and 50 U/ml penicillin‐streptomycin). 
Peptides were added at a final concentration of 2 μg/ml. Negative controls consisted of wells containing 
PBMCs incubated with medium alone. Positive controls consisted of wells containing PBMCs and 12.5 
μg/ml of the mitogen, phytohaemagglutinin (PHA) (Murex Biotech). Plates were incubated overnight at 
37°C in a 5% CO2 incubator and washed the next day. To each well, 0.5 μg/ml biotinylated anti–IFN‐γ 
antibody (7‐B6‐1; Mabtech) was added and incubated for 1.5 hr, then the plates were washed and 
incubated with streptavidin‐alkaline phosphatase (ALP) conjugate (Mabtech) for 45 min. Plates were 
developed with the ALP-substrate, 5-bromo-4-chloro-3-indolyl phosphate and nitro-blue tetrazolium 
chloride in Tris buffer (pH 9.5). The reaction was terminated by washing with water after the appearance 
of blue spots in the positive control wells. Spots were counted on an ELISpot plate reader (AID), and 
responses were considered to be positive if the number of spots per well minus the background value 
was three standard deviation greater than the responses in the negative control wells.  
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Chapter 3 
 
 
A high through-put neutralization assay for HIV-1  
Env-pseudotyped viruses. 
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3.1 Introduction 
Microtitration of envelope-pseudotyped HIV-1 is widely used to study infectivity (Pastore et al., 2006), 
drug susceptibility (Petropoulos et al., 2000, Zennou et al., 1998, Ogert et al., 2009) and virus tropism 
(Pastore et al., 2004), and has been standardized for quantitative and qualitative assessments of NAb 
responses (Wei et al., 2003). Pseudovirus infectivity assays allow for high through-put assessment of 
NAb responses and this has facilitated the discovery of novel antigenic targets for HIV-1 vaccine 
research.  For example, the discovery of the first gp120 trimer-specific NAbs, PG9 and PG16, required 
prior screening of approximately 1800 HIV-1 infected donors and 30,000 B cell clones (Scheid et al., 
2009, Simek et al., 2009). This level of through-put was achieved using standardized panels of 
heterologous Env-pseudotypes which represented a genetically-diverse array of recently transmitted 
viruses with various neutralization epitope specificities. However, when assessing the role of NAbs in 
vivo, it follows that it is necessary to assay the patient’s plasma for antibodies against their autologous 
virus.  
Envelope cloning is a significant rate-limiting step in neutralization assays that use autologous Env-
pseudoviruses. It is often necessary to screen tens of cloned envelopes in order to identify those that 
are both representative of the quasispecies majority and capable of producing high enough titres to 
assay antibody-mediated inhibition of infection.  Alternative methods have been described that 
circumvent envelope cloning, by splicing mammalian transcription promoters onto amplified envelope 
genes using PCR (Beels et al., 2008, Kirchherr et al., 2007). However, amplification of plasmid DNA in 
bacteria is still widely used in the construction of Env-pseudotypes, because it is more straight-forward 
and less error-prone than amplifying large amounts of DNA by PCR. 
Envelope cloning is complicated by HIV-1 envelope cytotoxicity in E.Coli, which has been attributed to 
cell membrane permeabilisation, mediated by the carboxy and transmembrane regions of the gp41 
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fusion peptide (Chernomordik et al., 1994, Arroyo et al., 1995, McDonald and Burnett, 2005). Herein, we 
report marked variation in the cytotoxicity of different envelope variants, and provide a solution for 
cloning toxic envelope genes. These findings have implications for phenotypic assays of HIV-1 Env 
pseudoviruses, where it is important to avoid selection-bias when sampling viral quasispecies. 
Pseudovirus infectivity can be quantified using HIV-1 permissible reporter cell lines that stably express 
reporter genes under regulatory control of HIV-1 or SIV LTR sequences (Montefiori, 2005). One such cell 
line, TZM-bl, expresses β-galactosidase (β –Gal) and luciferase in response to the viral Tat protein (Platt 
et al., 1998b, Wei et al., 2002). Luciferase activity is quantified from D-luciferin-treated cell lysates by 
luminometry. Alternatively, β–Gal-expressing cells can be stained with X-gal substrate and quantified by 
spectrophotometry of cell lysates, or manually counted on fixed-cell monolayers (Figure 3.1). 
Automated counting procedures for high-throughput quantification of histochemically-stained cell 
monolayers have been reported (Morcock et al., 2008, Patiris and Hanson, 2005). Here, we report the 
validation of this technique for assaying neutralization of HIV-1, and demonstrate sensitivity and 
reproducibility equivalent to those of standardized luciferase-based neutralization assays. 
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Figure 3.1: Schematic representation of the HIV-I Env-pseudotype neutralization assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 demonstrates the key steps of the HIV-1 pseudovirus neutralization assay: 
A.  Full length HIV-1 env is amplified by nested RT-PCR from viral RNA extracted from plasma.  
B.  Amplified Env amplicons are restriction-cloned in the eukaryotic expression vector pcDNA3.1.  
C. Cloned envelope expression plasmids (pcDNA.env) are mixed with the HIV-I backbone, pNL4-3Δenv, 
and transfected into 293T cells.  
D. Transfected 293T cells produce virus particles pseudotyped with Env-glycoprotein expressed from 
pcDNA.env. Virions incorporate NL4-3Δenv genomic RNA but lack function envelope genes. 
E. Env-pseudotyped virus is titrated, and known quantities of virus are neutralized with plasma (or NAbs) 
and added to TZM-bl reporter cells. 
F. Infected cells express β-Galactosidase in response to the viral Tat protein. Cells are fixed and stained 
with X-gal substrate and infected cells are counted. Neutralization is calculated as the percentage 
reduction in infected cells, relative to wells that receive virus without plasma. 
pcDNA. 
env 
pNL4-3 
Δenv 
Without plasma With plasma 
A B C 
D E F 
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3.2 Results 
 
3.2.1 Optimization of molecular cloning to construct HIV-1 Env-expression cassettes. 
Envelope expression cassettes (pcDNA.env) were cloned from viral RNA extracted from plasma of 22 
HIV-1 infected patients enrolled into the SPARTAC clinical trial. These envelopes were used to construct 
Env-pseudotyped viruses for neutralization experiments that will be described in Chapter 5. Full-length 
env genes were PCR-amplified from reverse transcribed viral-RNA derived from 14 patients. Initial 
attempts failed for eight patients with low viral loads ranging from 120 to 1,490 RNA copies per ml of 
plasma (Figure 3.2A). Hence, viral RNA isolations were repeated using 3 ml of plasma that were 
ultracentrifuged for 1 hr to pellet the virus prior to RNA extraction. Subsequently, the entire 30 μl of 
eluted viral RNA were used in the RT step. After 70 cycles of nested-PCR, amplified envelope genes were 
detected by agarose-gel electrophoresis (Figure 3.2B, amplified env from patient S37 is shown). In the 
case of patient S10, who had the lowest VL, envelope genes were successfully amplified from 
approximately 360 RNA copies (Table 3.1).  
Initial attempts to clone full-length env amplicons into pcDNA3.1 (+) using ApaI and XhoI restriction sites 
resulted in digestion of the PCR product for patient S37 (Figure 3.2B). This was not surprising as 5% of all 
clade B and clade C HIV-1 envelope sequences in the Los Alamos database contain the CTCGAG XhoI 
restriction site. For this reason, each envelope primer had been designed to include two 5’ restriction 
sites, which allowed us to repeat the restriction digest using ApaI and NotI without destroying the 
envelope open reading frame (ORF).  
Cloned plasmids of the correct size were identified by agarose-gel electrophoresis of transformed-
bacterial lysates. For the majority of patient-env libraries (18/22), the percentage of screened colonies 
containing the envelope insert ranged between 80%-100%. In contrast, repeated attempts to transform  
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Figure 3.2 Isolation of env by RT-PCR amplification of viral RNA was variably efficient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 A: Amplification of viral env from plasma taken from 8/16 patients is shown (S7, S21, S17, S33, 
S128, S116, S8 and S35), demonstrating inconsistency of the reaction at low VL (see Table 3.1). Five 
microlitres of each second-round-PCR product were separated by agarose-gel electrophoresis and 
amplicons were visualized by UV-transillumination. Plasma collected from uninfected donors was 
processed using a Viral RNA Extraction Kit (Qiagen) and subjected to RT-PCR as a negative control. 
pHXB2-env (100ng) was subjected to nested PCR as a positive control. A molecular weight (MW) marker 
(1Kb, Promega), is shown in lane 1.  
Figure 3.2 B: Ultracentrifugation of plasma derived from patient S37 yielded a DNA product after 2x35 
cycles of nested RT-PCR. Restriction enzymes ApaI and XhoI digested the S37 PCR product at a restriction 
site within env. The 2.6Kb env gene was left intact following digestion with ApaI and NotI.  
       S37 
ApaI      ApaI 
XhoI      NotI 
1Kb 
Ladder 
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Table 3.1. Identification of samples with low VL that underwent ultracentrifugation prior to RT-PCR  
 
 
Patient   VL   
Weeks 
post 
ART 
  
Plasma 
ultracentrifugation 
 
Alternative 
restriction 
sites 
         
S3  16311  12     
S7  17890  4     
S8  28253  4     
S10  120  4  Yes   
S14  187  4  Yes   
S17  62875  12     
S21  20200  4     
S33  361246  12     
S35  N/T  4     
S37  255  12  Yes  ApaI/NotI 
S41  6289  4     
S46  400  12  Yes   
S94  292  12  Yes   
S99  1490  12  Yes   
S116  42604  12     
S128  74857  4     
S132  39354  4     
S171  1030  12     
S181  400  4  Yes   
S185  8060  4     
S194  851  12  Yes   
S199  5264  12     
                 
 
 
Table 3.1. Ultracentrifugation was used to pellet virus from eight patients with VL <1500 RNA copies 
per/ml prior to RNA extraction and RT-PCR. To produce Env-expression plasmids, env was cloned into 
pcDNA3.1 using ApaI/XhoI restriction sites for all samples except S37, which was cloned with NotI and 
ApaI.  
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E.coli with pcDNA.env derived from patient samples S3, S199, S8 and S17 yielded fewer colonies, none 
of which contained env. Restriction digested env DNA was gel-extracted then concentrated by ethanol 
precipitation and molarities of pcDNA.env were normalised to 83 nM (1.1 μg per reaction, 888.132 kDa) 
prior to DNA ligation. This suggested that the low cloning efficiencies were not due to insufficient 
quantities of env, particularly as 1.1 μg of env derived from patient S194 was used in a ligation reaction 
that efficiently transformed E.coli (40/40 positive colonies). Alternative reasons for the failure to clone 
HIV-1 envelopes from these patients included low efficiencies of restriction-digestion or T4-ligation 
steps that preceded transformation. However, transforming DNA samples for patients S3 and S194 both 
contained ligated pcDNA.env product that produced similar signal intensities when analyzed by agarose-
gel electrophoresis, suggesting that the cause of these cloning failures lay down stream of E.coli 
transformation (Figure 3.3)  
Previous reports of HIV-1 envelope-mediated cytopathology suggested the possibility that expression of 
env in E.coli may be inhibiting the growth of transformed bacteria (Miller et al., 1993, Comardelle et al., 
1997, Chernomordik et al., 1994, Arroyo et al., 1995). This rationale was based on reports of 
transcription in E.coli, initiated from the eukaryotic CMV-promoter located upstream of the MCS of 
pcDNA3.1 (Lewin et al., 2005). To test the contribution of gene-promoter activity to the stability of 
pcDNA.env-transformed E.Coli, the problematic env genes were religated into Bluescript II vectors with 
MCS orientated in either direction. For KSbluescript II, this placed env in the opposite orientation to the 
prokaryotic lac promoter. Conversely, the same vector with the reverse MCS (SKbluescriptII) put env 
downstream of this promoter. Only transformation with KSBluescript.env produced stable colonies 
containing the env insert (Figure 3.4), inferring that transcription of HIV-env was inhibiting bacterial 
growth. Excising env from KSbluescript and re-ligating into pcDNA3.1 failed to yield stable colonies, even 
at a lower incubation temperature of 22°C, previously shown to stabilise HIV-envelope plasmids in 
replicating bacteria (McDonald and Burnett, 2005). 
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Figure 3.3: Efficiency of ligation reactions used to construct env expression plasmids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Agarose-gel electrophoresis was used to visualise env amplicons from patients S194 and S3 
before and after ligation into pcDNA3.1 using ApaI and XhoI restriction sites (lane 1). Nucleotide 
concentrations of restriction-digested PCR-products were standardized after agarose gel-purification 
and ammonium-acetate ethanol precipitation (lanes 2 and 3). Lanes 5 and 6 show products of overnight 
ligation with T4 ligase. Final products composed of pcDNA3.1 and env (8kb) are visible in lanes 5 and 6, 
but not lane 4 (ligated vector without insert). 
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Figure 3.4: Toxicity of HIV-1 env variants in E.coli is associated with transcription-promoters 
orientated with the env ORF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 demonstrates variable cloning efficiencies for RT-PCR amplified envelope genes derived from 
two SPARTAC subjects. Transformed XL1-Blue strain E.Coli colonies were screened by agarose gel-
electrophoresis of bacterial lysates. Migration of larger-supercoiled plasmids containing env was slower 
compared to those lacking the insert. All clones for patient S194 incorporated full-length env (confirmed 
by sequencing), while clones derived from patient S3 did not. Restriction-digested env from patients S3 
was successfully cloned into KSBlueScript II but could not be cloned into the same vector with a reversed 
MCS (SKBluescript II), which placed the env open reading frame in the same orientation as the LacZ 
promoter (see Figure 2.1 for details of Bluescript vectors). 
  
   1KB       env-PCR 
ladder   S194     S3 
S194 
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3.2.2 MACH-1 strain E.Coli are partially resistant to HIV-envelope toxicity. 
These data provided an explanation for the failure to clone env from patients S199, S8, S17 and S3, but 
did not explain why these particular env variants were more problematic than the others, nor did it offer 
a solution for cloning these particular env genes into mammalian-expression vectors. The production of 
Env-pseudotyped viruses in 293T cells requires the expression of envelope glycoprotein, which in turn 
requires fusion of env to a promoter sequence that is functional in eukaryotic cells. The possibility of 
using plasmids encoding alternative viral promoters derived from SV40 or HIV-I was not pursued, 
because the early SV40 promoter and the 5’ HIV-1 LTR have been shown to have structural features 
used by E.coli RNA pol to initiate transcription (Lewin et al., 2005).  
Ignoring these patients would have introduced selection-bias into the study, so alternative strains of 
E.coli were tested for their capacity to host pcDNA.env libraries. Competent strains of K12 E.coli (TOP10, 
DH5α, and XL1-blue) all failed to host pcDNA.env, while transformation of W strain E.coli, MACH-1, 
produced stable colonies from the same DNA-ligations. In contrast to the K12 strains, MACH-1 
transformations yielded a mixture of large and small colonies (approximate diameter, 1 mm vs. 2 mm 
after 16 hr incubation at 37 °C). Only smaller colonies contained env, while the larger colonies contained 
re-ligated pcDNA without full-length envelope, confirming that HIV-1 env was inhibiting bacterial growth 
(Figure 3.5 shows a representative example for S3). This assorted pattern of colony growth was not 
apparent for all patient-derived envelopes, suggesting that some inhibited bacterial growth more than 
others.  
Previously, Monogram Biosciences (Trophile) had been unable to clone HIV-1 envelope from patient S17 
as part of a separate collaborative study with our group. Although reasons for this cloning failure were 
not given, it is possible that envelope-mediated cytotoxicity was responsible, particularly as envelope 
expression cassettes used in the Trophile assay are produced in K12 strain E.coli (US Patent 7169551 B2). 
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Figure 3.5: Susceptibility to HIV-env toxicity is dependent on E.coli strain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Competent E.coli strains were transformed with 300 ng of a pcDNA.env library derived by T4-
ligation of env (Patient S3) with pcDNA3.1. Colony lysates were subjected to agarose-gel electrophoresis 
in order to identify plasmids containing the env insert. All colonies of DH5-alpha, XL1-blue, and 
commercial preparations of TOP10 (Invitrogen) contained ligated vector without env, while MACH-1 
transformed colonies stably hosted pcDNA.env (confirmed by nucleotide sequencing). Small (S) and 
large (L) MACH-1 colonies were identified by visual inspection. 
No. 
Positive 
colonies 
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3.2.3 Envelopes derived from different HIV-I isolates exhibited variable levels of toxicity in E.coli 
In order to confirm the apparent variation in cytopathic effect mediated by different env-variants, 
bacterial growth curves were plotted for env-transformed MACH-1 cultures. However, because β-
lactamase is a secreted protein, outgrowth of bacteria lacking pcDNA.env was anticipated, which would 
have masked the inhibitory effect of Env on bacterial growth. To control for this, cultures were diluted 
and plated onto LB-Agar and the proportion of bacteria that had lost pcDNA.env was calculated by 
comparing the number of colonies grown on Amp+ and Amp- LB-agar. Cultures sampled at an A600 of 
0.75-0.89 produced 1.5-2 fold more bacterial colonies on Amp- LB-agar than on Amp+ LB-agar, 
confirming that pcDNA.env had been lost from a proportion of cells when cultures reached high 
densities. However, there was no significant difference in the number of colonies at lower absorbances 
(A600) of 0.31-0.6 in the absence of ampicillin, confirming that cultures at this stage of bacterial growth 
consisted of a homogenous suspension of stably transformed bacteria (Table 3.2).   Differences in the 
rates of bacterial growth after short periods of culture were, therefore, not due to outgrowth of 
pcDNA.env - bacteria. 
Comparison of bacterial-growth curves plotted for each MACH-1 transformation showed temporal 
variation in the lag-phases of growth between pcDNA.env variants, with those clones that failed to grow 
in K12 E.coli taking longer to reach the logarithmic phase of growth (Figure 3.6). All pcDNA.env clones 
showed some inhibition of bacterial growth relative to control cultures transformed with pcDNA3.1 
without env, suggesting that all envelopes were partially toxic. By contrast, pcDNA3.1-transformed XL-1 
blue E.coli took 5 hr longer to reach the log-phase, in accordance with the rapid doubling times of the 
MACH-1 strain. Bacterial-growth entered the log-phase at A600 values of approximately 0.4; above this 
value no difference was observed in the doubling times of clones. Cloned envelope derived from patient 
S3 exhibited the greatest cytopathic effect and produced a noticeably less turbid culture after 16 hr 
which yielded 3-fold less plasmid DNA than for the other patients. Overall, these data demonstrate that 
the rapid growth rate of MACH-1 E.coli is partially able to circumvent HIV-1 Env cytotoxicity that is fatal 
to slower-growing strains. 
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Table 3.2: Stability of pcDNA.env plasmids in transformed MACH-1 E.coli  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2: To assess the stability of patient-derived pcDNA.env transformed-E.coli, loss of ampicillin 
resistance was quantified from samples of bacterial cultures containing ampicillin (120 μg/ml). One 
envelope clone (c) was sampled from each patient. Cultures were sampled when light absorbance (A600) 
reached values of 0.3-0.6. Bacteria were diluted 1:10
6 
and incubated overnight on Amp+ and Amp- LB-
agar. Three cultures sampled at higher absorbance values (0.75 to 0.89) produced more bacteria on 
plates without ampicillin (*). 
pcDNA.env clone  
E.Coli culture 
A600  
 
Colony forming units 
(10
7
 per ml) 
Amp +ve  Amp -ve 
S46 c2  0.31  8.5  4.0 
S194 c4  0.31  9.9  7.9 
S181 c16  0.31  5.3  3.4 
S99 c17  0.32  4.5  3.0 
S21 c1  0.32  7.1  6.3 
S185 c8  0.32  4.1  3.7 
S171 c10  0.34  2.8  2.6 
S35 c22  0.37  4.6  4.4 
S132 c16  0.37  3.2  3.3 
S128 c4  0.41  2.6  2.7 
S41 c19b  0.46  2.3  2.5 
S8 c4  0.48  3.4  3.6 
S10 c4  0.51  2.6  3.0 
S17 c13  0.55  1.8  2.5 
S3 c4  0.60  3.1  5.1 
S33 c12  0.60  3.2  5.8 
       
S46  c2*  0.75  7.0  11.4* 
S194 c4*   0.81  8.4  12.6* 
S181 c16*  0.89  9.0  17.8* 
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 Figure 3.6: Envelope clones exhibit variable levels of toxicity in E.coli. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Competent MACH-1 strain E.coli were transformed with 100 ng of patient-derived pcDNA.env 
plasmids derived by standard alkaline-lysis and silica-resin based purification techniques (Fermentas, 
Genejet). Bacterial growth was assessed at 40 minute intervals by spectrophotometry at λ=600nm. took 
longer to reach the logarithmic phase of bacterial growth. All pcDNA.env-transformed MACH-1 cultures 
grew slower than bacteria transformed with pcDNA3.1, while pcDNA3.1-transformed XL-1 blue E.coli 
took approximately 5 hr longer to reach the logarithmic phase of growth. 
 
 
Legend 
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3.2.4 Optimization of 293T/17 cell transfections for the construction of Env-pseudotyped viruses 
 
 
Pseudovirus particles were produced by co-transfection of 293T/17 cells with cloned envelope genes 
and a full-length HIV-1 NL4-3env plasmid. A modified version of the microtitration assay described by 
the Central-reference laboratory at Duke University medical centre (North Carolina, US) was used to 
quantify infectious titres of pseudovirus in 293T/17 cell supernatant fluids (Montefiori, 2009). In this 
modified assay, β-galactosidase activity was quantified in place of luciferase, both of which are 
expressed by infected TZM-bl reporter cells under regulatory control of a Tat-responsive LTR-promoter. 
Initially, fixed-cell monolayers were histochemically stained with X-gal substrate and “blue” foci were 
counted manually under light microscopy. 
Pseudoviruses constructed with HIV-1 env sequences from five patients by transfection with 
Lipofectamine had an infectious titre below 2x103 IU/ml, which was insufficient to assay neutralization. 
Therefore, non-branched PEI (25kDa) was investigated as an alternative transfection reagent. In order to 
optimize pseudovirus expression by PEI transfection, molecular weight ratios of DNA to PEI, ranging 
from 1:1 to 1:10, were tested using HXB2 pcDNA.env and the infectious titres of the pseudovirus were 
compared. Transfection with 800ng of DNA (533 μg of pNL4-3env and 267 μg of HXB2 pcDNA.env) 
with 2.4 – 4.0 μg of PEI produced pseudovirus titres of approximately 1.5 x105 IU/ml, which were 1.5-
fold higher than viruses produced with Lipofectamine using the same quantity of DNA (Figure 3.7A). 
Quantities of PEI greater than 4.0 μg per ml of DMEM caused 293T cell monolayers to detach following a 
4 hr incubation period, indicating that PEI-mediated cytoxicity was responsible for the decreases in 
infectious titre observed with DNA:PEI ratios greater than 1:5 (Figure 3.7A). In contrast to Lipofectamine 
transfections, optimized PEI transfection conditions produced infectious Env-pseudotyped virions for all 
patients selected for study.  
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In order to rule out ‘carry-over’ of residual DNA:PEI complexes during pseudovirus titrations, NL4-
3env plasmid was transfected without env to produce non-infectious ΔEnv-virions. Harvested 
supernatants titrated onto TZM-bl cells did not produce foci of infection after 48 hrs, confirming that the 
reporter cells had not been transfected (Figure 3.7B). Nevertheless, 293T cells were washed after each 
transfection and supernatants were filtered prior to the virus-titration and neutralization experiments. 
To test whether patient-derived HIV-1 envelopes were toxic to mammalian cells, TZM-bl monolayer 
confluency was visually inspected by light microscopy, and Trypan-Blue dye exclusion was quantified 
after 48 hrs infection with 200 IU per well of each pseudotype. The percentage viability of Trypan-Blue 
stained trypsinized-monolayers ranged between 82% - 100%, and monolayer confluence was estimated 
to be greater than 95% in all cases. Cell viability was not a specific property of individual Env-clones, 
because variations between different Env-pseudotypes were of similar magnitude to variation observed 
between triplicate wells receiving the same virus. Moreover, there was no correlation between Env 
toxicity in TZM-bl cells and E.coli. In fact, TZM-bl cell monolayers infected with S3 Env-pseudotyped virus 
reached 100% confluence, despite cytopathic effects of S3 pcDNA.env in E.coli (Figure 3.7B). Infectious 
titres greater than 5x103 IU/ml resulted in monolayer confluence less than 50% for virus pseudotyped 
with HXB2. It was not possible to compare all viruses at this level of infectivity because the majority had 
titres below 5x104 IU/ml. Eukaryotic cytotoxicity resulting from HIV-I env expression in 293T cells could 
not be ruled out because of the cytotoxic effects of the PEI transfection reagent. 
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Figure 3.7 Optimization of pseudovirus production by PEI transfection 
 
 
 
 
 
 
 
 
             Δ Env              S3.Env    HXB2.Env 
 
 
 
 
Figure 3.7A.  Co-transfection procedures were optimized for pseudovirus production with plasmids NL4-
3Δenv and HXB2.env, mixed in a ratio of 3:1. A total of 800 ng of DNA mixture was combined with 
relative quantities of PEI shown on the x axis. Pseudoviruses were harvested after 48 hr and titrated on 
TZM-bl cells, and infectious titres (IU/ml) were calculated from the number of infected cells in each well.  
Figure 3.7B. Viruses pseudotyped with functional HIV-1 envelopes infect TZM-bl cells, leading to 
expression of β-Gal. Virus like particles that lack functional envelopes cannot infect the reporter cells 
(left panel). After 48 hr incubation with 200 IU of S3 pseudotype, TZM-bl cells remained 90-95% 
confluent (central panel). Conversely 50% of the TZM-bl cell monolayer detached following infection 
with 5x104 IU/ml of HXB2-Env pseudotyped virus (right panel). 
A 
B 
DNA:PEI ratio 
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3.2.5 Optimization of a high-throughput pseudovirus-microtitration assay. 
Manually counting pseudovirus-infected cells proved to be time-consuming, unreliable and subjective, 
as counts varied between different assay operators. Therefore, conditions were optimized for 
automated counts with an ELISpot plate reader (AID). An important step in the modification of this assay 
was achieving an evenly-distributed cell-monolayer that improved the reproducibility of the assay. For 
this, opaque 96-well microtitre plates were seeded with reporter cells 24 hr prior to the addition of 
virus-plasma combinations. This method was compared to the cell-seeding protocol described for the 
standardized luciferase-based assay in which pseudovirus is added simultaneously with freshly-
trypsinized cells. The striking infection-enhancing effect of this minor amendment can be seen in Figure 
3.8. In addition to a more even cell distribution, pre-seeded cell monolayers were more permissible to 
infection, producing 3-5 fold more infectious foci than in the original protocol.  
Uninfected cells did not produce a background-noise with the image correction settings described in 
section 2.20. However, pipette scratches occasionally left distinctive lines on the base of microtitre 
wells, causing with the ELISpot-reader software to erroneously count high numbers of FFUs. Therefore, 
each image was manually inspected and automated-counting errors caused by these pipette scratches 
were corrected. With careful pipetting this affected less than 0.2% of microtitre wells. 
The quantifiable limits associated with β-Gal or luciferase as the readouts for the pseudovirus-infectivity 
assay were compared. A five-fold serial dilution of HXB2 Env-pseudotyped virus was quantified by 
luminometry and by automated counts of infected-cell foci (Figures 3.9A and 3.9B, respectively). The 
quantifiable-linear ranges resulting from both readouts reached a plateau above 103 foci per well 
(8.7x105 relative light units; RLU). Above this limit, light detection approached saturating levels and it 
was not possible to differentiate between individual stained-foci and clusters of β-galactosidase 
expressing cells. Automated cell counting slightly increased the sensitivity of the assay to permit 
detection of single cell infections, in comparison to light detection from D-luciferin-treated cell lysates, 
which approached background levels below 10 infectious particles per well (2.5x104 RLU). Virus titres  
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Figure 3.8 Optimised cell-seeding protocol for HIV-1 pseudotype microneutralization assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: An even distribution of cells is a prerequisite for accurate counts of pseudovirus-infected 
TZM-bl reporter cells using ELISpot readers for automated read-outs. The cell-seeding protocol 
described by the Duke University Central Reference Laboratory (left panels) was compared to the 
modified protocol (right panels), in which cells were seeded 12 hr prior to titration of HXB2 pseudovirus. 
Cell distribution patterns resulting from each protocol are shown by images acquired with an AID 
ELISpot plate reader. A “halo” effect was observed when virus was mixed with freshly-trypsinized cells 
which substantially reduced counts of infected cells, given by the numbers to the right of each image 
HXB2 Env 
Pseudovirus 
Dilution 
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Figure 3.9 Comparison of luminometry with automated spot counting for TZM-bl based pseudovirus 
infectivity assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. The quantifiable-linear range of pseudovirus infected TZM-bl cells was assessed by 
luminometry (Figure 3.9A) and automated spot counting (Figure 3.9B). Titrations of HXB2 Env-
pseudotyped virus were prepared in parallel and assayed for luciferase expression using a luminometer 
(section 2.23) or β-Gal expression by automated spot-counting of X-gal stained cell monolayers using an 
ELISpot plate reader (section 2.21). Readouts for both techniques reached a plateau above 103 infected 
cells per well (5x104 IU/ml or 8.7x105 RLU). Percentages give the intra-assay coefficient of variance for 
10 replicates of virus dilutions assayed using each technique. 
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that fell within a linear range of 10-103 infectious particles per well produced standard deviation to 
mean ratios below 1:10 for both protocols, confirming equivalent levels of accurate reproducibility. 
Histochemically stained cells were dried prior to reading, so plates could be kept indefinitely at ambient 
temperatures and anomalous results could be reassessed. This offered a distinct advantage over the 
original luciferase assay. 
3.2.6 Validation of the β-Gal neutralization assay. 
The optimized β-galactosidase infectivity assay was validated as a means of measuring neutralization 
with patient plasma by direct comparison with the luciferase-based assay. The plasma-titres required to 
neutralize 50% of a HXB2-Env pseudotyped virus (IC50) were calculated from neutralization curves 
derived from each assay. Using the β-gal system, mean IC50 plasma-titres calculated for patients S181 
and S10 were 1:25 and 1:232, respectively (Figures 3.10A and 3.10B, respectively). These values fell 
within the 95% confidence intervals of titres detected by the luciferase-assay, confirming that the 
protocol modifications do not bias the neutralization recorded for patient plasma.  Sub-neutralizing 
concentrations of both plasma enhanced virus infectivity by 10-30%. This level of enhancement 
corresponded to 15-45 infected cells, which was not detected by the luciferase assay. Optimising the cell 
distribution had the knock-on effect of reducing the variance of replicate tests, thus narrowing the 
confidence intervals of the β-gal assay (Figures 3.10C and 3.10D). Overall, automated counting of 
pseudovirus-infected cell monolayers provided a cost-effective alternative to luciferase-based 
luminometry with similarly high-levels of throughput, sensitivity and reproducibility. 
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Figure 3.10 Validation of the high-throughput microneutralization assay for HIV-Env pseudotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. The β-gal microneutralization assay was compared to the standardized luciferase-based 
assay. Neutralization of a HXB2 env-pseudovirus is shown for plasma derived from representative 
patients exhibiting low neutralization (Figure 3.10A; patient S181) or high neutralization (Figure 3.10B; 
patient S10). Similar patterns of neutralization were detected by luminometry (open circles) and 
automated cell counting (black triangles). Neutralization curves (black lines) were plotted from the 
percentage-reductions in spot-forming units (y-axes) relative to no-plasma controls. Neutralizing plasma 
titres (IC50) are shown by dashed-intercepting lines. Curve fits were plotted using XLfit software.  Figure 
3.10C gives an example of a HXB2-neutralization curve (β-Gal) acquired using the cell-seeding protocol 
described by the original assay. Virus was neutralizing with plasma derived fom patients S30, for whom 
pseudovirus was not cloned. For comparison Figure 3.10D shows the equivalent result generated using 
the modified protocol. The 95% confidence intervals (grey lines) were narrower when virus-plasma 
mixtures were added to pre-seeded plates. 
Cells seeded simultaneously with virus Cells seeded 24 hours prior to infection 
C D 
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3.3 Discussion 
The Env-pseudotype HIV-1 neutralization assay has produced an invaluable tool with which to identify 
and characterise HIV-1 neutralizing antibodies. However, the assay was primarily developed for vaccine 
research, so its capacity to measure natural antibody responses in vivo requires appraisal. Adapting the 
endpoint measurement from luciferase detection to quantification of β-galactosidase did not affect the 
intra-assay variation and marginally improved sensitivity to allow detection of a single infected cell. This 
added sensitivity is unlikely to improve assessments of 50% or 90% neutralizing titres, but could offer a 
benefit to studies of the non-neutralized fractions of HIV-1 that are commonly detected at saturating 
concentrations of NAbs in vitro (Burton et al., 2001). 
Seeding cells one day prior to incubation with virus/plasma enhanced susceptibility to pseudovirus 
infection four-fold, perhaps because trypsinisation removes virus-receptors required for entry into host 
cells. This protocol amendment should also be considered for the original luciferase system, to reduce 
the number of rejected env-pseudotypes with titres that are considered too low for viral-inhibition 
assays. 
Arguably, PBMCs and wild-type viruses are more relevant to the NAb response, in vivo, than reporter 
cell systems engineered to be susceptible to molecularly cloned virus, although lectin-stimulated PBMCs 
are not representative of HIV-1 target cell populations in vivo (Jackson et al., 1988). However, levels of 
neutralization detected by PBMC-based assays are confounded by the effects of i) cytokines and 
chemokines that can inhibit or enhance virus replication (Kinter et al., 1996) ii) Fcγ-receptor-dependent 
cellular mechanisms involving non-neutralizing antibodies (Holl et al., 2004) iii) heterogeneity between 
PBMCs populations from different donors (Polonis et al., 2009) iv) variable replication kinetics of quasi-
populations of cultured virus (Binley et al., 2004) and v) variable plasma concentrations of p24 antigen 
and anti-p24 antibodies that interfere with the end-point measurement of the assay (Mascola and 
120 
 
Burke, 1993). Consequently, an international collaborative study by NeutNet reported that pseudovirus 
assays generate results that are generally more reproducible than PBMC-based approaches (Fenyo et 
al., 2009). 
This withstanding, the possibility of selecting minority env-clones that are unrepresentative of the major 
circulating quasispecies is a problem with assays using molecularly cloned virus. This problem is further 
exacerbated by the findings of this study, which demonstrates variable degrees of HIV-1 Env-mediated 
cytotoxicity in K12 E.coli strains that are widely used for virus cloning. Potentially, this could bias the 
selection of patient viruses in favour of those Env-variants that are non-cytotoxic. These findings are 
particularly relevant to HIV-1 pseudotype assays used in the clinical setting, including the Trofile assay 
currently licensed to predetermine susceptibility to CCR5-anatagonist, virus-entry-inhibitor, Maraviroc 
(Pfizer). The possibility of Maraviroc-treatment failure resulting in the selection of minority X4-tropic 
virus requires this assay to be highly sensitive (Archer et al., 2009, Fatkenheuer et al., 2008, Saag et al., 
2009).  Therefore, the possibility of Env-toxicity leading biased-sampling of virus quasispecies should be 
assessed, specifically in this clinical setting. 
Previously described methods of culturing env-transformed bacteria at ambient temperature did not 
yield envelope clones from some patients (McDonald and Burnett, 2005), whereas competent MACH-1 
cells derived from E.coli strain W, facilitated env cloning from all patients selected for study. On a per 
cell basis, it seems likely that MACH-1 cells are susceptible to env toxicity, but compensate with rapid 
rates of cell division. Correspondingly, those env genes that were toxic to K12 E.coli strains produced 
‘small’ MACH-1 colonies that took longer to reach logarithmic phases of growth in suspension culture. 
Negative-selection mediated by toxic plasmids resulted in outgrowth of faster-growing E.coli that lacked 
pcDNA.env at A600 values greater than 0.8, which may partly explain why toxic and non-toxic envelopes 
exhibited similar kinetics of logarithmic-growth. However, this does not explain why cultures of E.coli 
transformed with the most toxic envelope clone, derived from patient S3, were considerably less turbid 
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after 16 hr of growth, and yielded significantly less plasmid DNA than the other cultures. This suggests 
that death rates were dissociated from higher rates of cell division during the initial part of the 
logarithmic phase, but subsequently caught-up, causing bacterial growth to plateau prematurely. This is 
to be expected, given a delay in env expression following mitosis, in keeping with the association of env 
toxicity with mammalian-transcriptional promoters that are not optimised for prokaryotic systems.  
Occasionally, repeated attempts were required to grow MACH-1 cultures transformed with particularly 
problematic envelopes. Therefore, this cloning adaptation may still fail for certain env genes, if the 
toxicities are greater than those observed here. Nevertheless, MACH-1 cells provide a marked 
improvement over the more commonly used K12 strains, in terms of their potential to limit sampling 
bias of HIV-1 env genes. A previous study demonstrates that viral promoters derived from SV40, CMV 
and HIV-1 possess structural elements that initiate transcription in E.coli, whereas the viral promoter 
derived from the thymidine kinase gene of herpes simplex virus 1 (HSV1) does not lead to gene 
transcription in K12 E.coli. Therefore, expression plasmids that use this HSV1 promoter should be 
assessed as alternative vectors for eukaryotic expression of HIV-I Env (Lewin et al., 2005). 
Previous studies have identified amphipathic α-helical structures within the gp41 fusion peptide, termed 
lentiviral-lytic peptides that permeabilise membranes of eukaryotes and prokaryotes (Chernomordik et 
al., 1994, Arroyo et al., 1995). This mechanism, along with transduction of signaling cascades through 
gp41-binding of calmodulin, has been implicated in human cytopathology (Tencza et al., 1997, Tencza et 
al., 1995). In this study, we did not detect Env-dependent cytotoxicity in the 293T or TZM-bl mammalian 
cell lines. However, pseudotyped viruses, that do not package HIV-1 env genes, are unsuitable for this 
investigation and observations in E.coli are of limited relevance to human infection. Further 
investigations into effects of more or less toxic envelope genes could indentify correlates of virus-
mediated pathogenesis.  
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Chapter 4 
 
B cell depletion in an HIV-1 infected human reveals a role 
for NAbs in the control of VL 
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4.1 Introduction 
During the chronic stage of HIV-1 infection, VL is maintained at a set-point that reflects a balance 
between antiviral immune responses and continuous viral turnover from steadily declining numbers of 
CD4+ T cells. Immunological control of viraemia varies considerably between individuals and a minority 
(less than 1%) maintains VLs below detectable levels (Lambotte et al., 2005, Madec et al., 2005a). 
Several studies have detected strong “polyfunctional” CD8+ and CD4+ T cell responses in some elite 
controllers (Betts et al., 2006, Emu et al., 2008, Migueles et al., 2002, Sarez-Cirion et al., 2007, Streeck et 
al., 2008, Pereyra et al., 2008b, Potter et al., 2007). Conversely, NAb responses against heterologous 
isolates are rare and responses against autologous viruses are frequently of lower potency in elite 
controllers than in chronic progressors (Bailey et al., 2006, Lambotte et al., 2009, Li et al., 2009b, 
Mahalanabis et al., 2009b, Pereyra et al., 2008a). In spite of low levels of circulating Env antigen, a 
minority of elite controllers have been shown to develop neutralizing responses (Doria-Rose et al., 2009, 
Scheid et al., 2009), but functional data linking such antibodies to the control of viraemia is lacking. 
Furthermore, the controlling effects of partially-neutralizing responses detected in the majority of 
chronically infected patients has been difficult to determine, due to other confounding factors that limit 
virus replication, such as T-cell responses, virus fitness and host genetics (Carrington and O'Brien, 2003).  
Lymphocyte depletion experiments have yielded information about the functional importance of 
specific immunological compartments. For instance, depletion of CD8+ T cells in SIV-infected macaques 
results in higher VLs and accelerated rates of CD4+ T cell destruction (Jin et al., 1999, Lifson et al., 2001, 
Metzner et al., 2000). Similarly, macaques depleted of B cells prior to SIV infection develop high levels of 
viraemia that inversely correlate with levels of anti-SIV IgG (Miller et al., 2007, Schmitz et al., 1999). 
While such data are readily available from animal models, they are rarely available in man. 
Rituximab is a mouse-human monoclonal antibody that targets and depletes CD20+ B cells by NK cell-
mediated and complement-mediated cytotoxicity (Gong et al., 2005, Taylor and Lindorfer, 2008). It does 
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not deplete antibody-producing plasma cells, because expression of CD20 ceases when late B cells 
differentiate into plasma cells (Ahuja et al., 2008).  The natural ligand of CD20 has not been defined, 
although it is thought to be involved in B cell activation and cell proliferation (Popoff et al., 1998). 
Rituximab therapy has been associated with declining antibody titres in the treatment of autoimmune 
disorders, such as systemic lupus erythmatous, pemphigus vulgaris and mixed cryglobulinaemia vulgaris 
(Eming et al., 2008, Saadoun et al., 2008, Stasi et al., 2007).  Here, we report a unique case in which 
rituximab monotherapy was used in a patient with stable HIV-1 viraemia, in the absence of ART. This led 
to a reversible loss of HIV-1 control, associated with reciprocal changes in NAb titres. Sequence analysis 
revealed diversification of virus as antibody levels declined, with subsequent selection of NAb-resistant 
mutants at sites consistent with antibody selection. These data suggest that B cell function contributed 
to long-term control of VL in this individual, and that NAbs may be more important in controlling chronic 
HIV-1 infection than previously suspected. 
The study described in this chapter was led by Professor Paul Klenerman (Nuffield Department of Clinical 
Medicine, Oxford University, Oxford). All neutralization assays, envelope mutagenesis, reverse 
transcriptase quantification and protein-binding experiments were carried out by the candidate. The 
phylogenetic analyses (shown in Figures 4.5-4.7) were carried out by Dr Gary Huang and Dr Aris 
Katzourakis at Oxford University. The CD8+ T cell functional analysis and the HLA typing was conducted 
by Dr John Frater at Oxford University. All clinical data (CD4+ T cell counts, HIV-1 VL, Hepatitis B VL, 
immunoglobulin quantification, and liver function testing) were acquired at clinical laboratories as part 
of the care the patient received at St Mary’s Hospital, London.  
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4.2 Clinical History 
The patient, a Caucasian male, was diagnosed with an asymptomatic lymphoplasmacytic lymphoma 
(LCL) in 1972. He did not receive treatment at the time. In 1999, he was diagnosed with acute Hepatitis 
B virus (HBV) infection. In 2002, aged 58, he was diagnosed with HIV-1 seroconversion illness (clade B). 
The date at which HIV-1 seroconversion was confirmed is designated as d0 throughout this case study. 
Following seroconversion, the patient was noted to have elevated numbers of CD138+ pre-B cells in the 
bone marrow and raised IgM (κ-light chain) paraprotein levels, attributed to progression of his LCL.  
On diagnosis of HIV-1 infection the patient was recruited into a prospective, non-randomised 
observational study of early treatment and received three months of combination ART (the pilot study 
to SPARTAC,(Fidler et al., 2002). Thirty months later he received thalidomide treatment for a rising 
paraproteinaemia without clinical effect. Rituximab therapy was initiated the following month, 1075 
days after HIV-1 seroconversion. Four months after the final dose of rituximab the patient became 
unwell with malaise, fever and unexplained pulmonary infiltrates. This coincided with a 1.7 log10 rise in 
HIV-1 VL, peaking at 737,400 copies/ml. In addition to rising HIV-1 VL, the patient’s HBV VL, previously 
undetectable, reached peak levels greater than 6x106 copies/ml and he developed a biochemical 
hepatitis (peak alanine transaminanse (ALT) 851 international units (IU) per L). In the absence of ART, 
HIV-1 VL declined over 3 months, reaching a nadir of 175 RNA copies per ml. Subsequently, long-term 
combination ART was initiated, 1392 days after seroconversion (emtricitabine, tenofovir disoproxil 
fumarate and lopinavir/ritonavir). His CD4+ count remained above 350 cells/mm3 throughout the follow-
up period, and the patient recovered with supportive treatment (Figure 4.1). 
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Figure 4.1 Clinical course of HIV-1 in relation to rituximab therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: The plasma VL (red; right y-axis) and CD4 count (blue; left y-axis) of the individual studied are 
displayed over time (days since seroconversion). The brief dip in VL over the first 100 days corresponds 
to course of ART administered as part of the short-course ART trial (d 0 - d 164). Subsequently, VL was 
maintained at approximately 105 copies per ml over approximately 1000 days without ART. The four 
week course of rituximab therapy is indicated by the grey shaded area. 
 
  
Days post-seroconversion 
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4.3 Results 
4.3.1 Impact of B cell depletion on plasma antibody concentration 
Before the first dose of rituximab, total IgG plasma concentrations were 16.1 g/l, which is within the 
normal range for a healthy adult (0.8 - 18 g/l, American Society for Clinical Laboratory Science). Fifteen 
days after the peak VL measurement, total IgG decreased to 10.8 g/l then subsequently increased to 
17.3 g/l as VL dropped. Reductions in IgG concentration coincided with reductions in total IgA and IgM κ-
light chain paraprotein concentrations. Subsequently, IgA levels returned to pre-rituximab levels, 
whereas IgM-paraprotein concentrations did not increase. These clinical data suggested that rituximab 
therapy resulted in modest decreases in total concentrations of different antibody isotypes, which is in 
keeping with a non-specific depletion of CD20+ B cells (Eming et al., 2008, Saadoun et al., 2008, Stasi et 
al., 2007). However, despite only modest changes to total antibody concentrations, antibody levels to 
the HBV surface antigen (HBsAb) declined from 7.8 IU/ml to undetectable levels (<1IU/ml) by the peak 
of HIV-1 VL (Table 4.1). This discrepancy implied that the effects of rituximab on different antibody 
idiotypes were variable.  
4.3.2 Neutralizing plasma titres against HIV-I temporarily decreased following rituximab therapy. 
The reciprocal association between antibody concentration and HIV-1 VL prompted the hypothesis that 
rituximab therapy caused a transient decrease in HIV-1 NAb titre and a transient loss of viraemia 
control. To evaluate NAb activity throughout this period, pseudoviruses were constructed from 
autologous env sequences derived from d 366 and d 1042 plasma. Despite sequence variation within the 
C2V3 env region involving less than 2% of the 770 sequenced nucleotides, there was no significant 
difference in neutralization sensitivity between three heterogenous clones assessed for each time point. 
Neutralizing plasma titres of three clones derived from each time point are shown in Table 4.2. Serum 
obtained prior to the first dose of rituximab (d 1042) potently neutralized pseudovirus constructed with  
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Table 4.1 Impact of rituximab on plasma immunoglobulin concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Total immunoglobulin concentrations were assessed at the Diagnostic-Immunology Laboratory 
at St Mary’s hospital as part of follow-up investigations of the patient’s LCL. Total IgG and IgA 
concentrations were assessed by immune-nephelometry (Beckman-Coulter) and concentrations of 
HBsAb were assessed by ELISA. Both assays are validated for clinical diagnositic purposes (section 2.5). 
  
Days post-
seroconversion 
IgG 
(g/l) 
IgA 
(g/l) 
IgM-κ 
paraprotein 
(g/l) 
HBsAb 
(IU/ml) 
Clinical details 
883    12.43  
1028 16.1 0.7 38   
1094 16 0.8 37  Pre rituximab 
1144 15.6 0.7 29  Post rituximab 
1204 12 0.5 24   
1239    7.8 During acute illness 
1254 10.8 0.6 25   
1295    <1  
1298 11.6 0.7 26   
1308    2.86  
1449 17.3 0.8 23  
On ART post-
convalescence 
1700    100.76  
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Table 4.2: Impact of rituximab on neutralizing plasma titres (IC50). 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2. Half-maximal inhibitory concentrations of sera (IC50, reciprocal dilutions) are shown for virus 
pseudotyped with Env-clones derived from d 336 and d 1042 plasma.  Neutralization of a HXB2 Env-
pseudotyped virus is also shown. Serum concentrations below 1:20 did not inhibit VSV-G pseudotyped 
virus indicating that neutralizing responses were HIV-Env specific. (*)1:120 was the highest 
concentration of d 1239 serum that could be tested against d 1042  virus due to limited availability. 
Mutant 339E/363R was constructed to represent envelope changes identified following rituximab 
therapy. “n/t” denotes virus-serum combinations that were not tested because of limited availability. 
autologous envelopes derived 2 years previously (d336, IC50<775
-1).  
Days post-
seroconversion 
d 336 
pseudovirus 
d 1042 
pseudovirus 
Mutant 
339E/363R HXB2 VSV-G 
Clinical 
details 
1042 >775 150 n/t 850 <20 Pre-Rituximab 
1135 >775 225 300 1000 n/t 
Post-
Rituximab 
1239 220 <120* n/t 875 20 Peak viraemia 
1295 250 150 n/t 325 20  
1308 360 375 n/t 1000 <20  
1353 600 425 600 3950 n/t 
Post-
convalescence 
negative serum <20 <20 n/t <20 n/t  
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autologous envelopes derived 2 years previously (d336, IC50<775
-1). The same serum neutralized 
contemporaneous Env-pseudotypes (d 1042), albeit to a lesser extent, with an IC50 of 1:150. This concurs 
with typical patterns of viral escape from NAbs previously reported (Mahalanabis et al., 2009b, Parren et 
al., 1999, Richman et al., 2003, Wei et al., 2003); it also confirmed this patient was able to mount a 
neutralizing response in spite of his LCL. 
Following rituximab therapy, IC50 serum titres against d 336 and d 1042 Env-pseudotypes decreased by 2 
to 3-fold and the neutralizing effects of 1:180 dilutions of sera reached nadir values concomitant with 
peak VL (Figure 4.2). Subsequently, neutralizing activity rebounded as viraemia was brought under 
control. Remarkably, as neutralizing plasma titres returned, VL decreased from 737,400 to 175 
copies/ml in the absence of ART, despite a pre-rituximab VL set-point of 1.7 x 105 RNA copies/ml (± 8.3 x 
104,
 d 153 to d 938,). Sera collected after VL had decreased neutralized d 1042 virus more effectively 
than sera collected before peak viraemia (Figure 4.2). Decreases in neutralizing activity against a HXB2 
Env-pseudotyped virus were also observed, and the changes in IC50 titre were greater than that 
observed for autologous virus strains. The potent levels of neutralization observed against HXB2 were 
not surprising, as diverse virus strains stimulate antibodies that neutralize HXB2 (Binley et al., 2008). 
To determine the breadth of this patients NAb response, heterologous NAb activity was tested against a 
standardized panel of clade-B reference strains. Eight of the twelve isolates were neutralized with titres 
ranging from 1:90 to 1:300 (Table 4.3). Virus pseudotyped with Env clones SC422661, RHPA4259, 
THRO4156, WITO4160, CAAN5342, were not neutralized by the patient’s sera (IC50 > 20
-1). Six isolates 
were more neutralized by serum collected post-rituximab than serum collected pre-rituximab, in 
agreement with the increases in neutralization observed with autologous virus. In comparison to other 
studies, this patient’s neutralizing response exhibited moderate breadth and potency with IC50 titres that 
fell within the inter-quartile ranges reported for chronically infected patients (Binley et al., 2008, Sather 
et al., 2009, Mahalanabis et al., 2009a). However, there was insufficient serum to assay heterologous  
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Figure 4.2: Autologous neutralizing antibody titres assayed over time.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Autologous viruses, constructed with cloned env genes derived from d 336  ()  and d 1042 
() post seroconversion, were neutralized with patient sera taken before and after rituximab therapy. 
Percentage reductions of infected cells mediated by serum diluted 1:180 in complete DMEM are shown 
(black lines: right y-axis). One representative clone from each time points is shown (Rit.336d. c3 and 
Rit.1042.c6). Plasma VL (red line; left y-axis) is shown over time (days post sero-conversion; x-axis). Grey 
shaded area indicates the four week course of rituximab therapy. Error bars show the standard 
deviations of triplicate tests for each clone. 
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Table 4.3 Neutralizing plasma titres against heterologous virus 
 
 
 
 
 
 
 
Table 4.3 A: Patient sera exhibited moderate neutralizing potency and breadth against heterologous 
pseudoviruses constructed from a standardized reference panel of heterogeneous envelopes (NIAID, 
NIH). (**) Reductions in FFU were detected with pooled HIV-1 negative sera, which were attributed to 
cellular toxicity that was not observed at concentrations below 1:20.  
  
Serum 
                                                         Pseudovirus 
6535 QH0692 PVO TRO AC10.0 
pREJO 
4541 
pTRJO 
4551 
pRHPA 
4259 
d 1042  
(pre rituximab) 
220 220 90 120 90 140 50 50 
d 1353  
(post rituximab) 
300 170 90 130 160 220 140 120 
Negative 20**  <20 <20 <20 <20 20**  20**  <20 
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neutralizing activity at the peak of viraemia (d 1239), so we were unable to assess whether decreases in 
autologous-neutralization correlated with changes in neutralizing breadth.  
These data suggest that, following B cell depletion, HIV-1 NAbs were transiently and partially-depleted, 
but returned with stronger neutralizing efficacy than pre-rituximab levels. Furthermore, the temporal 
relationship between VL and neutralizing plasma titre was in keeping with the hypothesis that NAbs 
contributed to the control of viraemia in this patient. However, it was important to characterize further 
the changes in NAb activity that followed rituximab therapy.  
4.3.3 Antibody characterization 
Neutralization was not detected against a VSV-G pseudotype. Because VSV-G envelope interacts directly 
with the lipid bilayer of the cytoplasmic membrane, VSV-G pseudotyped HIV-1 bypasses the 
requirement of the interaction between HIV-1 envelope and its receptor and coreceptor to enter cells 
and is therefore not susceptible to inhibition by HIV-1 neutralizing antibodies. Therefore, neutralizing 
activity detected against the HIV-1 Env-pseudotyped virus was assumed to be HIV-1 Env specific and 
antibody mediated. Additionally, HIV-1 negative serum did not neutralize the patient’s Env-pseudotyped 
virus. However, B cell depletion has been shown to affect cytokine responses (Agarwal et al., 2004), 
which could potentially affect rates of viral replication in vitro and be mistaken for neutralization. 
Therefore, it was important to confirm that the changing neutralizing activity was HIV-1 envelope 
specific. 
To define the specificity of the patient’s NAbs, we measured binding competition with envelope-specific 
monoclonal antibodies using soluble-HIV envelope as the antigenic target (Figure 4.3). Viruses 
pseudotyped with BaL envelope are highly susceptible to neutralization by heterologous sera (Li et al., 
2006b). Therefore, recombinant BaL gp120, purified from transfected CHO-K1 cell supernatants, was 
expected to bind antibodies in the patient’s plasma that did not neutralize the patient’s own virus. 
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However, by measuring competition between the patient’s antibodies and biotinylated NAbs that are 
known to neutralize diverse HIV-1 isolates, it was possible to assess relative titres of antibodies that bind 
conserved epitopes. This experiment showed competition between patient sera and antibodies b12 and 
447-52D (which targets a conformational epitope that includes a conserved GPXR motif in V3). 
Additionally, the patient’s antibodies competed with 48d in the presence of the CD4 peptide mimic 
M33, confirming that this patient had antibodies overlapping with a CD4 inducible epitope. There was 
no competition observed with 2G12, which was not surprising because carbohydrate-specific antibody 
responses to HIV-1 are rarely detected in vivo (reviewed in (Haynes and Montefiori, 2006)) (Figure 4.3). 
Conversely, antibodies targeting the CD4bs, and V3 loop are commonly detected in patients with cross-
neutralizing antibody responses (Binley et al., 2008).   
The concentration of patient serum at which NAb binding was blocked by 50% were calculated for 
serum samples collected before and after the peak in VL. This revealed a transient decline in binding-
competition with b12, 447-52D and 48d during the peak of viraemia, in accordance with decreasing 
neutralization titres detected with autologous virus and HXB2-env pseudotype (Figure 4.4). This 
confirmed that the individual had antibodies that bound to epitopes within gp120 and that HIV-1 
specific antibodies were partially depleted following rituximab therapy. In order to establish a causal 
relationship between the dynamics of the NAb response and the observed changes in VL, phylogenetic 
analyses were carried out on virus envelope sequences derived at multiple time points before and after 
rituximab therapy. The aim of these experiments was to see if transient losses of antibody-selection 
pressure affected viral evolution.  
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Figure 4.3 Antibody binding to HIV-1 envelope decreased following rituximab therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: The Env-epitope specificities of the patient’s antibodies were characterized by competitive-
binding ELISA using a panel of biotinylated NAbs: b12, 447-52D, 2G12 and 4.8d. Serial dilutions of 
patient serum (x-axes) collected on 1042 d (), 1270 d (), 1295 d () and 1353 d () post-
seroconversion were bound to gp120 and incubated with non-saturating concentrations of each NAb. 
Binding-competition corresponds to the reduction in light absorption (A450nm, y-axes) after addition of a 
streptavidin-HRP conjugate and TMB substrate. To assay binding competition with NAb 447-52D, which 
binds to a CD4i epitope, patient sera was mixed with the CD4-peptide mimic, M33. 
Figure legend  
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Figure 4.4 Antibody binding to HIV-1 envelope decreased following rituximab therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 shows the reciprocal dilutions of sera collected from the patient before and after rituximab 
therapy (grey shaded area), that reduce gp120-NAb binding by 50% (IC50, right y-axis). Titres were 
calculated from interpolations plotted against the curves shown in Figure 4.3. One hundred percent 
binding was taken as that detected in wells containing either IgGb12 (), 4.8d () or 447D () in the 
absence of patient sera. Corresponding VLs are shown by the red line (left y-axis). 
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4.3.4 Analysis of sequence evolution in HIV-1 envelope over time 
The patient’s virus was subtype B, confirmed using the REGA subtyping tool (100% bootstrap) (de 
Oliveira et al., 2005). To evaluate sequence evolution over time, partial env genes were cloned from 
amplified viral RNA derived prior to, and following, rituximab therapy (Figure 4.5A). This uncovered clear 
sequence diversification as the VL peaked after rituximab treatment. Prior to rituximab therapy the 
mean pair-wise genetic distance, calculated using the Juke-Cantor method (Section 2.27.3), was 0.004 
base substitutions per sites, which increased to 0.02 at the peak of VL (p<0.0001) (Jukes, 1969). In order 
to determine the likely genealogy of the cloned envelope sequences, a time-structured phylogenetic 
tree was constructed using a Bayesian relaxed molecular clock, and a general time-reversible model of 
nucleotide substitution (Drummond et al., 2006, Drummond and Rambaut, 2007). This showed that the 
increase in genetic distance manifested as a 5-fold increase in effective population size (Ne), as shown by 
the skyline plot in Figure 4.5B. In other words, the number of genetically distinct viruses that 
contributed to successive generations increased at a time when NAb titres were decreasing, suggesting 
that selection pressures acting on the virus were temporarily relaxed following rituximab therapy. 
An alternative explanation for the diversification of env following rituximab therapy was considered. 
Latent HIV-I is known to persist in resting CD4 T cells for several years and rates of viral evolution within 
these reservoirs are slow (Siliciano et al., 2003). However, sequences from latent reservoirs have 
increased intra-patient diversity because virus is archived at different times during infection (Nickle et 
al., 2003, Ruff et al., 2002). In this patient, high levels of HIV-1 or HBV viraemia could have resulted in 
reactivation of latently infected CD4+ T cells, which would lead to increases in viral RNA sequence 
diversity. To assess whether diverse strains represented re-emergence of archived virus we analyzed 
proviral DNA from PBMC samples available from the time of seroconversion up to day 1042 and placed 
these sequences on a time-structured tree (Figure 4.6). Viruses found post-rituximab did not represent 
re-emergence of early archived strains; those strains present as VL peaked were most-closely related to 
strains present in plasma at day 1042, with a subset related to provirus DNA detected at day 1042. 
Seemingly, quasispecies had diversified from multiple lineages that were replicating before VL increased.  
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Figure 4.5 Diversification of HIV-1 env sequences after rituximab therapy 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5A: A time-structured tree, showing divergence time estimates among intra-host plasma HIV-1 
clonal sequences before and after rituximab therapy (shaded grey), based on a Bayesian relaxed 
molecular clock applied to 969 nucleotides (Drummond et al., 2006). The external nodes represent 
sequences taken from time-points indicated by the colours given in the Figure key (inset). The topology 
is a maximal-clade credibility tree calculated using BEAST, with branch lengths proportional to time 
estimates for the subtending nodes (summarising 60 million Markov chain Monte Carlo (MCMC) 
simulations, generated after discarding 6 million as burn-in). All the parameters in the MCMC started 
from random values, except for substitution rates and population size, where priors were imported from 
the combined proviral and plasma viral sequence data of the same host calculated by BEAST software. 
Figure 4.5B. The effective population sizes (Ne) were calculated using BEAST. The x-axis (days post-
seroconversion) is the same as for Figure 4.5A (Drummond et al., 2005). 
Days post-seroconversion 
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Figure 4.6 Ancestral analyses of emerging strains  
  
Days post-seroconversion 
 
Days post-seroconversion 
 
140 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Ancestral analyses of emerging strains  
Figure 4.6A: The amino acid status change in viral Env protein at site 339, which was under positive 
selection following rituximab therapy. A time-structured maximum clade-credibility tree, showing 
reconstruction of the probable ancestral amino acid changes at Env position 339 of the plasma viral 
samples and proviral samples over time. The maximum clade-credibility tree was constructed using 
methods described in Figure 4.5A.  
Figure 4.6B: shows amino acid changes in viral Env proteins at position 363 over time (also under 
positive selection). Data are presented as described in the legend for Fig 4.6A. 
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This added credence to the argument that virus diversification had resulted from a transient loss of 
selection pressure. 
Loss of immune selection may have resulted from the observed declines in NAb titres, or decreased B 
cell support of antiviral CD4+ and CD8+ T cell responses (reviewed in (Moir and Fauci, 2009a)). It was not 
possible to delineate either of these causes from a non-specific increase in viral diversity. However, as 
VL declined and neutralizing activity rebounded, envelope sequences became less diverse and the 
effective population size decreased. If sequence changes corresponded to reapplication of antiviral 
immunity, the emerging population would be expected to bear the hallmarks of selection at epitopes 
involved in antibody or T cell recognition. This prompted a search for epitopes in Env under positive 
selection.  
Maximum likelihood phylogenetic trees were analysed using the CODEML algorithm, in order to identify 
sites under selection from rates of non-synonymous to synonymous mutations (dN/dS= ω) (Yang et al., 
2000). By this method, the goodness-of-fit of two codon substitution models were compared using a χ2-
test. The first model (M7) assumes a beta distribution of ω without positive selection, whereas the 
second model (M8) assumes a beta distribution of ω with positive selection at individual sites (ie. ω>1). 
Two sites in Env were shown to be under positive selection: Position 339 (dN/dS=7.6; p<0.0001) and 
position 363 (dN/dS=6.977, p=0.03) (Figure 4.6 & 4.7).  Interestingly, glycosylation at site 339 has 
previously been shown to affect neutralization by the carbohydrate specific antibody 2G12, while 
mutations at sites 339 and 363 have been shown to affect neutralization by the CD4bs antibody, b12 
(Duenas-Decamp et al., 2008, Duenas-Decamp et al., 2009, Scanlan et al., 2002)  
Residue 363 intersperses the β14 and β15 anti-parallel strands of gp120 and is exposed on the surface 
of the outer-domain in close proximity to the CD4 binding loop (Figure 4.8A) (Kwong et al., 1998). 
Computational modeling of atomic-level envelope structures has demonstrated that mutations proximal 
to the CD4-binding loop are critical in conferring resistance to CDbs antibodies (Wu et al., 2009). 
Furthermore, site-directed mutagenesis of site 363 has previously been shown to affect neutralization of 
the CD4bs antibody, M-14 (Zhang et al., 2004b). Prior to the first dose of rituximab (d 1042 post- 
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Figure 4.7 Tracking of selected envelope mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Stacked percentage histograms display the relative frequencies of polymorphisms at sites 
339 (top panel) and 363 (bottom panel) from historical samples and plasma samples obtained at the 
time of rituximab therapy. Each bar shows the frequency of residues at these positions. 
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Figure 4.8 Locations of selected mutations within HIV-1 envelope.  
A B 
C D 
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Figure 4.8 Locations of selected mutations within HIV-1 envelope. 
Figure 4.8A. The ribbon diagram of the gp120 core structure (Kwong et al, 1998) shows the inner, outer 
and bridging domains. The structure is in a CD4-bound and 17b-bound state. Structural data were 
obtained from the RCSB protein data bank and imported into PyMol software to generate three-
dimensional images. The α3 helix is highlighted, as are the β14 and β15 domains.  
Figure 4.8B. Site 339 (blue), is located in the α3-helix, while site 363 (pink) is located proximal to the CD4 
binding-loop (yellow).  
Figure 4.8C shows the surface composition of gp120 (light blue) in the same rotational plane as Figure A 
and B. Sites 339 and 363 are exposed on the surface of the gp120 core. Site 363 is shown in close 
proximity to the bound CD4 molecule (D1-D2; orange), while the Fab domain of 17b (purple) indicates 
the approximate location of the co-receptor binding site.  
Figure 4.8D is the same as Figure 4.8C, but rotated 80° to show the distance between residue 339 and 
the CD4bs.
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seroconversion) position 363 was occupied by an arginine in all viral RNA sequences, while all proviral 
DNA clones sampled up-to, and including, d 1042 had a glutamine at the same position. Following 
rituximab therapy, R363 variants were temporarily replaced with Q363 variants, which reverted back to 
arginine residues as NAb titres rebounded and viraemia was controlled (Figure 4.7). Prior to rituximab 
therapy, an asparagine at site 339 formed part of a possible NDT glycosylation sequon. This residue is 
located within the α3 helix, which is exposed on the surface of the protein according to atomic level 
structures (Figure 4.8B). A previous study demonstrated site 339 is involved in 2G12-binding, and also 
affects b12 binding, despite being some distance away from the CD4bs (Figure 4.8C and 4.8D) (Scanlan 
et al., 2002). No other sites in envelope were found to be under positive selection, suggesting that sites 
339 and 363, alone, conferred a selective advantage to the virus, thus leading to the founder effects 
observed in Figures 4.5 and 4.6. 
4.3.5 Neutralization susceptibility of mutated Env-pseudotypes to NAbs and patient plasma 
Although previous studies demonstrate that sites 363 and 369 are involved in NAb escape, it could not 
be assumed that different mutations at the same sites would affect neutralization of this patient’s virus 
in a similar manner. Therefore, pseudoviruses mimicking N/E339 and R363 variants were constructed by 
site-directed mutagenesis and used in neutralization assays with the patient’s serum and NAbs b12 and 
2G12. The template used for site-directed mutagenesis was envelope clone 3 derived 336 days post-
seroconversion (Rit.336d.c3), which had residues R339 and Q363 (the same clone shown in Table 4.1). 
This clone was shown to be partially susceptible to 2G12 and b12 neutralization with IC50 titres of 
3μg/ml and 5μg/ml, respectively (Figure 4.9A and 4.9B). Concentrations of 20 μg/ml of either antibody 
neutralized less than 90% of the wild type virus (IC90>20 μg/ml). Mutant N339/R363, which 
corresponded to viral RNA sequences detected immediately prior to rituximab therapy, was more 
susceptible to 2G12 (IC90 3μg/ml), indicating that this mutation introduced an N-linked glycan. The same 
mutant was less susceptible to b12 (IC50<10μg/ml) and infectivity was enhanced by 10-20% in the 
presence of sub-neutralizing concentrations of antibody (1.25 – 0.08 μg/ml) (Figure 4.9B). Mutant virus 
mimicking the majority phenotype at peak viraemia, N339/Q363, was the most susceptible to 2G12  
146 
 
Figure 4.9 Impact of selected mutations on susceptibility of the virus to neutralizing antibodies 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9A.  Cloned HIV-1 envelope derived from the patient at d 336 (pre-rituximab) was mutated at 
sites 339 and 363, which introduced the specific sequence changes observed following rituximab 
therapy (see section 2.24 for methods). Each mutant virus, along with the d336 R339/Q363 wild-type 
variant, was used in the β-Gal neutralization assay to assess the impact of the selected mutations on 
neutralization sensitivity to antibody 2G12. Pseudotyped viruses are listed below in the order that each 
mutation occurred in vivo. The percentage neutralization of each mutant is given by the y-axis. The 
asparagines at site 339 formed part of an NDT glycosylation sequon. 
 
Figure 4.9B Pseudoviruses mimicking the predominant variant immediately before peak viraemia (blue 
line; N339/Q363) were transiently more susceptible to b12 than variants present before rituximab 
therapy (purple line; N339 R363).  
 
Figure Key 
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neutralization (IC50 0.2 μg/ml).  As VL declined the majority of virus clones acquired E339 and R363 
mutations, which further reduced susceptibility to both NAbs. Twice the concentration of d1042 serum 
was required to neutralize 50% of the E363/R363 mutant in comparison to wild-type d 336 Env-
pseudotype (IC50 1:600 vs. 1:300) (Table 4.1). Thus, env mutations were selected over time that modified 
sensitivity to neutralizing antibodies, and to the patient’s own plasma. Importantly, these mutations 
were temporally associated with a transient loss of viral control and reciprocal changes in antibody 
titres, indicating that NAbs contributed to the control of VL in this patient. 
4.3.6 Mutant Env-pseudoviruses exhibited similar levels of infectivity after correction for RT activity 
Intra-host diversity of HIV-1 envelope can affect virus infectivity (Nora et al., 2008), which could lead to 
selection by antibody-independent mechanisms. Therefore, the infectious titres of the mutant 
pseudoviruses were compared using the β-Gal infectivity assay. Initial titrations of mutant N339/R363 
revealed an infectious titre that was 1.8-fold higher than wild-type virus (R339/Q363). However, it was 
not clear whether this resulted from the mutations in envelope or from higher concentrations of virions 
harvested from transfected 293T supernatants.  
In order to standardize the concentration of pseudovirus particles prior to titration, RT activity was 
measured using the SG-PERT assay that was developed as part of a separate study, led by Dr Masssimo 
Pizzato in collaboration with the candidate (Pizzato et al., 2009) (see section 2.25). Retrovirus particles 
are quantified from levels of reverse transcribed BMV RNA (cDNA) using SYBR Green II-quantitative PCR. 
The quantitation standard (QS) for the assay consisted of an HIV-1 nl4-3 virus, previously shown to 
contain 355 ng/ml p24, 136 ng/ml RT and 11.6 × 109 HIV-1 RNA copies/ml (see (Pizzato et al., 2009) for 
details). Ten-fold dilutions of the standard revealed that levels of fluorescence tended to plateau 
prematurely after approximately 25 PCR amplification cycles (Figure 4.10A and 4.10B). This resulted in 
an amplification efficiency of 1.585 as determined from the slope of the standard curve (optimal 
efficiency = 2) (Figure 4.10C). Because differences in the infectious titres of the mutant pseudoviruses 
were subtle, the SG-PERT assay was first optimized before it was used to quantify RT activity in virus-
containing supernatants. 
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Figure 4.10 Optimization of the SG-PERT assay for the quantification of pseudovirus particles 
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Figure 4.10 Optimization of the SG-PERT assay for the quantification of pseudovirus particles 
The SG-PERT assay was used to compare efficiencies of RT-PCR amplification of BMV RNA using primers 
BMV131/BMV129  (left panels) and BMVF1/BMVR1 (right panels) with virion derived HIV-1 RT.Tenfold 
dilutions of nl4.3 virus were lysed then incubated with reaction mixes containing Taq polymerase and 
BMV RNA for 30 min to allow HIV-1 RT to reverse transcribe a BMV RNA template. The cDNA product 
was the quantified by SG-quantitative PCR. For primer sequences see Table 2.1 (Materials and 
Methods). 
Figure 4.10A: Primers 129/131 produced amplification curves that plateaued prematurely in reactions 
containing low concentrations of virus (1:104, dashed line). Blue lines show amplification of DNA product 
in the absence of HIV-1 RT (negative control) 
Figure 4.10B: The amplification cycle at which fluorescence exceed background levels recorded prior to 
PCR amplification (crossing points) was calculated by the LightCycler software from log fluorescence 
recorded for each reaction. 
Figure 4.10C: Crossing-points were used to construct standard curves. The co-efficients of the 
logarithmic regression lines represent the amplification efficiencies of each primer set 
(BMV129/BMV131=1.5861, BMVF1/BMVR1 = 1.8645) 
Figure 4.10D: Melting peaks of the final amplified products reveal two products in the reactions with 
primers BMV129/BMV131 and only one product in reactions with primers BMVF1/BMVR1. 
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Poor amplification efficiency could have been due to waning activity of Taq polymerase, degradation of 
other heat labile components within the reaction mixture, or sequestrations of reaction components 
within non-BMV specific amplifications. Non-specific products of amplification were identified by 
analyzing melting curves of the final PCR product. Negative-first-differential fluorescence, plotted 
against temperature, revealed two distinct melting peaks (Figure 4.10 D), which was consistent with the 
formation of primer-dimers.  
Secondary structure predictions using the NetPrimer online tool (http://www.premierbiosoft.com/) 
identified five self-dimerising structures for forward primer BMV131 and three cross-dimers with primer 
BMV129. Three of these structure predictions had 3’ recesses that would facilitate polymerase 
extensions and cause destruction of BMV-primer specificity. Primers were redesigned with the intention 
of eliminating all possible secondary structure formations. Primer-dimers were not detected using the 
modified primers (BMVF1/BMVR1), and the amplification curves did not plateau at low concentrations 
of virus. Additionally, the amplification efficiency increased from 1.585 to 1.86 (Figure 4.10 A-D). This 
suggested that eliminating the formation of primer dimers had the effect of reducing competition for 
PCR reagents within each reaction, thus allowing reliable detection of low levels of HIV-1 RT. However, 
the extra sensitivity afforded by the optimized primer set increased background detection of BMV 
amplified product in the absence of HIV-1 RT. This has previously been attributed to RNA-dependent 
DNA polymerase activity of the Taq enzyme which reverse transcribes BMV-RNA during PCR 
amplification cycles (Maudru and Peden, 1997). This was not considered to be a confounding factor 
because DNA product amplified in the absence of HIV-1 RT was not detected until after the 33rd 
amplification-cycle.  
The modified SG-PERT assay was used to compare RT activity in mutants R339/Q363, N339/Q363 and 
E339/R363. Mutant N339/Q363, was constructed at a later time point and was not assessed in this 
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experiment. The amplification cycles at which amplified BMV DNA products were detected (crossing 
points) were 15.0, 15.3 and 16.4 for mutants N339/R363, E339/R363 and R339/Q363, respectively 
(Figure 4.11A). These crossing-points corresponded to the following concentrations of RT, determined 
from the standard curve shown in Figure 4.10 C (BMVR1/BMVF1 primers): 26.8 ng/ml (N339/R363), 
22.85 ng/ml (N339/R363), 12.7 ng/ml (R339/W363). Therefore, the concentrations of reverse 
transcriptase detected in virus N339/R363 were 2.1-fold higher than that of the wild-type virus 
R339/Q363. After normalizing the concentrations of RT for each mutant and the wild type virus the 
resulting infectious titres, as assessed in the TZM-bl infectivity assay, ranged from 3.3x103 – 3.7 x103 
IU/ml (Figure 4.11B). Subsequently, supernatant fluid containing mutant N339/Q363 was shown to have 
an RT concentration of 17.3 ng/ml and produced an infectious titre of 3.0x103. The difference between 
the highest and lowest infectious titre (N339/R363 and R339/Q363) was not significant because the 
coefficient of variation of the SG-PERT assay was previously calculated at 4.1-7.6%. These data suggest 
that the envelope mutations observed following rituximab therapy did not affect virus infectivity.  
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Figure 4.11 Impact of selected mutations on pseudovirus infectivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 4.11A Supernatant harvests were assayed for reverse transcriptase activity by SG-PERT. The 
fluorescent signals (y-axis) correspond to quantities of reverse-transcribed, PCR-amplified BMV RNA 
template, which are proportional to concentrations of RT from lysed pseudovirus particles. Supernatants 
were assayed undiluted and diluted 1:10 in tissue culture medium. Mutants R339/Q363, N339/Q363 
and E339/R363 are show with the same colour scheme used in Figure 4.11B.  
 Figure 4.11B. Concentrations of RT detected in each supernatant were normalized prior to titration 
onto TZM-bl cells. Titres of each mutant virus are shown by the y-axis. 
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4.3.7 Analysis of CTL responses prior to Rituximab therapy 
Other possible causes for the clinical findings of this case were considered, particularly the possibility of 
an indirect impact on cellular immunity. The patient was found to be homozygous for HLA Class IB allele 
B0801 and heterozygous for Class IA alleles A0101 and A1101. Four A1101-restricted, optimal epitopes 
and six B0801-restricted optimal epitopes were identified from HIV-1 sequences published in the Los 
Alamos Database (www.hiv.lanl.gov). Six of these were in Gag, one was in Pol and three were in Nef. 
Peptides corresponding to these epitopes were designed to match the consensus sequence of the 
patient’s virus, assessed 20 days after diagnosis of HIV-1 seroconversion. Each peptide was used in an 
IFNγ-ELISpot assay to assess CTL responses using PBMCs collected from the patient 1 year post-
seroconversion and immediately prior to rituximab. Responses directed at three epitopes in Gag and 
one in Pol were detected 1 year post-seroconversion; only two of these (both in Gag) were detected 
prior to the first dose of rituximab, three years after seroconversion (Table 4.4).  
Viral gag pol and nef genes were sequenced at d 20, d 1042 and d 1353 post-seroconversion. At day 
1042 post-seroconversion, this patient had an N242T mutation in Gag that was not detected at d 20. 
This mutation is known to confer susceptibility to CTL responses in patients with HLA B57 alleles. It is 
possible that this mutation represents reversion to a fitter virus phenotype following virus transmission 
from an HLA B57 positive donor (Navis et al., 2008). Mutations were detected in five epitopes that were 
relevant to the patients HLA class I phenotype. Two of these mutations corresponded to epitopes that 
elicited autologous CTL responses one year post seroconversion, but not immediately prior to rituximab 
therapy. Importantly, none of the observed mutations were temporally associated with the VL changes 
observed following rituximab therapy. From these data we concluded that CTL escape was not 
responsible for the sequence changes observed following B cell depletion. However, PBMCs were not 
available to assess T cell function at the peak of VL. Although loss of T cell function secondary to B cell 
depletion, may have contributed to increases in VL, this would not result in the envelope-sequence 
changes observed at this time (Table 4.4). 
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Table 4.4 Analysis of CD8+ T cell responses and epitope evolution over time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4 CD8+ T cell responses were analysed by IFN-γ -ELISpot analysis against a panel of HLA-
restricted autologous peptides (spot forming units/million PBMCs are shown). The patient’s HLA Class IA 
and Class IB genotypes were shown to be A0101, A1101 and B0801 homozygous (Section 2.28). 
Sequencing of the corresponding peptides was carried out at the time-points shown, and mutating 
residues have been underlined. The results reveal that pre-rituximab there were two main T cell 
responses detectable, neither of which showed evidence of immune-escape throughout the rituximab-
induced viral flare and recovery period.  
Gene
Autologous 
Sequence  
Pre-Rituximab Post-Rituximab  
Pre-Rituximab 
Year 1
Pre-Rituximab 
Year 3 
A1101 gag TLYCVHQK K8N Q7A 1200 -
A1101 pol ACQGVGGPGHK - G9A 300 -
A1101 net QVPLRPMTYK - - - -
A1101 pol AIFQCSMTK - - - -
B0801 gag GGSKKYQLK K3R/K7Q K3R/K7Q - -
B0801 gag ELKSLYNTV - - 160 200
B0801 gag DIYKRWII - - 640 600
B0801 gag DCKTILKAL - - - -
B0801 nef WPKVRERM K3G/E6D K3R - -
B0801 nef FLKEKGGL K5Q K5Q - -
(B57) * gag TSNLQEQIGW* N3T (242)* N3T (242)* - -
IFN‐γ response (SFU/106 PBMC)Epitope  
Patient HLA 
Mutation
nef 
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4.3.8 Impact of rituximab monotherapy on HBV co-infection 
Immune activation through recrudescence of other infectious agents may play a role in this case. 
Concurrent with the VL rise, the patient developed elevated levels of ALT which is released from 
damaged hepatocytes.  This was associated with reactivation of the patient’s HBV infection, which was 
confirmed by detection of HBV surface antigen (HBsAg) and HBV nucleocapsid (HBeAg) proteins that 
were previously undetectable. This is consistent with a previous report of reactivating HBV infections 
following rituximab therapy (Garcia-Rodriguez et al., 2008). Prior to rituximab, HBV DNA was not 
detectable, but following the final dose of rituximab, HBV VL increased to 6x106 copies per ml (Figure 
4.12).  As shown in Table 4.1, changes in HBV viraemia were associated with reciprocal changes in 
antibody titres to HBsAg which declined to undetectable levels (<1 IU/ml) at the peak of viraemia. 
Importantly, HBV VL remained high as control of HIV-1 VL was regained. This dissociation between HIV-1 
VL and HBV VL suggests that HBV replication was not responsible for the decrease in HIV-1 VL, or the 
sequence changes observed in Env. However, it is possible that reactivation of HBV infection observed 
following rituximab therapy contributed to the initial flare in HIV-1 VL. 
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Figure 4.12 Clinical course of HIV-1, HBV and ALT in relation to Rituximab therapy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Plasma VL of HIV-1 and HBV, and the liver function marker, ALT, were quantified in clinical 
laboratories at St Mary’s Hospital. Values are displayed over time (days post-seroconversion) and the 
time of rituximab therapy is indicated by the grey shaded area. The left y-axis corresponds to HBV VL 
(DNA copies /ml) and HIV-I VL (RNA copies /ml). The right y-axis shows quantities of ALT, which is an 
indicator hepatocyte damage. 
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4.4 Discussion 
 
Rituximab therapy was used to treat a rising IgM-κ light chain paraproteinaemia in a patient who was 
also co-infected with HIV-1 and HBV. Following B cell depletion, the patient’s VL increased concurrent 
with decreases in total IgG levels and HIV-1 neutralizing activity. Recovery of NAb titres coincided with 
control over viraemia. Multiple analytical techniques were employed to characterize the virus 
population that was selected as NAbs re-emerged. Emerging virus was defined by polymorphisms at two 
residues exposed on the virus envelope, both of which showed evidence of positive selection. These 
data led a strategy of mutagenesis which confirmed that the sequence changes detected affected 
susceptibility to neutralizing antibodies targeting the CD4bs. In short, all avenues of this investigation 
contributed to a coherent picture consistent with the hypothesis that NAbs played a major role in 
containing HIV-1 in this individual. 
It was not surprising that this patient had antibodies targeting the CD4bs and V3 loop as these are 
frequently detected in chronically infected individuals (Binley et al., 2008, Scheid et al., 2009). 
Competitive-binding experiments were conducted with heterologous BaL envelope glycoprotein, so the 
titres reported may not reflect levels of antibody binding to autologous virus. This patient’s virus was 
generally resistant to b12 neutralization as demonstrated by the fact that microgram quantities of 
antibody failed to neutralize more than 60% of wild type or mutant viruses and lower concentrations of 
antibody actually enhanced infectivity of the N339/R363 mutant. Antibody mediated enhancement of 
infectivity has been reported and is associated with sub-neutralizing concentrations of antibody 
(reviewed in (Burton et al., 2001)). Approximately 25% of clade B field isolates are resistant b12 (Binley 
et al., 2004, Li et al., 2005, Moore et al., 1995). However, mutations detected at site 363 resulted in 
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modest changes to b12 neutralization sensitivity, suggesting that antibodies targeting the CD4bs were 
partly responsible for driving viral evolution in this case.  
Residue 363 is adjacent to the CD4 binding loop and a recent structural study demonstrates that 
residues proximal to the CD4 binding loop are important in conferring resistance to b12 and b12-like 
antibodies (Kwong et al., 1998, Wu et al., 2009). Sites surrounding the CD4bs are more amenable to 
sequence variation because they have greater structural plasticity than conserved sites directly involved 
with CD4 binding (D'Costa et al., 2001).  Mutations at site 363 have been shown to confer resistance to 
the CD4bs antibody M-14 (Zhang et al., 2004a), so it is likely that this patient had antibodies targeting 
epitopes that included this residue. However, it is unclear how this residue affects neutralization by b12, 
because site 363 resides outside the b12 binding site (Zhou et al., 2007). Previous studies have also 
implicated this residue in resistance to b12. Duenas-Decamp et al. showed that P363Q mutations 
cooperate with S364P mutations to confer partial resistance to b12, yet P363Q alone had minimal effect 
on neutralization sensitivity (Duenas-Decamp et al., 2008, Duenas-Decamp et al., 2009). In this study we 
observed a transient arginine to glutamine mutation at residue 363 that effectively removed a positive 
charge at this site. This may have affected neutralization through interactions with other charged 
residues residing within the b12-binding site, or alternatively, these mutations may have altered local 
conformation at the antibody binding site and changed the shape-complementarity of the 
epitope/paratope interface (Lawrence and Colman, 1993) and reviewed in (Epa V.C. and Colman P.M., 
2001). 
Immediately prior to the first dose of rituximab there was an absolute discrepancy between proviral 
DNA and contemporaneous viral RNA sequences: All of the proviral DNA sequences had a glutamine at 
position 363 (n=12), while all of the viral RNA sequences had an arginine at the same position (n=12). 
Compartmentalization of distinct virus populations has been suggested as a possible explanation for 
159 
 
similar discrepancies between proviral DNA and viral RNA (Simmonds et al., 1991). However, this is 
unlikely as there was some overlap in the phylogeny of variants R363 and Q363 (Figure 4.6). An 
alternative explanation is that virions may have been sampled immediately after selection of R363 
variants, before Q363 HIV-1 infected cells had died off. Therefore, it is possible that this patient had 
recently mounted an effective neutralizing response prior to rituximab-therapy and this may have 
contributed to the near log-fold decline in VL between d 995 and d 1042. However, this cannot be 
confirmed because serum was not available to assess neutralization prior to d 1042. 
Relaxation of antibody selection pressure is likely to have decreased levels of purifying selection, thus 
increasing the effect of random genetic drift leading to diversification of the virus and increased Ne 
population size (Shriner et al., 2004). Alternatively, previously acquired antibody-escape mutations that 
incurred fitness costs to the virus may have reverted in the absence of antibody selection pressure 
leading to increased replication rates of individual variants. When antibodies returned, mutants carrying 
reversion type mutations conferring neutralization susceptibility would have been lost, which could 
explain why VL subsequently decreased to such low levels (175 RNA copies per ml). Previous studies 
have suggested that antibody escape does not impact on replicative fitness detected in vitro (Bunnik et 
al.,)2010), and the mutations observed in this study did not significantly impact on TZM-bl infectivity. 
However, pseudovirus infectivity assays are not entirely suitable for investigating viral fitness because 
the envelope composition of pseudotyped virions differs from that of wild type virus (Louder et al., 
2005). It is, therefore, not clear whether the transient reversion of R363Q detected at peak viraemia 
affected viral fitness.  
Pseudotyped viruses with N339 mutations were more susceptible to 2G12 neutralization indicating that 
this site was glycosylated. It is not surprising that mutants lacking this NDT sequon remained partially 
susceptible to 2G12 because other N-linked glycosylation sites were present elsewhere in Env. 
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Mutations at residues 339 was not related to the transient loss of viraemia control because the R339N 
mutation occurred prior to rituximab therapy and the N339E mutation was not detected until peak VL 
had fallen. Nevertheless, glycosylation at this site may have contributed to neutralizing antibody 
resistance by shielding the conserved receptor binding sites (Koch et al., 2003, Li et al., 2008). Previous 
studies have demonstrated that site 339 can impact on b12 neutralization, despite being distal to the 
CD4bs (Scanlan et al., 2002).  
Rituximab is commonly given to HIV-1 infected humans to treat lymphoma arising as a complication of 
late-stage HIV infection, whereas in this case, lymphoma preceded acquisition of HIV.  Under normal 
circumstances antiretrovirals are routinely given, which would confound attempts to assess the impact 
of rituximab on HIV-1 VL. For this reason there are no published studies on the impact of rituximab in 
HIV-1 infection. Studies of acute SIV infection in macaques treated with rituximab indicate a role for NAb 
responses in containing post-acute VL (Miller et al., 2007, Schmitz et al., 1999). In contrast, a recent 
study of African Green monkeys did not reveal any impact from rituximab treatment during acute SIV 
infection (Gaufin et al., 2009). Moreover, the aforementioned animal studies initiated rituximab 
treatment before or immediately following virus inoculation. Future primate studies might investigate 
the effects of administering rituximab after NAb responses are detected. 
The individual in this study received three months of ART started during his seroconversion illness. There 
is an association between rebounding NAb responses and viraemia control after ART-cessation 
(Montefiori et al., 2001, Montefiori et al., 2003). Early therapy may preserve numbers of B cells that are 
critical for NAb development, yet irreversibly depleted during untreated PHI (Titanji et al., 2005, Hart et 
al., 2007). Further investigations of NAb responses following early short-course therapy are warranted 
and will be discussed in chapter 5. 
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Given the unusual clinical nature of this case, is it likely that the effects of rituximab would be similar in 
the majority of HIV-1 infected patients? Prior to rituximab therapy, evolution of Nab responses and virus 
envelope sequences followed a typical pattern, resulting in modest neutralizing serum titres against 
autologous-contemporaneous virus, yet stronger responses against earlier strains (d1135 vs. d336; Table 
4.2). Further analysis of the ability of this patient’s serum to neutralize a panel of diverse strains 
revealed that the Nab activity was broadly directed (Table 4.3), although with average titres compared 
to other studies (Mahalanabis et al., 2009a, Sather et al., 2009, Binley et al., 2008). Thus, antiviral 
activity mediated by such a response may not be untypical.  
It is possible that depletion of B cells had an indirect impact on VL through modulation of CD4+ or CD8+ T 
cell subsets. While we cannot exclude this, the mechanism for such an indirect effect is not clear and no 
impact on CD8+ T cell responses has been observed in the SIV models quoted above (Miller et al., 2007). 
The delay of several weeks that is seen between rituximab treatment and the change in VL is consistent 
with the observed decline in antibodies, which have a half life of approximately 21 days (Morell et al., 
1970). Conversely, disrupting direct B cell/T cell interactions would be expected to take effect 
immediately. Additionally, changes in the prevailing sequences (ie. reversion and subsequent re-
selection of a mutated NAb epitope) are consistent with relaxation and reapplication of NAb-mediated 
selection pressure. 
Declining antibody responses have not been reported by all human and animal studies of rituximab-
mediated B cell depletion (reviewed in (Lund and Randall)), which does not deplete CD20- long-lived 
plasma cells (Ahuja et al., 2008). However, rituximab therapy will prevent de novo production of 
antibodies, which probably led to declining antibody titres in this case, particularly as B cells of HIV-1 
infected individuals have relatively short half lives (Moir et al., 2004). In order to match rapid rates of 
virus evolution, the antibody response must evolve in parallel (Richman et al., 2003). Therefore, B cell 
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depletion may have preferentially depleted (or prevented) HIV-1 specific antibody responses that were 
most relevant to virus circulating at the time of rituximab therapy.  
The impact of T cell responses on the control of VL is highly variable, with possession of the most 
favourable HLA allele (B57) delivering a mean affect on VL to the order of one log (Kiepiela et al., 2004). 
Additionally, subsets of elite controllers have been shown to have strong functional CTL responses 
directed at sites in HIV-1 Gag (Betts et al., 2006, Emu et al., 2008, Migueles et al., 2002, Sarez-Cirion et 
al., 2007, Streeck et al., 2008, Pereyra et al., 2008b, Potter et al., 2007). Although NAbs are low or 
absent in some elite controllers with detectable CTL responses, there is no evidence to suggest that T 
cell responses control VL independently of humoral immune system in the majority of cases. Likewise, it 
is not suggested that T cell responses were absent in this patient, particularly as sequence changes were 
detected at known HLA restricted epitopes prior to rituximab therapy. However, this individual did not 
have a B57 allele or any other HLA-type associated with HIV control, and it may be that the absence of 
an effective CD8+ T cell response allowed us to detect a NAb effects on VL. 
The impact of other reactivating viruses on HIV-1 load is complex. Rituximab treatment has been shown 
to reactivate hepatitis B virus (HBV) (Aksoy et al., 2007) in patients with previously controlled infection 
(HBsAg-ve, HBcAb +ve). This implicates B cells in long-term control of HBV; a virus where CD8+ T cells 
also play an important role in acute disease. The relationship between HBV VL and HIV VL is not fully 
understood, but overall they appear to be independent (Rockstroh, 2006). In this case HBV and HIV VL 
rose within a similar timeframe. However, HIV-1 load was brought under control, while HBV load 
remained high, indicating that they were differentially regulated.  
Overall, our findings support previous suggestions of paralleled evolution of virus and NAbs (Richman et 
al., 2003, Frost et al., 2005a). The speed and extent to which quantitative changes occurred following 
rituximab therapy, not only to the virus, but also to the evolving antibody response, are testament to 
the fragility of this balance. These findings appear at odds with previous studies that fail to confirm an 
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association between long-term virus control and Nab responses (Bailey et al., 2006, Bradney et al., 1999, 
Deeks et al., 2006c), but these studies have focused on patients with either strong or poor HIV-1 control, 
in whom other factors (such as T cell response) may be more important.  
Cross-sectional studies of VL set-point and neutralizing activity are unlikely to confirm or refute the 
findings we report here because they overlook the dynamic complexity of the virus/host interaction. 
Modest NAb activity contributed to VL control in this patient, which implies that serum titres may be 
ineffective at gauging the clinical impact of NAbs. Furthermore, VL set-point may not be the most 
informative marker of viraemia control. Notably, VL remained above 105 copies per ml for more than 
two years prior to rituximab, despite strong evidence that antibodies subsequently controlled viral 
replication. Therefore, there is a need to assess both neutralizing titre and the continuously adapting 
virus in evaluating their overall relationship in vivo. Questions relating to the generaliseability of this 
case might be answered by longitudinal analyses of NAb response and virus evolution in subjects 
exhibiting significant changes in VL under other clinical circumstances.   
This unique case study suggests that B cells, and their secreted NAbs, can impact upon HIV VL in chronic 
infection. This evidence, derived directly from observations in man, may inform the rational design of 
future immunotherapies and HIV-vaccines.  
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Chapter 5 
 
The neutralizing response to HIV-1 following short course 
antiretroviral therapy in PHI 
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5.1 Introduction 
Chapter 4 provided evidence for antibody-mediated control of HIV-1 VL in a single patient. However, 
there were several irregularities with this case, so it was necessary to investigate the importance of 
NAbs under more-typical circumstances.  
Broadly-specific NAb activity has been detected in a minority of patients with suppressed viraemia and 
there is circumstantial evidence supporting a protective role for NAbs in control of VL set-point (Doria-
Rose et al., 2009, Mahalanabis et al., 2009b, Deeks et al., 2006a, Richman et al., 2003, Rong et al., 2009, 
Wei et al., 2003). The most convincing of these demonstrate antibody-selection of neutralization-
resistant viruses (Richman et al., 2003, Rong et al., 2009, Wei et al., 2003). Envelope mutations that 
confer antibody-resistance become fixed in HIV-1 quasispecies as early as 12 weeks after transmission, 
implying that humoral responses can eliminate neutralization-sensitive founder populations 
(Goonetilleke et al., 2009). Sequential rounds of selection could feasibly contribute to control of VL, yet 
several cross-sectional studies have failed to identify clinical correlates of NAb activity detected in vitro 
(Bailey et al., 2006, Euler et al.).   
Passive transfusions of NAbs in macaques challenged with SHIV were shown to lower VL and delay early 
disease onset (Haigwood et al., 2004, Mascola et al., 2000). In humans, passive transfusion of NAbs and 
natural antibody responses may delay viral rebound after structured interruptions of ART (Montefiori et 
al., 2001, Trkola et al., 2004, Trkola et al., 2005). However, studies of treatment interruption in chronic 
infection are confounded by pre-existing antibody responses and immune-escape variants present pre-
ART. Additionally, antiviral effects of NAbs are masked by the inter-dependence of Env-antigen load with 
antibody production. By contrast, studies of recently infected individuals undergoing treatment 
interruption are potentially more straightforward because the duration of antigen exposure is short and 
the clinical history is known.  
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The SPARTAC clinical trial considers the long-term impact of structured-intervention with short courses 
of ART administered during PHI. This international randomised-controlled trial compares the effect of 
ART taken for 48 weeks or 12 weeks with a no-intervention arm. Upon ceasing therapy, all patients 
continue to have regular blood samples taken with VL and immunology assessments. This trial provided 
a valuable platform for a longitudinal study of early antibody responses and the associated kinetics of 
VL, which rebound after discontinuing ART. 
Following the termination of ART, autologous Env-pseudotyped viruses were used to assess neutralizing 
responses with the β-gal-based microneutralization assay described in chapter 4.  The extent of 
neutralizing activity detected against autologous viruses positively correlated with VL, yet within the 
same system, delayed viral rebound was observed in those patients with detectable responses 
immediately post-ART. There was no evidence for NAb-mediated control after viral-rebound. However, 
the dynamic inter-dependency of neutralizing titre with viraemia helps to explain the limitations of 
cross-sectional analyses as a means of assessing the role of NAbs in vivo. 
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5.2 Results 
5.2.1 Patient demographics 
A total of 43 individuals were recruited from the SPARTAC cohort. All patients received either 12 weeks 
or 48 weeks ART following diagnosis of PHI and were selected for study on the basis of partial or 
complete VL suppression while on therapy. Those patients with CD4 counts that fell below 350 cell/mm3 
within 48 weeks of stopping primary ART were started on long-term ART and were excluded from this 
sub-study, so that neutralizing responses could be assessed from plasma samples that did not contain 
antiretroviral drugs. Most patients (32/43) presented with one or more symptoms characteristic of PHI. 
Seventeen patients had a non-specific, flu-like or glandular fever-like illness, with fever and rash being 
the commonest specific symptoms. The following criteria were used to confirm PHI:  i) positive HIV-1 
serology following a negative test within 6 months, ii) low level “incident” result (<0.6) using a detuned 
HIV-1 ELISA, iii) rising antibody levels detected by progression of protein bands on Western blot, or iv) 
positive HIV-1 proviral PCR or p24-antigen ELISA in the absence of HIV-1 specific antibodies (Fidler et al., 
2002). The median duration of infection prior to the first dose of ART was 12 weeks (inter-quartile range 
(IQR): 8.8-14.3 weeks) (Table 5.1). 
Most patients were European males of median age 35 (n=33, IQR: 32 – 40), while ten patients were 
South African females recruited at a median age of 28.5 (IQR: 21.75 – 38.5). All the men were infected 
with HIV-1 subtype B and the women with HIV-1 subtype C. This bias was unintentional and reflects the 
high rates of male to male transmission of HIV-1 subtype B in Europe and the high prevalence of subtype 
C infections in women living in Sub-Saharan Africa (UNAIDS, 2008 report) (Garcia-Calleja et al., 2006). 
There was no significant difference in baseline log10 VL between males and females (Mean ± SD, 4.6  ± 
1.0 vs. 4.3 ± 0.8, P=0.3, student t-test)  (Figure 5.1).  Females infected with subtype C virus had 
significantly fewer CD4 T cells at enrolment into the trial compared with males infected with 
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Table 5.1 Patient demographics and clinical manifestations during PHI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1. Details are shown for 43 patients undergoing assessment of neutralizing antibody activity 
against autologous and/or heterologous viruses. Clinical data were collected upon enrolment to the 
SPARTAC clinical trial prior to the first dose of ART. 
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Figure 5.1 Pre-ART CD4 counts and VLs were not significantly affected by gender or HIV-1 subtype 
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Figure 5.1 Viral load (top panel) and CD4+ T cell counts (bottom panel) recorded at enrollment into the 
SPARTAC trial (baseline)  are shown for European males infected with HIV-1 subtype B (grey boxes) and 
South African females infected with HIV-1 subtype C (white boxes). Boxes show the interquatile ranges 
and the verticle lines extend to the minimum and maximum values. Median values are shown as 
horizontal lines within each box. Data are shown for all 43 patients and the 22 patients for whom 
autologous neutralizing responses were assessed. 
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subtype B virus (Mean ± SD, 518 ± 106 vs. 651 ± 19, student t-test, P=0.04). From these forty-three 
patients, sixteen men and six women were selected for neutralization studies with autologous viruses 
(n=22). The women in this smaller subset of patients had lower baseline CD4 T cell counts (P=0.2) and 
Log10 VL (P =0.12) than the men although the differences were not statistically significant (Figure 5.1). 
In accordance with previous studies, chronic VL set-points were calculated from geometric means of 
log10 VL measurements assessed longitudinally, starting 40 weeks after treatment cessation (the longest 
period observed before vireamia reached steady state levels) (Hollingsworth et al.)2010). The males had 
significantly higher VL set-points than the females (3.4 ± 0.6 vs. 4.5 ± 0.7, P=0.002) (Figure 5.2). Viral load 
set-points were used to assign patients to three groups: Low level viraemia (n=10 VL <3 log10 RNA copies 
per ml), intermediate viraemia (n=8 VL 4-5 log10 RNA copies per ml) and high level viraemia (n=4 ,VL >5 
log10 RNA copies per ml). These groups were chosen to represent a diverse range of VL set-points and 
were used to compare the neutralizing activity of patient’s plasma against autologous Env-pseudotyped 
viruses and against a panel of heterologous Env-pseudotyped reference strains. 
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Figure 5.2  Men infected with subtype B virus had higher VL set-points than women infected with 
subtype C virus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Viral load set-points were calculated from mean Log10 VL measurements assayed every 4-12 
weeks from 40 weeks after ART cessation. Boxes show the IQ ranges and the vertical lines extend to the 
minimum and maximum values within each patient group. Data are shown for twenty-two patients who 
were assessed for levels of autologous neutralization. Grey boxes show VL set-points for men (n=16). 
White boxes show VL set points for women (n=-6).  
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5.2.2 Neutralizing responses were variably detected within 4-12 weeks of stopping ART. 
In order to assess neutralization after the cessation of ART, virus pseudotyped with cloned envelopes 
were neutralized with contemporaneous-autologous plasma (n=22). Plasma collected from 11 patients 
after 4 weeks was used for HIV-1 envelope cloning, but due to difficulties in amplifying env from plasma 
containing low quantities of virus (≤ 50 RNA copies per ml in some cases), plasma collected after 12 
weeks post-ART were used in the remaining 11 cases (see section 3.2.1). Importantly, 
contemporaneous-neutralizing plasma titres sampled at week 4 and week 12 were not statistically 
different (Mean IC50 ± SD; wk 4  31.0 ± 24.0 vs. wk 12 43.2 ± 49.4, p=0.52, unpaired student T test) (Table 
5.2).  
Plasma neutralized Env-pseudotyped viruses in a concentration-dependent manner and virus infectivity 
was not inhibited by pooled plasma collected from HIV-1 uninfected individuals. Furthermore, patient 
plasma did not inhibit a VSV-G pseudotyped NL4-3env virus, ruling out neutralization by residual 
concentrations of ART (Figure 5.3). From these data it was deduced that neutralization was HIV-1 Env 
specific and, therefore, antibody-mediated. 
Approximately half of the patients (12/22) had no detectable neutralizing activity against their 
contemporaneous virus (IC50<20) and the majority of these patients (10/12) developed low VL set-points 
(group 1: VL <4 log). In contrast, eight of the remaining ten patients, who had detectable levels of 
neutralization immediately post-ART (IC50 1:20 to 1:153), developed VL set-points greater that 10
4 RNA 
copies per ml (Figure 5.4A) (p=0.04, independent T-test). Prolonged exposure to high levels of Env-
antigen are known to stimulate the production of NAbs, but it was not clear why high VL set-points were 
associated with preceding neutralizing responses.  
It was hypothesized that antibody responses were primed prior to the initiation of ART. Hence, the 
extent of viraemia and the duration PHI prior to ART would be expected to influence post-ART NAb  
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Table 5.2 Half maximal neutralizing titres of patient sera tested with autologous Env-pseudotypes  
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2 Reciprocal plasma-titres that reduced autologous-Env pseudovirus infections by half (IC50) are 
shown. Potent neutralizing responses are indicated by darker shades of grey. Patients are shown in 
ascending order of VL set-point calculated from 40 weeks post-cessation of ART. (*) denotes neutralizing 
response tested with virus and plasma from the same time points. All other plasma were tested against 
the same “earlier” pseudovirus. Patients S7, S14, S35, S132 were not tested regularly owing to limited 
availability of plasma. Titres reported as “<20” inhibited less than 50% of virus infections at the highest 
plasma concentration tested (1:20). The amino acid sequence of the conserved V3 crown motif is shown 
in column 3.  
NS 
 48 
Patient 
HIV-1 
clade 
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Figure 5.3: VSV-G pseudotyped virus was not neutralized by patient plasma  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Virus pseudotyped with VSV-G was incubated with 1:20 dilutions of patient plasma for 1 hour 
before titrating onto TZM-bl reporter cells. Plasma derived from patients S7, S14, S35 and S132 was 
tested. Images show FFU detected by X-Gal staining and counted using an AID ELISpot reader. The 
number of infected cells counted by the ELISpot reader software is shown below each figure. The image 
on the far right shows FFU produced by VSV-G pseudotyped virus in the absence of plasma. 
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Figure 5.4:  VL detected during PHI correlated with chronic VL set-points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4A: Patients with detectable NAb responses after ART-cessation went on to develop 
significantly higher VL set-points compared to patients with undetectable NAb titres (reciprocal IC50<20).  
Figure 5.4B: patients with detectable NAb response tended to have higher VL prior to the first dose of 
ART (Not statistically significant). Figure 5.4C: Post-ART VL set-points correlated with single VL 
measurements recorded pre-ART (linear regression with F-test). 
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levels. This could explain the association between NAb responses and subsequent VL set-points, because 
prolonged seroconversion illnesses, characterized by high levels of viraemia, have been associated with 
high VL set-points at later stages of infection (Madec et al., 2005b, Mellors et al., 1995). In fact, VLs 
assessed prior to the first dose of ART were approximately 0.5 log higher in patients with post-ART 
neutralizing activity than patients without detectable responses, although there was considerable 
variation in both groups and the difference was not statistically significant (mean ± standard deviations; 
5.1 ± 5.2 vs. 5.6 ± 6.0, P=0.24) (Figure 5.4B). However, pre-ART VL measurements strongly correlated 
with VL set-points detected during the chronic stages of their infection (Figure 5.4C), suggesting that 
levels of vireamia in PHI were linked to subsequent neutralizing responses and high levels of VL detected 
post-ART.  
The estimated duration of PHI prior to initiation of ART was not significantly different between patients 
with detectable neutralizing responses and patients without neutralizing responses (77 ± 36 vs. 86 ± 33 
days, respectively). Furthermore, no correlation was observed between the duration of PHI and chronic 
VL set-points. However, clinical histories were not available for all patients so it was not possible to 
validate the estimated dates of infection. No correlation was detected between baseline CD4+ counts 
and post-ART neutralizing responses, despite a two-fold discrepancy between the highest and lowest 
CD4 T cell count measurements (397 to 807 cells per mm3). However, CD4+ T cell counts are known to 
fluctuate during PHI and additional data were not available to validate these one-off measurements 
(Schacker et al., 1996). 
High levels of VL were not always predictive of high levels of NAb response detected after ART was 
discontinued. For instance, patient S33 had a pre-ART VL of 4x105 RNA copies per ml and went on to 
develop the highest VL set-point of all patients (5.42 log), yet NAb activity was not detected with week  
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12 plasma against his contemporaneous Env-pseudotyped virus. Additionally, patient S181 had a pre-
ART VL of 2.73x105 RNA copies per ml prior to ART, yet failed to develop a NAb response post-ART (Table 
5.2).  
In summary, the correlation between VL and neutralizing activity suggests that NAb responses were 
primed prior to the initiation of ART in patients with high levels of viraemia. However, the correlation 
between pre-ART VL and post-ART NAb responses was weak, thus implying that factors other than VL 
are also important in controlling the production of NAbs. However, from these single assessments it was 
unclear whether patients with undetectable levels of neutralization had low levels of NAbs, or 
neutralization resistant virus.  Because previous studies have demonstrated that virus is less sensitive to 
neutralization by contemporaneous plasma than plasma derived later in infection, neutralizing 
responses were assessed longitudinally to determine whether all patients went on to develop 
detectable levels of neutralizing activity (Frost et al., 2005b, Richman et al., 2003, Wei et al., 2003). 
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5.2.3 Longitudinal assessment of NAb responses following discontinuation of early ART 
Neutralizing responses were assayed longitudinally by testing sequential samples of autologous plasma 
against the same pseudovirus derived post-ART. Only plasma at week 4 and week 48 was available for 
patients S7, S14, S35 and S132.  For the remaining patients, neutralization was assessed, on average, at 
4-12 week intervals and the total follow-up period averaged 102 weeks (range: 60-144 weeks) (Figure 
5.5A longitudinal assessments for patient S171 are shown).  Throughout the follow-up period, 7/10 
patients with VL set-points below 104 RNA copies per ml showed no improvement in IC50 plasma-titres, 
which were maintained below the 1:20 cut-off. A notable outlier was patient S194, who exhibited low-
level neutralization 12 weeks after treatment cessation (IC50 1:75) and subsequently developed an IC50 of 
1:375 by week 48, despite maintaining a VL set-point below 103 copies per ml (Figure 5.5B).  
All patients with intermediate and higher VL set-points (>4 logs) exhibited a significant increase in IC50 
neutralizing-plasma titres by week 48, (paired sample T-test, p<0.001) (Figure 5.6A). Correspondingly, 
analysis of week-48 plasma responses stratified according to the three original sub-groups revealed a 
positive correlation with set-point vireamia (ANOVA, p<0.01; Figure 5.6B). In cases where neutralization 
was detected after ART-cessation, IC50 plasma titres reached peak levels after 36-108 weeks post-ART. 
Increases in neutralizing activity lagged behind rebounding-viraemia. Time taken to reach peak levels of 
neutralizing activity weakly correlated with time-to-peak viraemia, calculated from ART-cessation to the 
first VL not succeeded by a lower or similar measurement within 0.1 logs (P<0.05, r2=0.472) (Figure 5.7). 
This lends further support to a causal link between antigen-load and NAb production.  
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Figure 5.5 Neutralizing responses rebounded after cessation of early ART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5.5 A. Neutralizing plasma-responses against autologous Env-pseudotypes were assessed 
longitudinally from the point at which ART was stopped and at 4 to 12 week intervals (week 0; x-
axes). Virus derived 12 weeks post-ART cessation was neutralized with sequential samples of plasma 
and inhibition of infection was assessed using the X-Gal neutralization assay.  Six alternate 
assessments out of twelve are shown for patient S171. IC50 neutralizing titres were calculated from 
interpolations shown as red lines. The corresponding neutralizing titres are shown in Table 5.2. 
 
Figure 5.5 B. Reciprocal IC
50
 titres (dashed lines; right y-axis) are shown with VLs (continuous lines; 
left y-axis) for three representative patients from each clinically defined subgroup: High VL (S116), 
intermediate VL (S171) and low VL (S194) 
 
 
Legend 
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Figure 5.6 Rebounding neutralizing responses were associated with high VL set-point  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6A. Post-ART neutralizing plasma titres (IC50) are compared with neutralizing responses 
assessed 36-48 weeks later.  Patients with a mean VL greater than 104 RNA copies per ml (black lines) 
exhibited significantly higher neutralizing titres over the follow-up period (paired sample T-test, 
p<0.001). In comparison, titres of plasma from patients with a mean VL set-point below 104 RNA copies 
per ml (red lines) did not change significantly in 7/10 cases (Independent T-Test, low viraemics vs. 
intermediate and high viraemics, P<0.001). 
Figure 5.6B. Neutralizing plasma responses detected 48 wk post-ART cessation (y-axis) show a positive 
association with patient sub-groups defined by VL set-point (x-axis) (ANOVA; p<0.01). Horizontal lines 
represent mean values for each group. Non-detectable neutralization titres are shown at half the 
detection limit of the neutralization assay (1:10) (*). 
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Figure 5.7 Neutralizing responses followed rebounding VLs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Univariate linear regression analysis showed a positive correlation of time-to-peak VL with 
time-to-peak IC
50
.  The number of weeks taken to reach peak-levels of VL and peak-levels of neutralizing 
activity are show for all patients with IC50 neutralizing plasma titres <20
-1.  
 
 
Time to peak IC50 
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5.2.4 NAb responses were associated with delayed viral rebound after cessation of early ART  
To determine whether contemporaneous-autologous neutralizing responses affected the kinetics of VL-
rebound when ART was terminated, the time taken for each patient to reach peak-viraemia was 
analysed. For this analysis, intervals were estimated from ART-cessation to the first VL that was not 
followed by a lower or similar measurement within 0.1 log (Figure 5.8A). Patients S46 and S116 were 
excluded from this analysis because neither patient suppressed VL <103 RNA copies/ml while on ART. 
Peak levels of viraemia were reached within one to four clinic visits (V1-V4) at average intervals of 5,  13, 
26 and 37 weeks from ART cessation (standard deviations; V0-V1 ± 1.7, V1-V2 ± 3.1, V2-V3 ± 2.1, V3-V4 ± 
3.3). An important caveat to this analysis is that actual peak VLs could have been reached before or after 
this measurement. Therefore, visit numbers rather than patient-specific time intervals were compared 
between patients. Patients with post-ART neutralizing responses detected with contemporaneous-
autologous plasma took longer to reach peak viraemia than those patients with undetectable responses 
(p=0.03; Mann-Whitney U Test) (Figure 5.8B).  
Neutralizing plasma titres were low immediately following-ART cessation (IC50 range 1:31 to 1:118) and 
may not have been sufficient to control viraemia. However, all but one patient developed IC90 titres at 
time points prior to peak VL. Furthermore, the actual levels of virus inhibition observed with the 1:20 
dilution of the contemporaneous plasma ranged from 70% to 92%, while none of the other patient’s 
plasma neutralized more than two standard deviations above background levels recorded with HIV-1 
seronegative plasma. Potentially, neutralizing responses may have contributed to virus control and 
delayed viral rebound in these patients. However, as mentioned in the previous section, patients with 
detectable neutralizing responses at treatment-cessation tended to develop higher levels of viraemia. 
Therefore, the observed delay in viral rebound could simply represent the extra time required to reach 
VL set-points (Figure 5.8A). However, peak levels of viraemia between patients with neutralizing 
responses and those without neutralizing responses were not statistically significant (log10 RNA copies 
per ml, 4.3 ± 0.7 vs. 4.3 ± 0.8, p=0.3) 
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Figure 5.8 Neutralizing responses against autologous-contemperanous Env-pseudovirus were 
associated with delayed viral rebound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8A. Rebounding patterns of viraemia are shown for patients with contemporaneous–
autologous neutralizing responses (left panel) and those without detectable responses (right panel) at 
ART cessation. Black lines give rebounding VLs prior to peak vireamia. Grey lines give VL data from peak 
viraemia up to 250 days after ART cessation.  
Figure 5.8B compares the time-intervals from ART-cessation to peak viraemia for patients with 
neutralizing responses and those without (left and right panels, respectively). VLs for patients with no 
detectable neutralizing activity (IC50>20
-1) decreased or plateaued to steady set-point levels sooner than 
those with detectable neutralizing responses. 
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5.2.5 Clade specific differences of VL and NAb response 
The six females infected with subtype C virus fell within the low VL group and three of these had VL set-
points below 103 RNA copies per ml. Only one of these patients exhibited any neutralizing activity 
against their autologous virus throughout the follow up period. Interestingly, two of the four clade C 
viruses that were not neutralized by the patient’s own plasma had unusual V3 domains (Table 5.2). 
Typically, clade C viruses possess a conserved isoleucine at position 309 followed by a GPGQ motif at the 
crown of the V3 loop, whereas envelope consensus sequences for patients S21 and S99 revealed a 
V/GPGQ and I/GPGR motif, the latter of which is more commonly found in clade B viruses.  
In contrast to the findings we report here, previous studies have shown strong autologous responses 
associated with recently transmitted clade C viruses that tend to have shorter, less glycosylated 
envelopes. We did not observe a difference in sequence length or glycosylation across C2V3 sequences 
of clade B and clade C clones. However, the sequenced regions only covered the C2V3 region and did 
not include the hypervariable V1/V2 regions that are more commonly associated with subtype C 
variation after transmission. Sequencing was not intended to identify genetic correlates of 
neutralization. Envelopes were sequenced to confirm that each patient clone closely resembled direct-
consensus PCR sequences, to rule-out cross-contamination between patient samples. 
5.2.6 Neutralization of heterologous HIV-1 Env-pseudotypes  
The breadth and potency of neutralizing responses against diverse heterologous isolates were assessed 
for thirty-eight patients using plasma sampled two years after enrolment onto the clinical trial. Plasma 
from an additional twenty-one patients with clade B infection and five patients with clade C infection 
were included in this analysis, while patients S171, S35, S128, S41 and S17, could not be investigated 
because plasma samples were not available.  
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Plasma samples were tested against an HXB2 Env-pseudotype virus and a diverse panel of clade-
matched reference isolates. These panels are widely used to identify broad antibody responses, and 
consist of envelope clones from diverse HIV-1 field isolates grouped according to neutralization 
sensitivity (Li et al., 2005, Bailey et al., 2006). Tier 1B isolates are generally more sensitive to 
neutralization by heterologous plasma than tier 2 isolates. Table 5.3A shows IC50 plasma titres for 
patients infected with subtype B virus, while Table 5.3B gives heterologous responses for those infected 
with subtype C virus. Plasma from patients infected with clade B virus exhibited detectable levels of 
neutralization against HXB2 with IC50 titres ranging from 1:20-1:2712. In general, HXB2-pseudovirus was 
more readily neutralized than the patient’s own autologous virus (Mean IC50 with standard deviations; 
278 ± 711 vs. 666 ± 278, P<0.001, paired sample T-test). Comparison of mean neutralizing titres 
stratified according to VL set-point revealed a similar pattern to that observed for the autologous virus 
(Figure 5.9 A). However, we observed dissociation between responses against autologous virus and 
HXB2, particularly for patients with low-level viraemia (Figure 5.9 B). Notably, four patients with 
undetectable titres against their own virus (IC50<20) neutralized HXB2 (IC50 58-477), suggesting that 
undetectable levels of autologous neutralizing activity did not reflect absent titres of HIV-1 Env-specific 
immunoglobulin. Clearly, these patients had antibodies that failed to neutralize their own virus.  
Plasma derived from patients infected with subtype C virus exhibited significantly less HXB2-
neutralization than plasma from subtype B HIV-1 infected patients (p<0.01, independent sample T-test), 
despite similar mean VLs in each group (average log VLs: 4.3±0.8 vs. 4.1±1, for clade B and C, 
respectively). Furthermore, neutralization of tier 1B viruses was not always predictive of neutralizing 
activity against tier 2 isolates. In particular, patient S1 poorly neutralized two Tier 1B isolates (reciprocal 
IC50 ≤ 30, HXB2 and ZM109F), yet neutralized three tier 2 isolates with IC50 titres ranging from 1:130 to 
1:556. Plasma from S84, infected with a clade B virus, neutralized the full panel of clade B reference 
isolates, including a tier 2 isolate (QH0692c3) with an IC50 titre of 1:1421. 
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Table 5.3A  Breadth and potency of neutralizing responses assayed in chronic infection. 
Clade B isolates. 
* 
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Table 5.3B Breadth and potency of neutralizing responses assayed in chronic infection.  
Clade C isolates. 
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Table 5.3 Breadth and potency of neutralizing responses assayed in chronic infection. 
Table 5.3A: Half maximal neutralizing titres of plasma (IC50), collected after 108 weeks post-
seroconversion are shown for subtype B standard-reference pseudoviruses (NIH, NAIDS) (Li et al., 2005). 
Patients infected with subtype B virus were identified by nucleotide sequencing of env and pol genes. 
Plasma was tested against an HXB2-Env pseudovirus along with two neutralization-sensitive (tier 1B) 
strains and two less-neutralization susceptible viruses (tier 2). Plasma responses that neutralized virus 
by 90% or more are marked with an asterisk (*).  
Table 5.3B. Plasma collected from patients with subtype C virus were sampled 108 weeks post-
seroconversion. Heterologous neutralizing activity was tested against HXB2 and an additional set of 
subtype-matched tier 1B and tier 2 pseudoviruses (Bailey et al., 2006). Serum responses that neutralized 
virus by 90% or more are marked with an asterisk (*).  
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Figure 5.9 Neutralization of Tier 1B heterologous strains weakly correlated with VL and autologous 
NAb titre.  
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Figure 5.9 Neutralization of Tier 1B heterologous strains weakly correlated with VL and autologous 
NAb titre. 
Figure 5.9 A: Neutralizing plasma responses against heterologous virus (y-axis) are shown for patients 
included in investigations of autologous neutralization (solid black squares) and additional patients not 
included in autologous neutralization studies (open squares). Neutralization is shown for two Tier 1B 
reference isolates, HXB2 and 6365. The observed trend was not statistically significant for either virus 
(NS, ANOVA).   
Figure 5.9 B: Linear regression of autologous-neutralizing plasma titres revealed a significant positive 
correlation with neutralizing responses against heterologous HXB2-pseudotyped virus (R2=0.64, 
P<0.001). The scatter plot highlights notable outliers with incalculable IC50 plasma titres against their 
own virus, despite having potent responses against a HXB2 pseudotype (dashed parentheses). 
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5.3 Discussion 
For the majority of patients stopping ART, neutralizing responses exhibited progressively increasing 
titres that lagged behind rebounding VL.  This is consistent with the theory that antibody production is a 
function of antigenic stimulation in early HIV-I infection (Piantadosi et al., 2009). In accordance with this, 
week 48 NAb responses strongly correlated with VL set-points and peaks of viraemia correlated 
temporally with peaks in neutralizing plasma titre. In contrast to these findings, Deeks et al. observed a 
weakly-negative correlation between VLs and autologous-NAb titres in individuals infected with HIV-1 
for an average of 5.4 years (Deeks et al., 2006a). Additionally, Bailey et al. failed to detect an association 
between VLs and neutralizing responses in chronic progressors and elite controllers (Bailey et al., 2006). 
In these previous studies, there was substantial variation in duration of HIV-1 infection, which is an 
important determinant of NAb breadth and potency, even after several years of infection (Sather et al., 
2009). Consequently, a major advantage of this study is that the time from transmission to the first dose 
of ART was similar for all patients. Knowing approximate exposure-times to viral antigen we could assess 
the relative importance of antigenic load on the development of NAb responses.  
Approximately half the patients (10/22) had detectable neutralizing responses within 4/12 weeks of 
stopping ART. This was surprising as neutralizing responses were detected using Env-pseudotyped virus 
and plasma derived from the same time-point. In contrast, a previous study detected rebounding 
autologous responses within 2-4 weeks after structured ART interruptions in 4/9 subjects treated during 
chronic infection (Montefiori et al., 2001), but only one of these patients had detectable levels of 
neutralization against contemporaneous virus. Different assay sensitivities could explain this 
discrepancy; particularly as pseudoviruses are generally more sensitive to neutralization than wild-type 
primary isolates which were used in the aforementioned study (Fenyo et al., 2009).  Alternatively, NAb 
responses may have been augmented by early interventions with ART. A possible mechanism for this 
194 
 
may be derived from studies that show preserved immune function and lower rates of viral evolution in 
response to ART-mediated VL suppression (Altfeld et al., 2001, Hecht et al., 2006, Malhotra et al., 2000). 
Specifically, B cell number and B cell phenotype have been shown to normalize in response to ART (Hart 
et al., 2007),(Moir et al., 2008b, D'Orsogna et al., 2007, Fondere et al., 2003). The effects of ART on NAb 
responses will be determined once the SPARTAC trial is unblinded, when patients who received early 
therapy can be compared with participants randomized to receive no therapy. 
It is likely that NAb responses were primed during PHI because patients with detectable levels of 
neutralizing activity after short-course ART tended to have high levels of VL during PHI. Although the 
association was not statistically significant, a causal relationship was inferred by the fact that pre-ART VL 
and post-ART NAb responses both correlated with VL set-points reached later in infection. Moreover, 
the median duration of PHI prior to the first dose of ART was 3 months, which corresponds to the initial 
detection of NAb responses reported by others (Gray et al., 2007, Richman et al., 2003, Wei et al., 2003), 
Aasa-Chapman et al., 2004). However, it was not possible to confirm that neutralization pre-ART 
corresponded to the levels detected after treatment cessation, because baseline plasma was not 
available for this investigation. 
Although we did not detect a direct correlation between NAb responses and baseline CD4+ T cell counts, 
women with subtype C infections tended to have fewer CD4+ T cells than the men infected with subtype 
B. The men tended to develop higher levels of neutralizing activity with higher VL set points, so it is 
possible that neutralization was affected by early changes to CD4+ T cell number and/or function. The 
major antibody isotype of HIV-1 neutralizing responses is IgG, which is produced from B cells following 
CD4+ T cell-dependant mechanisms of isotype switching and affinity maturation (Aruffo et al., 1993) 
(reviewed in (Parker, 1993)). Additionally, IgG antibody production requires the production of cytokines, 
such as IL-4, IFN-γ and TGF-β that are produced from activated CD4+ Th1 and Th2 lymphocytes (reviewed 
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in (Stavnezer, 1996)). Wide-spread immune hyperactivation in PHI is associated with a “cytokine storm” 
that can lead to B cell hyperactivity, hypergammaglubulinaemia and depletion of B cell germinal centres 
(Hart et al., 2007, Moir et al., 2008a). Therefore, it is possible that high levels of VL could have 
augmented the production of NAbs indirectly, by stimulating cytokine production from CD4+ T cells.  
Additional data on CD4+ T cell number, phenotype and function will become available when the 
SPARTAC trial is unblinded. It will be interesting to see if changes in neutralizing activity correlate with 
rates of CD4+ T cell decline. 
Five patients exhibited up to 0.3-0.9 log decreases in neutralizing plasma titres. The reasons for this are 
unclear, particularly in the case of patient 116, who maintained a VL above 0.5x105 copies per ml (Figure 
5.5B). This patient failed to suppress VL while on ART, so it is possible that declining neutralizing titres 
were caused by B cell exhaustion and B cell germinal-centre depletion in response to sustained levels of 
viraemia (Carotenuto et al., 1998a). Alternatively, declines in neutralizing titre may have resulted from 
changes in antibody-affinity, leading to a loss of binding to the earlier Env-pseudovirus. In support of 
this, Richmann et al, also reported waning neutralizing titres against ‘earlier’ HIV-1 Env-pseudotypes, 
despite observing sustained levels of neutralization over time against contemporaneous virus (Richman 
et al., 2003).  The observation that NAb activity declined in some patients highlights the importance of 
using a longitudinal models to compare neutralizing responses between patients.  
High levels of VL were associated with the rapid development of autologous NAb responses in all 
patients with VL set-points greater than 104 RNA copies/ml. It is, therefore, unclear how patient S194 
rapidly developed a neutralizing antibody response, despite maintaining a VL below 103 copies per ml. 
Doria-Rose et al. demonstrated broad and potent neutralizing responses in 25% of patients with elite 
control of viraemia (Doria-Rose et al., 2009). The longitudinal data for patient S194 adds to this finding 
by demonstrating the speed at which NAb responses can develop in the presence of low antigenaemia. 
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This is encouraging for HIV-1 vaccine research which aims to induce a strong antibody response in the 
absence of replicating virus. A second notable outlier was patient S33, who had a pre-ART VL of 4x105 
and a VL set-point of 5.42x105 RNA copies per ml, yet failed to develop detectable levels of neutralizing 
activity until 6 months after the termination of ART. Patients S33 and S194 illustrate that factors other 
than VL are clearly important in controlling the production of NAbs. Possible explanations may relate to 
physiological variations in B cell sensitivity to Env-antigen, or variations in immune dysfunction during in 
PHI (Hart et al., 2007, Moir et al., 2008a). Alternatively, differences in the immunogenic potential of the 
Env-antigen could also result in variable levels of B cell stimulation and antibody production (reviewed in 
(Forsell et al.,)2010)). More work is needed to understand why some patients respond well to low 
quantities of virus, while others fail to respond to high levels of virus replication. 
Autologous neutralizing responses failed to supress viraemia, despite half-maximal neutralizing titres 
exceeding 1:103. Why then did we fail to detect declines in VL following increases in NAb activity? Firstly, 
T cell responses and other host factors are known to be important in the control of viraemia and may 
well have been more important than NAb-responses in the cases examined here (Pereyra et al., 2008a, 
Pereyra et al., 2009). Secondly, small reductions of VL resulting from increases in neutralizing titre are 
likely to be overwhelmed by the reciprocal effect of antigen-stimulation, resulting in the production of 
more antibodies. Consequently, partially effective NAb responses in patients with higher VLs cannot be 
ruled out.  
Patients with detectable NAb responses after ART-cessation took longer to reach peak levels of VL. The 
higher VL set-points observed in these patients may be the sole reason for this discrepancy. However, it 
is unclear why rates of VL increase tended to plateau in patients with detectable levels of neutralizing 
activity, while VL rebounded more abruptly in patients with undetectable responses. Additionally, peak 
VLs were not significantly different between these two groups. Previous studies of macaques and 
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humans have demonstrated that NAbs can delay viral rebound after treatment interruption in acute and 
chronic infections (Trkola et al., 2004, Trkola et al., 2005). Therefore, it is possible that neutralizing 
antibodies were responsible for delayed rebounds observed in this study. However, there is a caveat to 
our analysis: So long as the SPARTAC trial remains blinded to treatment arm, it is not possible to exclude 
the possibility that length of ART (either 12 weeks or 48 weeks) influenced the kinetics of rebound post-
ART. Although patients who failed to suppress VL below 103 copies per ml were excluded from this 
analysis, patients S132 and S8 exhibited incomplete suppression of VL while on treatment (65 and 195 
RNA copies per ml, respectively). Nevertheless, these patients took longer to reach peak viraemia than 
the majority, suggesting that incomplete suppression did not lead to rapid VL rebounds.  
Five of the six patients infected with HIV-1 clade C virus failed to develop neutralizing responses against 
their autologous virus. This conflicts with previous reports showing rapid development of NAbs in clade 
C infections (Derdeyn et al., 2004, Blish et al., 2009, Li et al., 2006a). Li et al. reported a trend towards 
higher levels of neutralizing responses in patients infected with subtype C virus, compared with those 
infected with subtype B (Li et al., 2006a). However, in contrast to our findings, the majority of these 
patients developed VL set-points >104 copies per ml. Therefore, the low VL set-points of the subtype C 
infected patients is the most-likely reason for the discrepancy with previous reports and suggests that VL 
maybe more important than virus subtype in controlling the humoral response. 
A major target of gp120-specific antibodies in subtype B infections is thought to be the V3 loop which is 
consequently, more variable than that of subtype C viruses (Gorny et al., 2004),(Wei et al., 2003, Zolla-
Pazner et al., 2004). All patients infected with subtype B virus, including those without detectable 
responses against autologous virus, neutralized HXB2 pseudotyped virus by at least 50% and most had 
IC90 titres greater than 1:60. It is known that HXB2, and to a lesser extent 6535, are susceptible to NAbs 
targeting epitopes within the V3 loop. These antibodies are commonly found in HIV-1 infected patients, 
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but are thought to be ineffective against most primary viruses due to the cryptic nature of the V3 
epitopes within trimeric conformations of Env  (Moore et al., 1995, Sattentau et al., 1993, Sullivan et al., 
1995, Xiang et al., 2002). Antibodies targeting the V3 loop are often dismissed as being clinically 
unimportant, since they fail to slow progression to AIDS (Hogervorst et al., 1995, Loomis-Price et al., 
1998) and to protect against maternal-fetal transmission (Robertson et al., 1992). However, the impact 
of depleting these antibodies on virus infectivity has not been investigated. Maintaining resistance to 
V3-specific NAbs may incur a fitness cost to the virus in terms of replicative capacity and susceptibility to 
other neutralizing antibodies. Accordingly, studies of viral evolution in a laboratory worker accidently 
infected with a TCLA strain, Lai/IIIB, revealed an accumulation of mutations in V3 that induced resistance 
to broadly specific NAbs and soluble CD4 (Beaumont et al., 2004, Beaumont et al., 2001).  
The clade C HIV-1 infected patient with the greatest neutralizing breadth and potency against a panel of 
clade C Tier II/III reference strains also had the lowest activity against the more sensitive Tier IB viruses. 
This finding highlights a caveat relevant to studies aiming to identify potential Env-antigen vaccine 
candidates by tiered assessment of neutralizing antibody responses (Mascola et al., 2005). Had we 
adhered to recommendations of limiting tier 2 tests to those plasma that neutralized tier 1 isolates, we 
would not have detected this neutralizing response. It will be interesting to see if this patient develops 
broader cross-clade neutralizing responses at a later stage of infection.  
The strength of the association between VL and neutralization was greater for autologous assessments 
than heterologous assessments, and there was no correlation between VL and breadth of neutralizing 
response against diverse isolates. Using autologous viruses to assess the impact of neutralizing antibody 
responses in early infection is more informative than heterologous responses, which are a poor 
surrogate marker of neutralizing activity against the patient’s own virus. Additionally, longitudinal 
assessments of VL and autologous antibody responses during early infection could be the only window 
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of opportunity for delineating cause from effect in vivo. This last point is illustrated by the fact that three 
patients with low VL set-points (<4 logs) showed increases in IC50 titre by the end of the follow-up 
period, suggesting that over time, NAb responses may begin to normalize across VL-stratified patient 
groups.  
In conclusion, these data show that NAb reponses develop during the early stages of infection in 
response to high VL, in agreement with previous studies of chronic infection (Doria-Rose et al., 2009, 
Sather et al., 2009). However, the dynamics of the neutralizing response are highly variable between 
patients and other factors are also likely to be important. The weak association between baseline NAb 
responses and time-to-peak viraemia is interesting, but needs to be confirmed by larger studies with 
shorter intervals between VL and NAb measurements. Our data suggest that if neutralizing antibodies 
afford any degree of protection in vivo, they do so within a complex inter-dependent system that cannot 
be observed by means of cross-sectional analyses of viraemia and total NAb response alone. 
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Chapter 6 
 
Conclusions 
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6.1 Conclusions 
The antibody response to HIV-1 has been studied extensively to meet global demands for a protective 
vaccine. The modest success of the RV144 HIV-1 vaccine trial, which failed to elicit NAbs or CTL 
responses, has prompted speculation that non-neutralizing antibodies were responsible for the 
protective effects observed (Rerks-Ngarm et al., 2009). Although the antiviral effects of NAbs may be 
enhanced by Fc-dependent mechanisms of cell-mediated cytotoxicity, there is no direct evidence to 
suggest that ADCC alone protects against transmission of HIV-1, in vivo (Hessell et al., 2007). On the 
other hand, passive transfer studies in macaques have shown that infection with SHIV can be blocked 
with broadly-specific NAbs (Baba et al., 2000, Emini et al., 1992, Mascola et al., 1999, Mascola et al., 
2003, Mascola et al., 2000, Putkonen et al., 1991, Zhang et al., 2004a). A fundamental hurdle to the 
development of a successful HIV-1 vaccine is the elicitation of antibodies capable of neutralizing diverse 
strains. A possible alternative may be the use of recombinant adeno-associated virus vectors to deliver 
genes encoding NAbs and NAb-like proteins to non-immune tissues (Johnson et al., 2009). This strategy 
has been shown to protect macaques against infection with SHIV, yet issues regarding the safety of gene 
therapy need to be resolved before studies can take place in humans. For now, eliciting immune 
responses by vaccination is the most-realistic approach towards curbing the HIV-1 pandemic. 
The neutralizing activities of patient plasma and monoclonal NAbs were measured using a pseudovirus 
infectivity assay adapted to use automated-counting procedures to quantify infected TZM-bl reporter 
cells. In order to ensure that pseudoviruses could be constructed for all patients, envelope genes were 
cloned using MACH1 bacteria that were partially-resistant to the toxic effects of HIV-1 envelope. 
Unexpectedly, different envelope genes were shown to be variably toxic to transformed K12 strains of 
E.coli that are commonly used for HIV-1 envelope cloning. Only envelope genes cis-linked to 
transcriptional promoters inhibited bacterial growth, confirming the mechanism of cytotoxicity involved 
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envelope expression. It is possible that the discrepancies observed between different envelope isolates 
in this study relate to differential fusogenic potentials of gp41 (Chernomordik et al., 1994, Arroyo et al., 
1995, McDonald and Burnett, 2005). Although this was not investigated, previous studies in E.coli 
suggest that gp41 can permeabilize cell membranes independently of virus receptors. Further 
investigations could determine whether particular HIV-1 envelopes mediate viral-cytolysis in mammalian 
cells independently of virus receptors, as this may uncover correlates of CD4+ T cell depletion, in vivo. 
Use of MACH1 strains improved the success rate of envelope cloning. Additionally, the modifications 
described for the X-gal-based pseudovirus neutralization assay provided a high-throughput and cost-
effective system to characterize NAb responses in vitro. The final optimized assay could be used in a 
variety of research and clinical settings, including phenotypic assays of virus infectivity, co-receptor 
typing and antiretroviral-resistance screening.  
A primary aim of this study was to understand the factors that control the development of NAb 
responses in early infection. Autologous NAb activity was assessed in twenty-two patients who went on 
to develop VL set-points ranging from 3 to 5 log10 RNA copies per ml. As demonstrated, plasma derived 
from HIV-1 infected patients exhibited variable levels of neutralizing activity against autologous and 
heterologous viruses. All patients exhibited VL rebounds after ART-cessation. Seven patients who 
subsequently controlled their viraemia below 4 log10 RNA copies per ml failed to develop detectable 
levels of neutralizing activity, while patients with higher VL set-points developed peak-level neutralizing 
titres (IC50) ranging from 95
-1 to 2946-1. The positive association between VL and NAb activity supports 
previous studies (Bailey et al., 2006, Piantadosi et al., 2009, Sather et al., 2009). However, low levels of 
VL were sufficient to stimulate the production of antibodies that neutralized an HXB2 Env-pseudotype. 
These data confirm that the production of HIV-1 specific antibodies is optimal in the presence of high 
concentrations of viral antigen. Furthermore, high levels of viraemia may need to be sustained in order 
to develop antibodies capable of neutralizing autologous viruses.  
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Two possible mechanisms could explain the concentration-dependant effect of VL on NAb production. 
Firstly, high levels of Env-antigen may be required to directly cross-link BCRs, leading to the 
differentiation and proliferation of antibody-producing plasma cells. Alternatively, high levels of viral 
replication could stimulate the production of NAbs indirectly, by activating CD4+ T cell responses. The 
former mechanism is more likely to be dominant as CD4+ T cell counts assessed prior to the initiation of 
ART did not correlate with levels of neutralizing activity. Additionally, wide-spread immune-activation in 
early infection leads to depletion and dysfunction of CD4+ T cells and B cells, which would be expected 
to inhibit the development of neutralizing responses (Doria-Rose and Connors, 2009, Hart et al., 2007, 
Moir and Fauci, 2009b, Moir et al., 2004). Nevertheless, it will be interesting to see if NAb responses 
correlate with CD4+ T cell number and function, assessed during the chronic stages of infection and this 
will be assessed when the SPARTAC trial has been unblinded. By extending this study to investigate 
those patients randomized to receive no therapy it will be possible to assess whether neutralizing 
antibody responses were augmented by short-course ART. 
Variation in the rates at which antibody responses mounted in response to rebounding viraemia has 
implications for vaccine development because the window-of-opportunity to prevent chronic HIV-1 
infection is limited to the first few days following transmission, before latent pools of HIV-1 become 
established (Haase, 2010, Virgin and Walker, 2010). Although neutralizing responses against autologous 
virus developed in most patients, the majority failed to develop antibodies capable of neutralizing Tier 2 
heterologous Env-pseudotypes at 2 years post-infection. Clearly, high levels of VL were not sufficient to 
induce cross-reactive NAbs and longer durations of infection may be necessary to detect such responses 
(Sather et al., 2009, Piantadosi et al., 2009). This is not surprising as antibodies that contribute to broad 
neutralizing activity in vivo target conserved epitopes on functional Env trimers, particularly the CD4bs, 
although antibodies targeting the MPER region of gp41 may also be important in a minority of cases 
(Moore et al., 1994, Binley et al., 2008). The CD4bs-specific NAbs that have been isolated to date are 
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characterized by long CDR3 loops (Prabakaran et al., 2006, Saphire et al., 2001, Wilkinson et al., 2005, 
Zhang et al., 2004b) and high levels of affinity maturation (Zhou et al., 2010). The former requires an 
atypical V(D)J recombination event and the latter involves successive rounds of AID-dependant point 
mutations. A continual supply of envelope antigen is required for affinity-guided selection of B cells and 
the likelihood that these processes will give rise to CD4bs-specific antibodies increases with time. With 
this in mind, in order to elicit protective titres of NAbs by vaccination, it may be necessary to administer 
several doses of Env antigen over long periods of time.  
A second objective of this study was to determine whether NAbs contribute to the control of HIV-1 VL in 
established HIV-1 infection. The answer to this question has implications for the development of 
vaccines which aim to limit disease progression in vaccinated individuals that become infected. 
Additionally, it is important to understand why some patients are able to control levels of viraemia, 
while others maintain high VL set-points and progress rapidly to AIDS. If the immunological correlates of 
long-term non-progression can be established, it may be possible to develop therapeutic vaccines and 
immunotherapies aimed at inducing clinically-beneficial responses in HIV-1 infected patients (reviewed 
in(Cadogan and Dalgleish, 2008). Although several studies have shown that high levels of neutralizing 
activity are most-frequently detected in patients with high levels of viraemia, neutralizing activity has 
been detected in a minority of elite controllers and it is unclear if these responses contribute to the 
control of VL in these patients (Doria-Rose et al., 2009, Mahalanabis et al., 2009b). Additionally, it is not 
known if NAbs or non-neutralizing antibodies contribute to the control of VL at high set-point levels.  
The interaction between the adapting NAb response and the counter-adapting virus has been likened to 
the Red Queen principle of evolutionary dynamics. The term is taken from Lewis Carroll's Through the 
Looking-Glass and What Alice Found There, in which the Red Queen tells Alice, "It takes all the running 
you can do, to keep in the same place" (van Valen, 1973). This analogy explicates how constant VL set-
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points are maintained despite successive rounds of escape from co-evolving neutralizing responses 
(Frost et al., 2005a). However, until now, there was no direct evidence to suggest that low-levels of 
virus-neutralization detected with contemporaneous-plasma could contribute to the control of VL, in 
vivo. To take the analogy further, it was not clear what the consequences would be if Alice were to stop 
running. 
In a unique case, rituximab-mediated B cell depletion led to a decline in antibody titre and increases in 
HIV-1 and Hepatitis B VL. Although the transient decline in NAb titre was not sufficient to attribute a 
causal link with the observed changes in VL, the impact of NAbs on viral replication was confirmed by 
evolutionary studies that showed site-specific selection of Env variants that were less susceptible to 
neutralization by autologous plasma and NAb, b12. These findings concur with previous studies that 
implicate the same sites in mechanisms of NAb escape (Duenas-Decamp et al., 2008, Duenas-Decamp et 
al., 2009, Scanlan et al., 2002). While HBV co-infection and B cell-associated changes in HIV-1 specific T 
cell activity may have contributed to the initial loss of viraemia control, there are no known mechanisms 
to link these factors to the sequence changes observed in Env.  
In chapter 5, three patients (S194, S8, S41) were shown to exhibit fluctuations in IC50 titres of a similar 
magnitude to that observed following B cell depletion. Why then, did we not observe reciprocal 
associations between VLs and NAb titres in all patients? A possible explanation is that changes in 
neutralizing titre detected after ART-cessation reflects counter-adaption of the antibody response to 
mutating viral-envelopes and fluctuating VLs. On the other hand, decreased neutralizing activity 
detected after rituximab therapy occurred independently of changes in Env, which prevented the 
humoral response from counter-adapting to the evolving virus. By depleting CD20+ B cells, de novo 
antibody responses to the evolving virus would have been inhibited, thus specifically affecting 
antibodies targeting the contemporaneous strain. At the same time, rituximab therapy does not deplete 
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archived CD20- plasma cells (Ahuja et al., 2008), which may continue to produce antibodies capable of 
neutralizing the “early” Env-pseudotypes but not the contemporaneous virus. In support of this 
suggestion, antibody-binding titres to HBsAb and the CD4bs of gp120 exhibited disproportionately 
greater decreases than total immunoglobulin concentrations.  
In summary, longitudinal follow-up of HIV-1 infected patients in separate clinical settings revealed 
positive and negative correlations between levels of viraemia and levels neutralizing activity. As 
hypothesized, a positive correlation was detected between levels of viraemia and autologous NAb 
responses after the cessation of early ART, yet in a separate case study, decreases in NAb titre led to 
significant increases of HIV-1 VL. While these findings appear to conflict, they are not mutually exclusive, 
as distinct mechanisms are responsible for i) the affect of VL on the production of NAbs and ii) the affect 
of NAbs on the control of VL. Therefore, neutralizing titres are not predictive of antibody-mediated 
control of HIV-1 VL, because the relationship between VL and the neutralizing antibody response is 
interdependent.  
The hypotheses of this thesis were constructed with the intention of resolving a question that is nearly 
as old as the discovery of HIV-1 itself: Are NAbs important in the control of HIV-1 VL? It is true that 
antibody responses must inhibit HIV-1 replication in cases where positive selection of NAb-resistant 
virus is detected. Chapter 4 is a case in point: the antibody resistant virus that emerged following B cell 
depletion did so only after neutralization-sensitive variants were eliminated. If antibodies eliminate 
neutralization-susceptible virus, then neutralizing responses must contribute, somewhat, to the immune 
control of HIV-1; to say this explicitly is almost a tautology. Despite this, many groups continue to 
suggest that neutralizing antibodies are not clinically important, or less important than other 
components of the immune response (Bunnik et al., 2010, Bailey et al., 2006, Euler et al., 2010, 
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Piantadosi et al., 2009). A major conclusion of this thesis is that it is unscientific to speculate on the 
clinical importance of the antibody response. 
Karl Popper, the father of critical rationalism, makes the following demarcation between scientific and 
non-scientific theory. ‘Every "good" scientific theory is a prohibition: it forbids certain things to 
happen…the scientific status of a theory is its falsifiability, or refutability, or testability’. (Popper, 1962) 
There is currently no consensus as to what constitutes a clinically important antibody response and 
there are no unifying measures that consolidate both sides of the dynamic relationship between 
antibody and virus. Therefore, it is currently not possible to falsify, refute or even test the theory that 
HIV-1 antibody responses are clinically important.  
From a clinical perspective, defining the role of antibodies in HIV-1 pathology is less important than 
finding ways to enhance the protective effects of NAbs, in vivo. Perhaps the most interesting finding of 
this thesis was the observation that B cell depletion appeared to enhance control of VL set-point after an 
initial flare in viraemia. With this in mind, a working hypothesis is proposed to explain this finding: In 
subjects with evidence of antibody-mediated inhibition of viral replication, rituximab-mediated B cell 
depletion will cause transient losses of viral load control, sensitization of virus to NAb responses and 
enhanced control of viral load set-point when antibody responses rebound. 
Theoretically, relaxing antibody-selective pressure will promote evolution of neutralization-susceptible 
virus that may be beneficial in the long-term. This hypothesis could be tested using SHIV-infected 
macaques and the ethical arguments against animal experimentation may be overcome using animals 
infected as part of vaccine trials. Not only would this corroborate or refute the hypothesis, B cell 
depletion may also help to determine if non-sterilizing immune responses, induced by vaccination, are 
clinically beneficial in controlling subsequent viral load set points. 
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In the proposed study, full-length envelope genes would be sequenced longitudinally subjected to time-
structured Phylogenetic and CODEML analyses, as described in chapters 2 and 4, in order to detect 
antibody-mediated positive selection. B cell depletion would be targeted to cases where effective 
antibody response are evident. As an experimental control, B cell depletion could be conducted on 
infected animals without evidence of positive selection, but with evidence of genetic drift and 
diversification in env, indicative of an ineffective antibody response (see Footnote 1). 
Knocking-out positive selective pressure should promote reversion to a neutralization-sensitive 
phenotype. Additionally, temporarily inhibiting B cell development should also relax antibody-mediated 
negative selection, leading to virus diversification and the acquisition of mutations that further sensitize 
the virus to the rebounding antibody response (see Footnote 2). If B cell depletion were to be sustained 
so that the least mutated genome carried at least one deleterious mutation, the decrease in viral fitness 
will become fixed in the viral population leading to enhanced control of viral load set-point; a 
mechanism known as Mullers Ratchet (Muller, 1964). 
In conclusion, longitudinal follow-up of the neutralizing response in HIV-1 infected patients has revealed 
a dynamic, yet fragile, evolutionary balance between antibodies and virus. B cell depletion interferes 
with this relationship with surprising consequences and further work into this particular area could help 
elucidate the true potential of neutralizing antibodies in the control of HIV-1 viral load. 
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6.2 Footnotes 
 
Footnote 1: It would be necessary to confirm that anti-CD20 therapy depleted those neutralizing 
antibodies responsible for the selection event. This would be done by isolating those B cell subclones 
that produce antibody capable of binding to autologous Env prior to, but not after, the selection event, 
using recently described techniques pioneered by Scheid et al, 2010. The antibody would subsequently 
be used in neutralization assays and competitive binding assays with serum collected prior to and after B 
cell depletion using autologous gp140 as the target protein. If rituximab effectively depletes the relevant 
antibody, binding competition would only be observed with serum derived prior to B cell depletion.  
Footnote 2: It may also be possible to further promote evolution of a neutralization-susceptible virus 
while limiting the flare in viraemia expected from B cell depletion. Chloroquine has been shown to 
reduce viral load while inhibiting glycosylation of viral envelope leading to losses of N-link glycosylation 
sites and shortening of Env variable regions (Sperber et al., 1995 and 1997, Savarino et al., 2001 and 
2004); a phenotype likely to be associated with increased susceptibility to NAbs. 
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a b s t r a c t
PCR-enhanced reverse transcriptase assays (PERT) are sensitive tools for the detection of retroviruses in
biological samples. The adaptation of real-time PCR techniques based on ﬂuorescent probes (F-PERT) has
added a reliable quantitative capacity to the assay. In the interest of economy and time, the SYBR Green
I-based real-time detection system was used to establish a convenient one-step PERT assay (SG-PERT).
This assay can be completed in 2h, is linear over six orders of magnitude and can be used to quantify
retroviruses belonging to divergent species, such as the human immunodeﬁciency virus type 1 (HIV-1),
murine leukemia virus (MLV) and prototypic foamy virus (PFV).
© 2008 Elsevier B.V. All rights reserved.
1. Type of research
Assays for the routine quantitation of retrovirus particles are
essential tools in research areas addressing the biology of retro-
viruses and the development and use of viral vectors for gene
transfer. To this end, ELISA-based techniques for the quantitation
of retroviral Gag proteins are often expensive and require extensive
sample dilution, because they are linear only over a limited range
of antigen concentration. RT-PCR strategies to detect and quan-
tify virion-associated retrovirus genomes rely on sequence-speciﬁc
primer design and require RNA isolation procedures which make
it expensive and labour intensive. In contrast, biochemical assays
which estimate the amount of virion-associated reverse transcrip-
tase (RT-assays) can universally detect and quantify retrovirus
particles. The enzymatic activity of RT, present in all retroviruses,
is measured using an RNA template which is reverse transcribed in
vitro by the retroviral enzyme. The resulting DNA product (cDNA) is
then quantiﬁed as ameasure of the amount of virions present. Con-
ventionally, quantitation of the cDNA is achieved bymeasuring the
amount of nucleotides incorporated using radioactively labelled
reagents or colorimetric techniques. However, during the last 15
years product-enhanced RT (PERT) assays have been developed
∗ Corresponding author at: Imperial College London, Jefferiss Research Trust Lab-
oratories, St. Mary’s Campus, Norfolk Place, London W2 1PG, United Kingdom. Tel.:
+44 20 7594 3918; fax: +44 20 7594 3906.
E-mail address: m.pizzato@imperial.ac.uk (M. Pizzato).
using PCR techniques to amplify the cDNA and to allow the detec-
tion of even single retrovirus particles (Chang et al., 1997; Fan et
al., 2006; Heneine et al., 1995; Pyra et al., 1994; Silver et al., 1993;
Yamamoto et al., 1996). Furthermore, the adaptation of real-time
PCR techniques based on the ﬂuorogenic 5′-nuclease chemistry (F-
PERT) to one- or two-step assays has coupled the high sensitivity
given by the PCR to the quantitative capacity given by real-time
analysis of product ampliﬁcation, making it linear over six orders
of magnitude (Arnold et al., 1998; Lovatt et al., 1999; Maudru and
Peden, 1998; Sears and Khan, 2003). PERT and F-PERT assays can
be used to detect low amounts of retroviruses in biological prod-
ucts (Brorson et al., 2001, 2002; Lovatt et al., 1999), HIV in serum
samples (Garcia Lerma et al., 1998; Pyra et al., 1994), replication
competent recombinant retroviruses in cultures producing vectors
for gene transfer (Sastry et al., 2005) and endogenous retroviruses
(Bisset et al., 2007; Khan and Sears, 2001).
SYBR Green I-based systems offer a popular alternative to ﬂuo-
rescent probe-based real-time PCR techniques and are based on its
ability to produce a 100-fold increase of ﬂuorescence when bound
to double-stranded DNA. Because the binding of SYBR Green I to
nucleic acid is not sequence-speciﬁc, the ﬂuorescent signal pro-
duced when in complex with DNA is directly proportional to the
length and amount of DNA copies synthesized during the reac-
tion, making this technique very precise and sensitive. Given the
popularity of the SYBR Green I-based systems and their cost efﬁ-
ciency, the SYBR Green I chemistry has been adapted to a one-step
PERT (SG-PERT). Several attempts were required in order to iden-
tify crucial reaction conditions and develop a robust and sensitive
0166-0934/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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assay, which is proposed as a fast and economic tool for the routine
quantitation of divergent retroviruses.
2. Time required for a 20 sample experiment: 1h 50min
(i) Sample preparation: 20min
(ii) Reaction set-up: 10min
(iii) RT and PCR reactions: 1h 10min
(iv) Data analysis: 10min
3. Materials
3.1. Cells and viruses
Human endothelial cells HEK 293T, human ﬁbrosarcoma cells
HT1080 and Hela-derived TZM-BL indicator cells were grown in
DMEM (Invitrogen, Paisley, UK). Human lymphoblastoid Jurkat E6.1
cellswere grown in RPMI (Invitrogen, Paisley, UK).Mediawere sup-
plemented with 10% fetal calf serum (Invitrogen, Paisley, UK) and
cell cultures were maintained at 37 ◦C and 5% CO2.
HIV-1 was generated using the proviral construct pNL4-3
(Adachi et al., 1986). Recombinant murine leukemia virus (MLV)
vector was produced using the gag-pol expression plasmid, pHIT-
60 (Soneoka et al., 1995), the VSV-G (G protein from the vesicular
stomatitis virus) expression plasmid, pMDG (Naldini et al., 1996)
and the retroviral vector, pCNCG-GFP (Neil et al., 2001). Recombi-
nant PFV vector was produced using the vector plasmid, pMH71
(Heinkelein et al., 2003) and pczHFVenv encoding the HFV (human
foamy virus) envelope glycoprotein (Pietschmann et al., 1999).
3.2. Special equipment and software
• LightCycler 2.0 (Roche Diagnostics, Burgess Hill, UK).
• LightCycler software 4.0 (Roche Diagnostics, Burgess Hill, UK).
• 7900HTReal-TimePCRsystemandsoftware (AppliedBiosystems,
Warrington, UK).
3.3. Chemicals and reagents
• 1kb plus DNA molecular weight marker, Sybr Green I, deoxynu-
cleotides and Platinum Taq (Invitrogen, Paisley, UK).
• Recombinant HIV-1 reverse transcriptase and AmpliTaq Gold
polymerase (Ambion/Applied Biosystems, Warrington, UK).
• Ammonium sulphate, potassium chloride, magnesium chloride,
manganese chloride, Tris–HCl, dithiothreitol, TritonX-100,DNase
and RNase-free water, glycerol, 1,4-dithioerythritol (DTT) and
agarose (Sigma–Aldrich, Gillingham, UK).
• Bovine serum albumin (New England Biolabs, Hitchin, UK).
• Hot-start Taq polymerase (MBI Fermentas, York, UK).
• Brome mosaic virus RNA and RNAsin ribonuclease inhibitor
(Promega, Southampton, UK).
• Forward (5′-GGTCTCTTTTAGAGATTTACAGTG-3′) and reverse (5′-
CGTGGTTGACACGCAGACCTCTTAC-3′) primer oligonucleotides
(Invitrogen, Paisley, UK).
• LightCycler 20l capillaries (RocheDiagnostics, BurgessHill, UK).
• Saquinavir (NIBSC, Potters Bar, UK)
• PFUultra, PFU turbo andEasyA (Stratagene, AmsterdamZuidoost,
The Netherlands)
• Murex HIV antigen mAB ELISA assay kit (Abbott Murex, Maiden-
head, UK).
• X-Gal (5-bromo-4-chloro-3-indolyl-b-galactopyranoside)
(Melford, Chelsworth UK).
4. Detailed procedure
4.1. Sample preparation
4.1.1. Production of viruses and recombinant retrovirus vectors
Jurkat E6.1 cellswere infectedwithHIV-1NL4-3, previously gen-
erated by transfection of HEK 293T cells with pNL4-3 and passaged
for more than 2 weeks to establish chronic infection.
Recombinant MLV and PFV (prototypic foamy virus) vectors
were produced by transfection of HEK 293T cells. Brieﬂy, 1.5 mil-
lion cells, seeded in T25 ﬂasks 1 day earlier, were transfected
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions with pHIT-60, pMDG and pCNCG-GFP (MLV)
and pMH71 and pczHFVenv (PFV). Vector-containing supernatants
were harvested 48h after transfection. After clariﬁcation by low-
speed centrifugation, supernatants were prepared for infectivity
assay and SG-PERT analyses by ﬁltering through a 0.45m pore
ﬁlter.
4.1.2. Infectivity assays
TZM-BL or HT1080 target cells were seeded onto 48-well plates
(2×104 cells/well) 1 daybefore infection or transduction. Virus and
vector supernatants were serially diluted 10-fold in triplicate in
culturemediumand target cells inoculatedwith 0.4ml of eachdilu-
tion. Virus supernatant was replaced with fresh medium 24h later
and end-point titers evaluated 72h post-infection (TZM-bl cells)
or post-transduction (HT1080 cells). To ensure that HIV-1 infection
of TZM-bl resulted in a single cycle of replication, target cells were
treatedwith 1Mof the protease inhibitor saquinavir. HIV-1 infec-
tion of TZM-bl cells was evaluated by staining infected cells with
X-Gal as previously described (Pizzato et al., 2001) The infectivities
of MLV and PFV GFP vectors were evaluated by counting ﬂuores-
cent foci by ﬂuorescence microscopy in transduced HT1080 cells.
Clusters of stained cells were attributed to a single infection event
and titre was expressed as infectious units (i.u.).
4.1.3. Measurements of p24 and HIV-1 RNA in virus supernatants
P24 antigen was measured in cell culture supernatants using
the Murex HIV antigen mAB ELISA assay kit following the manu-
facturer’s guidelines.HIV-1RNAwasquantiﬁedbySiemensVersant
HIV-1 bDNA (branched-chain DNA) assay, after the sample was
diluted 105-fold in normal humanplasma to obtain a concentration
falling within the range of the assay.
4.1.4. Preparation and storage of SG-PERT assay buffers
All buffers were prepared using RNAse-free reagents:
2× virus lysis buffer (0.25% Triton X-100, 50mM KCl, 100mM
TrisHCl pH7.4, 40% glycerol) was stored at −20 ◦C. RNAse inhibitor
(0.4U/l) was added to the volume of buffer needed for virus dis-
ruption immediately before use.
10× sample dilution buffer (50mM (NH4)2SO4, 200mM KCl and
200mM Tris–HCl pH 8.3) was stored in aliquots at −20 ◦C.
2× reaction mix (10mM (NH4)2SO4, 40mM KCl and 40mM
Tris–Cl pH 0.3, 10mM MgCl2, 0.2mg/ml BSA, 1/10,000 SYBR
Green I, 400MdNTPs, 1M forward primer,1M reverse primer,
1.2g/ml BMV RNA) was stored in aliquots at −80 ◦C. Hotstart Taq
was added (0.2U/reaction) immediately before use.
4.1.5. Preparation of virus lysates
Fivemicroliters of undilutedordilutedvirus supernatant, or 5l
of recombinant HIV-1 RT diluted in sample dilution buffer, were
mixed with 5l of 2× virus lysis buffer in a 1.5ml microfuge tube.
After 10min incubation at room temperature, 90l of sample dilu-
tion buffer were added and the tube vortexed to obtain a 10-fold
dilution.
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Fig. 1. The SG-PERT assay. (a) Melting curve of PCR products obtained by testing the indicated amount of recombinant HIV-1 RT with SG-PERT. (b) Agarose gel visualizing
the DNA products in the SG-PERT reactions analyzed in (a). M: molecular weight marker with indicated molecular sizes. (c) Real-time ampliﬁcation curves of the reactions
visualized in (a) and obtained by acquiring the ﬂuorescence at 83 ◦C.
4.2. Reaction set-up
Ten microliters of the diluted virus lysate samples were mixed
immediately with 10l of 2× reaction mix already aliquoted into
the reservoir of pre-chilled 20l capillaries (lightcycler) or optical
tubes (HT7900). The capillaries or tubeswere brieﬂy centrifuged to
sediment the reaction components and applied to real-time plat-
forms. Thermal cycler conditions used were: 30min RT reaction at
37 ◦C, 5min hot-start Taq activation at 95 ◦C and 45 cycles of ampli-
ﬁcation. Each ampliﬁcation cyclewas composed of 5 s denaturation
at 95 ◦C, 5 s annealing at 55 ◦C, 15 s extension at 72 ◦C, 7 s acquisition
at 83 ◦C, using the lightcycler; 5 s denaturation at 95 ◦C, 5 s anneal-
ing at 55 ◦C, 20 s extension at 72 ◦C, 11 s acquisition at 83 ◦C, using
the 7900HT platform.
Where indicated, the 20l PCR products were visualized after
electrophoretic separation in 1.8% agarose gel and stained with
ethidium bromide.
4.3. Data analysis
Ampliﬁcation curves and melting temperatures were gener-
ated by recording ﬂuorescence at 530nm and analyzed using the
LightCycler software 4. For each ampliﬁcation curve the software
calculates the crossing point, deﬁned as the cycle number at which
the ﬂuorescence of a sample rises above the background ﬂuores-
cence. Theﬁtpointsmethodwitharithmeticbackgroundcorrection
was used to calculate the crossing points and generate the stan-
dard curves following the operator’s manual. First, the noise band
was adjusted using the software automatic option. The maximum
number of ﬁt points ﬁtting the linear portion of the curve was then
added. The software option “minimize errors” was chosen to auto-
matically adjust the threshold line for the calculation of crossing
points. The regression analysis of crossing points versus dilution
factors of virus supernatants or recombinant RT was automati-
cally calculated by the software. The slope of the curve, which is
referred to as the efﬁciency of the reaction, indicates the efﬁciency
of the ampliﬁcation, the perfect value being 2. Melting peaks were
calculated automatically by the software.
For data acquiredwith the 7900HT system, crossing pointswere
calculated automatically by the software.
5. Results
5.1. SG-PERT reaction conditions
A one step real-time based PERT assay was established using
the BMV RNA template and primer set which have already been
described (Silver et al., 1993) and which amplify a 168bp frag-
ment at the 3′ end of the BMV genome. After screening several
thermophilic DNApolymerases, the hot-start Taq-polymerase from
MBI Fermentas was chosen for the PCR ampliﬁcation because it
was found to lack signiﬁcant RT activity (not shown), as already
suggested (Fan et al., 2006; Maudru and Peden, 1997).
Since the binding of SYBR Green I to DNA is sequence-
independent, non-speciﬁc PCR fragments can contribute to the
ﬂuorescent signal recorded by the instrument. A melting curve
analysis of the PCR products obtained was, therefore, performed
to conﬁrm the presence of the speciﬁc DNA fragment which cor-
relates with a distinct melting peak at 86 ◦C (Fig. 1a). Accordingly,
agarose gel electrophoresis analyses of the PCR product obtained
in the light cycler conﬁrmed the presence of the predicted 168bp
speciﬁc fragment and theabsenceof non-speciﬁcproducts (Fig. 1b).
Primer–dimer formation was often detected in negative or weakly
positive samples, characterized by a melting peak at 79 ◦C (Fig. 1b
Fig. 2. SG-PERT detection of recombinant HIV-1 RT. (a) Ampliﬁcation curves obtained with 10-fold serial dilutions of recombinant HIV-1 RT, performed in duplicate. (b)
Standard curve showing the input of recombinant HIV-1 RT against the respective crossing points of ampliﬁcation curves shown in (a) and calculated by the LightCycler
software 4. Reaction efﬁciency is shown.
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Fig. 3. SG-PERT detection of HIV-1 with two different real-time PCR platforms.
Crossingpointsobtainedwith the lightcycler and theABI7900HTusing10-fold serial
dilutions of HIV-1NL4.3 retroviral supernatants containing 3×105 i.u./ml. Results of
triplicate samples and linear regression are shown.
and1c). To avoidnon-speciﬁc signal detectionofprimerdimers, ﬂu-
orescence was acquired at 83 ◦C (Fig. 1c). The melting temperature
of the PCR product was found to remain constant when recom-
binant MLV RT or different virus supernatants were tested (not
shown), indicating no need to adjust the acquisition temperature.
5.2. Sensitivity of the assay
The sensitivity of the SG-PERT was tested with the lightcycler
using 10-fold serial dilutions of recombinant HIV-1 RT, starting
from1mU. The assay provided a detectable and reproducible signal
down to the 10−7 dilution equivalent to 100pUofHIV-1 RT (Fig. 2a),
indicating a sensitivity close to that reported by other real-time
PCR-based RT-assays for the detection of HIV-1 RT (Arnold et al.,
1998; Lovatt et al., 1999; Maudru and Peden, 1997). The diagram
generated by plotting the crossing points against the enzyme dilu-
tion factor shows linearity over six orders of magnitude (Fig. 2b).
The ability of SG-PERT to detect HIV-1 virus particles in cell
culture supernatants was then tested in the lightcycler using cell
culturemediumderived fromJurkat E6.1producingHIV-1NL4.3. This
virus suspensionhad an infectious titre of 3×105 i.u./ml, a p24 con-
tentof355ng/mlandavirus loadof11.6×109 HIV-1RNAcopies/ml.
The SG-PERT could detect RT activity down to the 10−5 dilution
(Fig. 3). Because only 0.5l of virus sample is added to the 20l
reactions, it can be concluded that the assay detects RT activity
associated with six HIV RNA copies (three virions) or 1.7×10−3 pg
of p24. To establish whether SG-PERT can be performedwith equal
sensitivity using different real-time PCR platforms, the same virus
supernatant was tested using the 7900HT apparatus. As shown in
Fig. 3, the sensitivity and linear range of the assay remain similar
using both real-time PCR platforms.
5.3. Speciﬁcity of the assay
The performance of SG-PERTwas evaluated for the quantitation
and detection of virus particles and recombinant retroviral vectors
based on divergent retroviruses. For this purpose, serial dilutions
of cell culture supernatants from cells producing HIV and recom-
binant MLV or PFV GFP transducing vectors were tested in parallel
and in triplicate using the lightcycler. End-point infectious titres
were ﬁrst determined to be 4.0×106 i.u./ml for the HIV-1 sam-
ple, 7.4×105 i.u./ml for the PFV sample and 4.2×106 i.u./ml for
the MLV sample. Results show that for all three types of retro-
virus the assay is linear over ﬁve to six orders of magnitude and
Table 1
Detection of divergent retrovirus particles and intra-assay variation with SG-PERT.
Virus dilution Crossing point and coefﬁcient of variationa
HIV-1 MLV PFV
Neat 13.47 (0.28%) 17.08 (1.00%) 18.15 (1.26%)
10−1 16.12 (0.31%) 19.18 (0.64%) 21.64 (0.70%)
10−2 19.33 (0.26%) 22.52 (0.76%) 25.09 (0.74%)
10−3 22.92 (0.64%) 26.13 (0.61%) 28.71 (0.98%)
10−4 26.20 (0.19%) 29.70 (1.07%) 32.45 (0.30%)
10−5 29.79 (1.19%) 33.48 (0.66%) 35.64 (2.08%)
10−6 33.10 (0.68%) 36.32 (1.97%) n.d.
10−7 n.d. n.d. n.d.
n.d.: not detected.
a Crossing point calculated with the ﬁt points methods. Values are average of
triplicate dilutions values. Intraexperimental coefﬁcient of variation is indicated in
parenthesis.
detects RT-activity in supernatants containing less than 10 i.u./ml
(Fig. 4). As shown in Table 1, for all three types of virus and for
all dilutions tested, the coefﬁcient of variation ranges between
0.19% and 2.08%. Reaction efﬁciencies of 1.995, 1.997 and 1.894
for HIV-1, MLV and PFV, respectively indicate that SG-PERT can
be reliably used as a tool for the quantitation of divergent retro-
viruses.
Retrovirus-free supernatants fromuninfected cell cultureswere
used as negative controls. Rarely and randomly was a weak signal
detected with crossing point above 39 PCR cycles. This signal most
likely results fromtheactivity of eukaryotic polymerases associated
with cellular debris, as reported elsewhere (Voisset et al., 2001).
Only samples generating a signal at an earlier PCR cycle than the
virus-free control are, therefore, considered positive in these cases.
5.4. Reproducibility of the assay
Reproducibility of the assay was evaluated by testing serial
dilutions of the sameHIV-1 virus suspension in independent exper-
iments using the lightcycler. Four serial dilutions of an HIV-1 virus
supernatant were tested in 18 experiments performed using stocks
of lysis buffers and reaction mixtures prepared in three indepen-
dent occasions. The coefﬁcient of variation ranged from4.1% to 7.6%
(Fig. 5).
Fig. 4. Detection of divergent retroviruses by SG-PERT. Crossing points and
linear regressions obtained with 10-fold serial dilutions of retroviral super-
natants performed in triplicate in the lightcycler, using HIV-1NL4-3 (infectious titre
4×106 i.u./ml), MLV GFP vector (transducing titre of 4.2×106 i.u./ml) and PFV GFP
vector (transducing titre of 7.4×105 i.u./ml).
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Fig. 5. Intraexperimental variation. Results of 18 SG-PERT independent experiments
performed with the lightcycler using the same four HIV-1NL4.3 dilutions and three
independent lysis and reaction buffer stocks. Coefﬁcient of variation is indicated as
percentage of the respective mean crossing point value.
6. Discussion
A SYBR green I-based real-time PERT assay (SG-PERT) for the
quantitation and detection of HIV-1 and other divergent retro-
viruses is described. The assay is linear over six orders ofmagnitude
and requires less than 2h from sample preparation to data analysis
when performed using the lightcycler.
Although PERT was originally established as a two-step assay
(Heneine et al., 1995; Lovatt et al., 1999; Maudru and Peden, 1998;
Pyra et al., 1994; Yamamoto et al., 1996) the one-step assay, pre-
viously proposed using the ﬂuorescent probes techniques (Arnold
et al., 1998), adds convenience and minimizes sample handling,
whichmay cause cross-contaminations and decreases quantitative
reliability.
Based on the quantitation of viral RNA copies in a cell culture
supernatant containing HIV-1 particles, a 1/1500 ratio of infec-
tious units/total HIV-1 particles was established, a value within
the range reported in literature (Dimitrov et al., 1993; Kimpton and
Emerman, 1992). It was therefore estimated that the SG-PERT assay
candetect thepresenceof threeHIV-1particles in the reaction tube.
Because the virus sample represents only 5% of the 20l reaction,
the assay can reveal RT-activity in HIV-1 supernatants contain-
ing 6000 virions or 4 i.u./ml. While this satisﬁes most needs of a
retrovirus research laboratory, the detection capacity of the assay
can be increased by the addition of an ultracentrifugation step to
concentrate the virus before performing SG-PERT.
The reaction conditions were originally optimised for use with
glass capillaries in the lightcycler, which requires the presence of
BSA to prevent abstraction of reagents on the glass surface (Teo
et al., 2002). However, the same reaction formulation has allowed
efﬁcient and quantitative detection of RT activity also with the
7900HT platform, indicating that the protocol described here can
be performedwith real-time PCR platformswhich use plastic tubes
insteadof glass capillaries. Because thebuffersused in this studyare
entirely home-made, stocks prepared on different occasions might
contain small differences which could affect assay efﬁciency. How-
ever, the small inter-assayvariationobservedbetweenexperiments
performedusing different stocks of lysis and reaction buffers shows
that the SG-PERT is reproducible.
While the use of PERT was proposed originally for the detec-
tion of retroviruses in clinical specimens (Garcia Lerma et al., 1998;
Pyra et al., 1994), undiluted human plasma was found to inhibit
potently the one-step SG-PERT (data not shown), suggesting that
the assay might not be suitable for analyses of some complex bio-
logical samples. However, given its linearity over six orders of
magnitude, the simple set-up, the rapid procedure and the low
intra- and inter-assay variation, SG-PERT represents an ideal tool
for the routine quantitation of retroviruses in cell culture samples.
The assay proved also to be a useful tool with which to screen cell
lines for retrovirus contamination of tissue cultures (Takeuchi et al.,
2008).
This report provides all the information required to perform
SG-PERTwithout the need of acquiring expensive buffers with pro-
prietary formulations. Because theSYBRGreen I reagent is relatively
inexpensive, the assay described allows signiﬁcant cost savings
compared with the use of most alternative techniques.
6.1. Trouble-shooting
The effects of several chemicals and reagents on the perfor-
mance of the assay were investigated and are discussed here.
6.1.1. BSA requirement
SYBRGreen I is offered currently by different providers in ready-
to-use real-time PCR and RT-PCR kits. As the formulation of the
reaction mixtures is generally proprietary and, therefore, unavail-
able, the optimal reaction conditions for the reverse transcription
and ampliﬁcation of BMV RNA in glass capillaries were ﬁrst inves-
tigated using 1mU of recombinant HIV-1 RT, 5mM MgCl2 and a
1:20,000 dilution of SYBR Green I, already reported to be compat-
ible with a real-time PCR system (Karsai et al., 2002). After testing
numerous buffer formulations, it was established that efﬁcient PCR
ampliﬁcation requires BSA at a ﬁnal concentration of 0.1mg/ml
(Fig. 6a).
The importance of BSA for the reaction in glass capillaries has
been linked to the propensity of the glass surface to sequester some
reaction components, such as the taq polymerase (Teo et al., 2002).
As shown in Fig. 1, the reaction buffer containing BSA can be suc-
cessfully used in a real-time PCR platform accepting plastic tubes.
6.1.2. The use of different thermophilic polymerases
Several polymerases from different suppliers were tested. PFU
Ultra and PFU Turbo, which are reported to lack RT activity ((Arezi
et al., 2003) and products speciﬁcation from suppliers) could not be
adapted to real-time PCR in the light cycler (not shown). Platinum
Taq, AmpliTaq Gold, Easy-A performed very efﬁciently in the light
cycler with SYBR Green I, but generated a strong background sig-
nal arising early between cycle 20 and 30 in the absence of added
retroviral RT activity. Hot-start Taq-polymerase from MBI Fermen-
tas was selected because it consistently failed to reverse transcribe
the BMV RNA in 45-cycle PCR reactions.
6.1.3. Concentration and storage of SYBR Green I
Repeated freeze-thaw cycles were avoided by storing multi-
ple aliquots of the SYBR Green I concentrated stock and the 1/100
diluted aliquots used tomake themastermix at−80 ◦C. The reagent
was diluted in TE buffer, pH 8.0, as suggested elsewhere (Karsai et
al., 2002).More than two freeze-thawing cycles of the 1/100diluted
SYBR Green I aliquots resulted in a signiﬁcant loss of assay sensitiv-
ity (not shown). The assay sensitivity and strength depend on the
SYBR Green I concentration. The effects of different dilutions of the
dye ranging from 1/60,000 to 1/10,000 (Fig. 6b) were tested. The
1:20,000 dilution was chosen because it combines high sensitivity
with a robust signal.
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Fig. 6. Crucial effects of different reagents on the assay performance. (a) Positive effect of BSA on the SG-PERT reaction. (b) Performance of the assay with varying SYBR Green
I concentrations, as indicated. (c) Inhibitory effects of different components of the virus lysate. (a), (b) and (c) were obtained by testing 1U of recombinant HIV-1 RT. (d)
Effects of varying amount of virus lysate on the assay performance using HIV-1 NL4-3 containing supernatant. Percentages in (c) and (d) indicate the reagent volume as a
proportion of the total reaction volume.
6.1.4. The effect of different components of the virus lysate on the
outcome of the assay
After optimising the reactionusing recombinantHIV-1RT, based
on previously described protocols (Heneine et al., 1995; Lovatt et
al., 1999; Maudru and Peden, 1998; Pyra et al., 1994; Yamamoto
et al., 1996), the assay was tested with a suspension of HIV-1 viri-
ons lysed in a buffer supplemented with 0.2U/l RNAse inhibitor,
1mM DTT. The assay repeatedly failed to generate any signal, indi-
cating that the virus lysate could contain inhibitory reagents. We
tested the effects of single components of the virus lysate on the
SG-PERT efﬁciency using 1U of recombinant HIV-1 RT (Fig. 6c).
We established that 0.1mMDTT acts as a powerful inhibitor, in line
with previous reports indicating a negative interference with SYBR
Green I-based RT-PCR (Lekanne Deprez et al., 2002; Pastorino et
al., 2005; Pierce et al., 2002; Varga and James, 2005). The presence
of RPMI culture medium in the reaction was also found to affect
negatively the assay when it represented 10% of the ﬁnal reaction
volume. Similarly, when 1.6U of the RNAse inhibitor was present in
the 20l reaction the assay failed. In contrast, other components of
the virus lysates did not signiﬁcantly affect the performance of SG-
PERT.WhileDTTcanbeomitted fromtheRT reactionwithout lossof
enzyme activity (data not shown and Lekanne Deprez et al., 2002),
the inhibitory effects of culture medium and RNase inhibitor were
avoided by minimizing the amount of virion lysate added to the
reaction mix. Given that the presence of RNAse inhibitor is strictly
essential, its negative effectswereminimized by treating the virion
lysate (which represents themain sourceof RNAses) rather than the
total reaction with a concentrated formulation of RNase inhibitor.
A robust signal was, therefore, obtained only when the virus lysate
was not exceeding 5% of the ﬁnal reaction volume (Fig. 6d).
6.1.5. Divalent cations
Since efﬁcient reverse transcriptase activity is known to require
Mg2+, MgCl2 concentrations ranging from 1.25 to 10mM were
tested and found to have no signiﬁcant effects on the assay sen-
sitivity (not shown). Although gamma-retroviruses are known to
prefer Mn2+, addition of 2mMMnCl2 to the reaction assay resulted
in 100-fold lower efﬁciency of detection of MLV virus suspensions
(not shown).
6.1.6. Absolute quantitation of virus suspensions
For experimental purposes, absolute values of the virus suspen-
sions tested can be retrieved from a standard curve created using
known amounts of recombinant RT or serial dilutions of a previ-
ously characterized virus stock.
6.1.7. Improved primer design
An alternative set of oligonucleotides (forward: 5′-
TAGTTGTTGGGCTTCGCTTT-3′; reverse:5′-TTGTCGGCTTTACCTGC-
TTT3′) was designed to avoid primer-dimer formation with SG-
PERT under the same conditions described in the article.While this
modiﬁcation does not alter the properties of the assay, it further
improves the signal generated by low levels of RT activity.
Essential literature references:
• Arnold et al. (1998)
• Chang et al. (1997)
• Lovatt et al. (1999)
• Maudru and Peden (1998)
• Pyra et al. (1994)
• Silver et al. (1993)
• Sears and Khan (2003)
7. Quick procedure
7.1. Sample preparation
• Virus supernatants areharvested, clariﬁedby low-speedcentrifu-
gation (400g) for 10min and ﬁltered through a 0.45m pore
ﬁlter.
• RNAse inhibitor (0.4U/l) is added to 2× virus lysis buffer.
• 5l aliquots of 2× lysis buffer are immediately dispensed into
1.5ml microfuge tubes.
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• 5l of virus suspensions are added to the tubes and mixed with
the 2× lysis buffer.
• Samples are incubated at room temperature for 10min.
7.2. Reaction set-up (for lightcycler)
• Taq polymerase (0.2U/reaction) is added to 2× reaction mix.
• Ten microliters aliquots of 2× reaction mix are placed into the
reservoir of pre-chilled glass capillaries.
• Virus lysates (10l) are dilutedwith the addition of 90l of sam-
ple dilution buffer and vortexed.
• Tenmicroliters of each diluted sample is immediatelymixedwith
the reaction buffer in glass capillaries.
• Capillaries are centrifuged in amicrofuge at 3000 rpm for 15 s and
inserted into the LightCycler carousel.
• Reaction is performed in the LightCycler using the following
parameters:
o 30min RT reaction at 37 ◦C.
o 5min hot-start Taq activation at 95 ◦C.
o 45 cycles of ampliﬁcation (5 s denaturation at 95 ◦C, 5 s anneal-
ing at 55 ◦C, 15 s extension at 72 ◦C, 7 s acquisition at 83 ◦C).
o Optional melting analysis of PCR products from 60 to 95 ◦C.
7.3. Data analysis
• Arithmetic background correction and automatic noise band
adjustment are performed.
• The maximum number of ﬁt points ﬁtting the linear portion of
the curve is added for the calculation of crossing points.
• A standard curvemay be obtained using known concentrations of
recombinantRTordeﬁneddilutionsof avirus suspension toallow
absolute quantitation or data comparison between experiments:
o A minimum of four standard samples are included in the RT
assay.
o The threshold line for crossing point calculation is automati-
cally deﬁned by the software in order tominimize errors of the
standard curve.
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HIV can be partially contained by host immunity and understanding the basis of this may inform 
vaccine design. The importance of B-cell function in long-term control is poorly understood. 
one method of investigating this is in vivo cellular depletion. In this study, we take advantage 
of a unique opportunity to investigate the role of B cells in an HIV-infected patient. The HIV-1 +  
patient studied here was not taking antiretroviral drugs and was treated for pre-existing low-
grade lymphoplasmacytoid lymphoma by depletion of CD20 +  B cells using rituximab. We 
demonstrate that B-cell depletion results in a decline in autologous neutralizing antibody (nAb) 
responses and a 1.7 log10 rise in HIV-1 plasma viral load (pVL). The recovery of nAbs results in 
a decline in pVL. The HIV-1 sequences diversify and nAb-resistant mutants are subsequently 
selected. These data suggest that B-cell function can contribute to the long-term control of pVL, 
and that nAbs may be more important in controlling chronic HIV-1 infection than previously 
suspected. 
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B-cell depletion reveals a role for antibodies in the 
control of chronic HIV-1 infection
Kuan-Hsiang G. Huang1,*, David Bonsall2,*, Aris Katzourakis3, Emma C. Thomson2, sarah J. Fidler2, Janice main2, 
David muir2, Jonathan n. Weber2, Alexander J. Frater1, Rodney E. Phillips1, oliver G. Pybus3, Philip J.R. Goulder1,  
myra o. mcClure2, Graham s. Cooke2,† & Paul Klenerman1,†
ARTICLE

nATuRE CommunICATIons | DoI: 10.1038/ncomms1100
nATuRE CommunICATIons | 1:102 | DoI: 10.1038/ncomms1100 | www.nature.com/naturecommunications
© 2010 Macmillan Publishers Limited. All rights reserved.
HIV-1 is readily able to evade host defence and establish per-sistent infection. The virus may, however, be partially con-tained by host adaptive immunity, including both B- and 
T-cell responses. There is good evidence that CD8 +  T-cell responses 
have a role in viral suppression. For example, there are strong HLA 
class I associations with clinical outcome1, and in the SIV model, 
macaques in whom CD8 +  T cells are depleted show significant 
increases in their viral load2. These findings have led to a major ini-
tiative to develop T-cell-based vaccines, and much work to define 
the correlates of protection based on assays of T-cell function3,4. 
However, as a leading HIV vaccine candidate failed to induce pro-
tective T-cell responses5 and recent trial data suggest partial protec-
tion from a vaccine including a gp120 component6, the incentive to 
understand the role of neutralizing antibodies (NAbs) and of B cells 
in HIV infection has increased considerably7–9.
B cells have a multifaceted role in humoral and cellular responses 
to HIV-1, yet their impact in containing the virus remains unclear. 
This is partly because of the complex nature of the antigenic target 
(gp120)10. Key obstacles to the development of both T- and B-cell 
defence are the abilities of the HIV-1 genome to integrate and also 
evolve rapidly in the face of immune selection pressure: the latter 
feature results from both the high replication rate of the virus and 
the error-prone nature of the HIV-1 reverse transcriptase, which 
lacks proofreading capacity11. These mutations are readily accom-
modated within gp120 because of plasticity of the structure and 
the capacity to acquire glycosylation sequons that provide a ‘glycan 
shield’12. Therefore, emerging NAbs repeatedly select mutant viruses 
that are resistant to neutralization13. The NAb response also evolves 
through somatic recombination and affinity maturation of prolif-
erating B cells, but is only partially effective against concurrently 
circulating viruses, while retaining potent activity against strains 
previously circulating within the patient13–15. Such data have cast 
doubt on the contribution of NAbs to the control of virus load, 
despite the counterargument that NAbs must inhibit virus replica-
tion to drive the selection of resistant variants.
Monoclonal antibodies have been identified that both cross-
 recognize and potently neutralize a variety of HIV-1 strains16–19. The 
targets for these are well defined and include, among others, CD4 and 
co-receptor binding sites and epitopes within the gp41 fusion subunit20. 
These areas are under some structural constraint compared with other 
epitopes, such as in the exposed variable loops. Few potent monoclonal 
antibodies have been isolated, yet the proportion of gp120-specific anti-
bodies capable of neutralization may be greater than once believed8,21. 
Recent studies indicate that some individuals possess NAbs that exhibit 
broad and potent neutralization capacity18,21,22, but functional data 
to causally link such antibodies to the control of viremia are lacking. 
Furthermore, the contribution of B-cell responses to the containment 
of plasma viral load (pVL) has been difficult to determine, because 
of other important factors that limit virus replication, such as T-cell 
response, virus fitness and host genetics23.
Historically, functional importance has been confidently attrib-
uted to specific arms of the immune response by means of experi-
ments that deplete or transfer that effector arm. Although such data 
are readily available in animal models, they are rarely available in 
humans. As recent vaccine studies have highlighted substantial dif-
ferences between SIV models and HIV, it is important to seek such 
evidence in human studies.
Rituximab (Rituxan, MabThera; Roche) is a monoclonal anti-
body targeting CD20 antigen expressed on most B cells, with 
the exception of the terminally differentiated plasma cells. It has 
become widely used for treatment of lymphoma and also of anti-
body-mediated autoimmune diseases24. We report a unique case 
in which rituximab monotherapy was used in a patient with stable 
viraemia, in the absence of antiretroviral therapy (ART).
By combined analyses of viral dynamics, viral evolution and 
autologous NAb responses, we show reversible loss of HIV-1 
control following rituximab monotherapy. Loss of control was associ-
ated with reduction in titres of NAbs targeting the CD4 binding site, as 
well as with an increase in genetic diversity and transient reversion to 
NAb-sensitive virus. As NAb levels later increased, pVL was once more 
controlled and this was accompanied by further immune selection of 
NAb-resistant viruses. These data suggest that despite ongoing immune 
escape, NAbs secreted by CD20 +  B cells may have a significant role 
in control of pVL during chronic HIV-1 infection, a finding of signifi-
cance for HIV-1 immunotherapies and vaccines.
Results
Clinical course of the study subject. The patient, a Caucasian 
man, was diagnosed with HIV seroconversion illness at the age 
of 58 years. Three years earlier, he was diagnosed with low-grade 
lymphoplasmacytoid lymphoma, for which he did not receive 
treatment25. Histologically, this was defined as a small lymphocytic 
B-cell lymphoma with plasmacytoid differentiation mostly 
expressing CD20 and CD79. The tumour was IgM secreting. His 
only other medical history of note was an acute hepatitis B infection 
approximately 30 years earlier. Following HIV-1 seroconversion, 
the patient was recruited into a prospective, non-randomized 
observational study of early treatment and received 3 months of 
highly active antiretroviral therapy26. After 30 months, he developed 
a rising paraproteinaemia, attributed to his lymphoma, and received 
thalidomide treatment without clinical effect. He initiated rituximab 
therapy 1,075 days after HIV seroconversion and received four 
weekly doses (375 mg m − 2). He felt unwell 20 weeks after the first dose 
of rituximab with malaise and fever associated with a marked rise 
in HIV pVL (increase of 1.7 log10; Fig. 1). In addition, he developed 
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Figure 1 | Autologous neutralizing antibody titres over time. (a) 
Pseudotyped virus particles were constructed using full-length envelope 
clones that represent majority quasi-species at 336 or 1,042 days after 
seroconversion. Plasma VL over time is indicated (red line). The brief dip 
in viral load over the first 100 days represents the period of initial ART 
as part of the short-course ART trial (shaded grey). The neutralizing 
effects (%; right y axis) of patient sera are shown for autologous viruses 
constructed with cloned env genes derived 336 days (black squares) and 
1,042 days (crosses) after seroconversion. Results from a single clone 
(tested in triplicate) representative of three clones are shown. serum was 
sampled sequentially before and after rituximab therapy (1,075–1,106 days, 
shaded grey), and assayed at concentrations ranging from 1:20 to 1:4,370; 
the neutralizing effects of sera diluted 1:180 are shown here. Error bars 
show standard deviations of triplicate tests. (b) CD4 T lymphocyte count 
(dashed line) is shown over time.
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biochemical hepatitis (attributed to reactivation of hepatitis B) 
that resolved with only supportive treatment. Antiretrovirals were 
initiated 1,392 days after seroconversion.
Impact of B-cell depletion on NAb titres. Following rituximab ther-
apy, the subject’s HIV-1 pVL, previously stable, increased by more than 
1.7 log10, peaking at 737,400 copies per ml 4 months after the final dose 
of rituximab (Fig. 1). The pVL subsequently returned to baseline levels 
in the absence of ART. We therefore analysed the impact of rituximab 
therapy on NAb titres in relation to viral dynamics.
Rituximab therapy led to a 30% reduction in total IgG levels, 
which reached their lowest point at the peak of virus load (10.8 g l − 1; 
normal range 8–16 g l − 1) and returned to pre-rituximab levels there-
after (Supplementary Table S1). To evaluate NAb activity throughout 
this period, we generated pseudoviruses derived from autologous 
envelope (env) sequences. Serum obtained before the first dose of 
rituximab potently neutralized virus pseudotyped with autologous 
envelope derived from plasma acquired 2 years previously (day 336 
after seroconversion) (Table 1). The same serum neutralized con-
temporaneous autologous Env pseudotypes, although to a lesser 
extent, with 1:60 serum dilutions effectively blocking more than 
90% infection. Heterologous NAb activity was also observed against 
HXB2 and 8/12 Tier 2/3 clade-B reference strains (NIH, AIDS) 
(Table 2). Following rituximab therapy, we observed a marked 
decrease in neutralizing activity characterized by a drop of more 
than threefold in IC50 serum titres against day 336 Env pseudotypes, 
which recovered over a 4-month period. Strikingly, these changes 
coincided with the increase in pVL. Recovery of NAb responses cor-
related with control of viraemia (Fig. 1).
Analysis of sequence evolution in HIV-1 envelope over time. 
To evaluate sequence evolution over this period, env products 
were generated by reverse transcription (RT)–PCR from plasma 
viral RNA, before and after rituximab therapy (days 1,075–1,392; 
Fig. 2a). We identified clear sequence diversification as the virus 
peaked during rituximab treatment (mean genetic distance = 0.02 
versus 0.004; P < 0.0001). This diversification manifested as an 
increase in effective population size as measured using BEAST27 
(fivefold change; Fig. 2b). To assess whether these diverse strains 
represented a re-emergence of archived provirus, we used an identi-
cal sequencing strategy to analyse stored peripheral blood mononu-
clear cell (PBMC) samples available from the time of seroconversion 
up to day 1,042; these sequences were placed on a time-structured 
tree (Supplementary Fig. S1). Viruses detected after rituximab 
treatment did not represent re-emergence of early archived strains; 
those strains present as pVL peaked were most closely related to 
strains present in plasma at day 1,042, with a subset related to those 
archived in PBMC at day 1,042.
Immune selection and neutralization of HIV-1 envelope. The appar-
ent in vivo impact of the NAbs in this individual prompted a search 
for the targets of binding. To identify potential NAb targets, we first 
analysed immune selection using CODEML, analysing the ratio of 
non-synonymous to synonymous mutations (dN/dS) at each site. We 
observed two sites under selection (Fig. 3; Supplementary Fig. S1)—
position 339 (dN/dS = 7.6, P < 0.0001) and position 363 (dN/dS = 6.977, 
P = 0.03). Residue 363 lies between the β14 and β15 anti-parallel 
strands of gp120 and is exposed on the surface of the outer domain in 
close proximity to the CD4 binding loop28. Computational modelling 
of atomic level envelope structures has shown that mutations proxi-
mal to the CD4-binding loop are critical in conferring resistance to 
CD4bs antibodies29. Furthermore, site-directed mutagenesis of site 363 
has previously been shown to affect neutralization of the CD4bs anti-
bodies M-14 and b1230,31. Before the first dose of rituximab (day 1,042 
after seroconversion), position 363 was occupied by an arginine in all 
viral RNA sequences, whereas all proviral DNA clones sampled up to 
and including day 1,042 had a glutamine at the same position. Fol-
lowing rituximab therapy, R363 variants were temporarily replaced 
with Q363 variants, which reverted to arginine residues as NAb titres 
rebounded and viraemia was controlled.
Before rituximab therapy, an asparagine at site 339 formed part 
of an N-linked glycosylation site. This residue is located within the 
α3 helix, which is exposed on the surface of the protein according 
to atomic level structures. A previous study showed that site 339 is 
involved in recognition by 2G12, a monoclonal antibody the bind-
ing of which is carbohydrate dependent32. However, in addition to 
this, mutations at site 339 have been reported to affect binding by 
monoclonal antibody b12: this effect is observed despite site 339 
being some distance away from the CD4 binding site, and poten-
tially occurs through conformational perturbation32. No other sites 
in the envelope were found to be under positive selection, indicating 
that mutations at these positions affected NAb binding.
To examine the effect of sequence changes on neutralization 
susceptibility, pseudoviruses mimicking Q363R and R339N/E were 
constructed by site-directed mutagenesis. The selected Q363/339E 
mutation reduced the IC50 titres of day 1,042 serum by more than 
twofold (IC50 from  > 775 to 300). Confirming previous data, the 
Q363R mutation was also shown to inhibit neutralization by fivefold 
by antibody b1231, whereas N339E inhibited neutralization suscepti-
bility by fourfold to the carbohydrate-specific antibody 2G1212,32.
To further define the site of binding of the patient’s NAbs, we 
performed a direct competition experiment using well-defined 
monoclonal antibodies and recombinant clade B envelope as the 
antigenic target (Fig. 4). This experiment showed strong binding 
competition between patient sera and antibodies b12, 4.8d (which 
targets an epitope overlapping with the co-receptor binding site) and 
447-52D (which targets the V3 loop). No competition was observed 
against 2G12. The experiment also revealed a clear decline in com-
petition for binding in samples taken during the peak of viraemia, 
which recovered as pVL declined, in good accordance with the data 
obtained from the neutralization experiments, but using an inde-
pendent system of evaluation (Fig. 4b).
Table 1 | IC50 neutralizing titres against autologous viruses.
Serum (day) D336 pseudovirus D1042 pseudovirus HXB2 VSV-G
1,042  > 775 150 850  < 20
1,135  > 775 225 1000 n/T
1,239 220  < 120* 875 20
1,295 250 150 325 20
1,308 360 375 1000  < 20
1,353 600 425 3950 n/T
negative serum  < 20  < 20  < 20 n/T
Abbreviations: n/T, virus-serum combinations that were not tested because of limited availability of sera; VsV-G, vesicular stomatitis virus control.
The mean half maximal inhibitory concentrations of sera (IC50, reciprocal dilutions) are given for three viruses pseudotyped with representative Env clones derived from d336 and d1042 plasma  
(autologous).
*1:120 was the highest concentration of day 1,239 serum that could be tested against day 1,042 virus due to limited serum availability.
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Analysis of other potential effects of rituximab. We investigated 
other possible causes for the observations made, particularly the 
possibility of an indirect impact on cellular immunity33. We ana-
lysed the sequence of key CTL epitopes over time, and carried out 
interferon-γ (IFN-γ) ELISpot analyses. Although some mutations in 
pre-rituximab sequences were observed, the majority of the epitopes 
remained stable (Table 3). It is of importance that control over pVL 
was regained without further escape/reversion at these sites.
Second, immune activation through recrudescence of other 
infectious agents may have a role in this case. Concurrent with the 
pVL increase, the patient also developed elevated liver transami-
nases, associated with reactivation of previously controlled hepatitis 
B virus (HBV) infection34. However, control of HIV was observed 
at a time when HBV load was still high, suggesting that HBV rep-
lication per se was not driving HIV replication (up to day 1,389; 
Supplementary Fig. S2) in this patient. In the setting of acute 
illness, there was no evidence of EBV, HHV-6, HHV-8 or HCV 
in blood. Cytomegalovirus was present only at low copy number 
(50 copies per ml). A bronchoalveolar lavage was tested for a broad 
panel of relevant viruses, all of which were negative, including VZV 
and HSV1/2. Clearly, these data do not exclude reactivation of a 
further latent infection, or concurrent superinfection, although 
the major herpesvirus infections appear unlikely to be contributing 
significantly.
Discussion
In this study, B-cell depletion led to a decline in NAb titres against 
HIV, concurrent with rising pVL. Recovery of NAb titres coincided 
with control over viral load. Multiple analytical techniques were 
used to longitudinally characterize the distinct virus population that 
emerged as NAbs returned. The common ancestor of this new virus 
population was defined by polymorphisms at two residues exposed 
on the surface of the virus envelope, both of which showed evidence 
of positive selection, with mutations affecting binding of NAbs.
There are no published studies on the impact of rituximab alone 
on HIV viraemia in humans. Studies on acute SIVmac infection in 
macaques treated with rituximab indicate a role for NAb responses 
in containing post-acute viral load35,36. In contrast, a recent study 
Table 2 | IC50 neutralizing titres against heterologous viruses.
Serum (day) HXB2 6535 QH0692 PVO TRO AC10.0 pREJO 4541 pTRJO 4551
pRHPA 
4259
1,042 850 220 220 90 120 90 140 50 50
1,353 3950 300 170 90 130 160 220 140 120
negative  < 20 20*  < 20  < 20  < 20  < 20 20* 20*  < 20
The mean half-maximal inhibitory concentrations of sera (IC50, reciprocal dilutions) are given for pseudoviruses derived  from a standardized reference panel (nIAID, nIH) (heterologous). Reductions in 
infected TZm-bl cells by pooled HIV-negative sera (*) were attributed to cellular toxicity which was not observed at concentrations below 1:20.
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Figure 2 | Diversification of HIV-1 env sequences after rituximab 
therapy. (a) A time-structured tree, showing divergence-time estimates 
among intra-host plasma HIV-1 clonal sequences before and after 
rituximab therapy (shaded grey), based on a Bayesian relaxed molecular 
clock applied to 969 nucleotides58. The external nodes represent 
sequences taken from time points indicated by the colours given in the 
figure key (inset). The topology is of the highest likelihood calculated 
using BEAsT, with branch lengths proportional to time estimates for the 
subtending nodes (summarizing 60 million markov chain monte Carlo 
(mCmC) simulations, generated after discarding 6 million as burn-in). 
All the parameters in the mCmC started from random values, except for 
substitution rates and population size, where the priors were imported 
from the combined proviral and plasma viral sequence data of the same 
host calculated by BEAsT software. (b) The effective population sizes 
(neτ) were calculated using BEAsT. The x axis (days after seroconversion) 
is the same as for Figure 2a59.
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Figure 3 | Tracking of selected envelope mutants. This figure shows 
the relative frequencies of polymorphisms at sites (a) 339, dN/dS = 7.61 
P < 0.0001 and (b) 363 dN/dS = 6.98 P < 0.031. The individual bars along 
the x axis represent the different time points of sequencing (comparable 
to Fig. 2; supplementary Fig. s1): these are taken either from proviral DnA 
samples (days 20–1,042) or from plasma samples (days 1,042–1,392). 
The time of rituximab therapy is indicated. Each bar shows the frequency 
of mutations at these positions, the key depicts the different amino-acid 
residues detected.
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using African Green monkeys did not reveal any effect of rituximab 
treatment during acute SIVagm infection37; thus, data from human 
studies are important to resolve this issue.
It is possible that depletion of B cells had an indirect impact on 
viral load through modulation of CD4 +  or CD8 +  T-cell subsets. 
Although we cannot exclude this, the mechanism for such an indi-
rect effect is not clear and, importantly, no impact on CD8 +  T-cell 
responses has been observed in the SIV models quoted above36. The 
delay of several weeks that is observed between rituximab treat-
ment and the change in viral load is much more consistent with 
the observed decline in antibody titres than a direct B-cell/T-cell 
interaction, which would be expected to take effect immediately. 
In addition, the changes in the prevailing sequence (reversion and 
subsequent re-selection of a mutated NAb epitope; Figs 2, 3; Supple-
mentary Fig. S1) are consistent with relaxation and re-application of 
NAb-mediated selection pressure.
The impact of other reactivating viruses on HIV load is complex. 
As in this case, rituximab treatment is known to have the potential to 
reactivate HBV38, even in those with previously controlled infection 
(HbsAg − , HBcoreAb + ). This points to an important role for B cells 
in long-term control of HBV—a virus in which CD8 +  T cells have 
an important role in acute disease39. The relationship between HBV 
pVL and HIV pVL is not fully understood, but overall these appear 
to be independent40,41. In this case, HBV and HIV pVL increased 
within a similar timeframe; however, control over HIV occurred 
spontaneously, whereas HBV load remained high, indicating that 
they were differentially regulated in this patient (Supplementary 
Fig. S2). However, this does not exclude a secondary impact of HBV 
through induction of liver inflammation or other consequences of 
immune activation. In addition, although we did not find other evi-
dence of systemic reactivation of other major pathogens in this indi-
vidual, it remains possible that local or low-level reactivation could 
also affect HIV pVL.
Overall, our findings support previous suggestions of an evolution-
ary balance between virus and NAbs12,42. At first sight, these findings 
appear at odds with previous studies that fail to confirm an associa-
tion between long-term virus control and NAb response, especially in 
elite controllers43. However, as shown here, the dynamics of immune 
responses are critical to their interpretation; therefore complex rela-
tionships could easily be missed in cross-sectional studies, especially 
analyses of those with favourable CD8 +  T-cell responses1,43,44.
There is a clear relationship between the changes in NAb titre 
and pVL demonstrated in this study, although the mechanism of 
action of such NAbs in vivo may be complex. Studies using engi-
neered antibodies in which Fc binding was disrupted have shown 
that interactions of NAbs with infected cells, leading to engagement 
of effector cells, may provide an important component of the pro-
tective capacity in vivo45,46. It is also possible that other non-NAb 
specificities not defined using in vitro NAb assays might have a role 
in vivo47. It is noteworthy that as B-cell responses to HIV envelope 
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Figure 4 | Characterization of patient antibodies by competition ELISA. 
(a) serial dilutions of patient serum (x axes) collected on days 1,042 (filled 
diamonds), 1,270 (filled circles), 1,295 (filled triangles) and 1,353 (filled 
squares) after seroconversion reduced gp120 binding with nAbs b12,  
447-52D and 4.8d, thereby reducing colorimetric change and light 
absorption (A450 nm, y axes). Pooled serum collected from HIV-uninfected 
subjects (stars) did not compete with any nAb for gp120 binding. All 
sera failed to compete with 2G12 for gp120 binding. (b) The reciprocal 
dilutions of sera, sampled before and after rituximab therapy, which reduce 
gp120-nAb binding by 50% (IC50, right y axis). Hundred percent binding 
was taken as that observed in microtitre wells containing IgGb12 (empty 
squares), 4.8d (empty triangles) or 447D (empty circles) in the absence of 
patient sera. Corresponding VLs are shown by the red line (left y axis).
Table 3 | Analysis of CD8 +  T cell responses and epitope evolution over time.
Epitope Autologous sequence
Response  
pre-rituximab Year 1
Response  
pre-rituximab Year 3
Mutation  
pre-rituximab
Mutation  
post-rituximab
A11 gag TK8 TLYCVHQK 1,200 — K8n Q7A
A11 pol AK11 ACQGVGGPGHK 300 — — G9A
A11 nef QK10 QVPLRPmTYK — — — —
A11 pol AK9 AIFQCsmTK — — — —
B8 gag p17 GK9 GGsKKYQLK — — K3R/K7Q K3R/K7Q
B8 gag p17 EV9 ELKsLYnTV 160 200 — —
B8 gag p24 DI8 DIYKRWII 640 600 — —
B8 gag p24 DL9 DCKTILKAL — — — —
B8 nef Wm9 WPKVRERm — — K3G/E6D K3R
B8 nef FL8 FLKEKGGL — — K5Q K5Q
B57 gag TW10* TsnLQEQIGW* — — n3T (242)* n3T (242)*
CD8 +  T cell responses were analysed using ex vivo IFn-γ-ELIspot analysis (spot forming units/million PBmCs are shown). The HLA Class IA and Class IB genotypes are A0101, A1101 and B0801, B0801. 
sequencing of the corresponding peptides was carried out at the time points shown, and mutating residues have been underlined.
*This epitope is a B57 escape mutant, transmitted to, but not recognized by the recipient, and which shows reversion pre-rituximab therapy.
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may be poorly sustained, it has been proposed that long-term plasma 
cell pools may not be established (reviewed in refs 48,49). As plasma 
cells are spared the effects of rituximab50 (and total IgG levels there-
fore remain relatively less affected), it is suggested that the antiviral 
NAbs identified here, and potentially elsewhere, are maintained by 
B-cell populations that express CD20.
In conclusion, this unique study suggests that B cells, and their 
secreted NAbs, can affect HIV viral load in chronic infection. This 
evidence, derived directly from observations in man, may inform 
the rational design of future immunotherapies and HIV vaccines.
Methods
Construction of HIV-1 env expression cassettes. The study was approved accord-
ing to local ethical review (IRB Number 99/IA/161E). Full-length virus env was 
PCR amplified from cDNA obtained by RT of plasma-derived viral RNA collected 
336 and 1,042 days after seroconversion for construction of pre-rituximab Env-
pseudotyped virus. The latter time point represented virus present around the time 
of rituximab treatment. The primers used were env1A (outer sense, 5′-CACCG-
GCTTAGGCATCTCCTATGGCAGGAAGAA3′), env1M (outer antisense and 
RT, 5′-TAGCCCTTCCAGTCCCCCCTTTTCTTTTA-3′)51, envF1/2 (inner sense, 
5′-GGGCTCGAGACCGGTGAGCAGAAGACAGTGGCAATG( ± A)-3′) and 
envR1/2 (inner antisense, 5′-AAATCTAGAGGGCCCCCATTGCCACCCATBTTA
( ± TAGC)-3′). Bulk PCR products were restriction-cloned into pcDNA3.1 (Invitro-
gen) using sites ApaI and XhoI to result in pcDNA3.1.env, followed by sequencing. 
Of 20 genetically distinct clones that were most representative of the consensus 
sequence, 3 were selected for neutralization experiments.
Site-directed mutagenesis. Where stated, 100 ng pcDNA3.1.env was used as a  
template for PCR amplification using PfuUltraII Fusion HS (Stratagene) in the  
supplied buffer supplemented with 250 µM dNTPs and 3% dimethylsulphoxide.  
Mutagenesis primers contained restriction sites inserted by synonymous  
mutation (underlined): R339Nf (5′-ATTGTAACATTTCTCGAGTAGAATGGAA 
TGACACCTTAA-3′), R339Nr (5′-TTAAGGTGTCATTCCATTCTACTCGAGAA 
ATGTTACAAT-3′), R339Ef (5′-ATTGTAACATTTCTAGAGTAGAATGGGAAGA 
CACCTTAA-3′), R339Er (5′-TTAAGGTGTCTTCCCATTCTACTCTAGAAATGT 
TACAAT-3′), Q363Rf (5′-TAAAACAATAATCTTTAATCGATCCTCAGGA-3′) 
and Q363Rr (5′-TCCTGAGGATCGATTAAAGATTATTGTTTTA-3′). After 18 
amplification cycles (95 °C for 50 s, 60 °C for 50 s and 68 °C for 9 min), dam-methyl-
ated PCR templates were eliminated by DpnI restriction digestion. Mutant clones 
were identified by restriction analysis and confirmed by nucleotide sequencing. 
Double mutants were constructed by sequential PCR amplifications.
Construction and neutralization of Env-pseudotyped virus particles. Autolo-
gous env clones and a heterologous panel of subtype-B reference strains52 were 
co-transfected with the HIV-1 backbone nl4.3∆env53 into 293T-17 human epithelial 
kidney cells using Lipofectamine 2000 (Invitrogen). At 48 h following transfection, 
supernatants were collected by 0.45-µm filtration and stored at  − 150 °C before ti-
tration onto the HIV-permissive reporter cell line, TZM-bl, which stably expresses 
Escherichia coli β-galactosidase under regulatory control of a Tat-responsive HIV-1 
long terminal repeat. Cells were fixed with glutaraldehyde (0.2%) and stained with 
X-gal substrate 48 h after infection. After staining, infected cells formed ‘blue’ 
focus-forming units, which were counted under light microscopy to determine the 
virus titre. Autologous Env-pseudotyped virus was confirmed to be R5 tropic by 
titration onto CD4 + CCR5 +  and CD4 + CXCR4 +  GHOST cell lines, which express 
green fluorescence protein in response to viral Tat.
For neutralization experiments, pseudotyped virus was incubated for 1 h with 
a threefold dilution series of heat-inactivated serum, or with broadly specific NAbs 
(b12 or 2G12)12. After 48 h, fixed and stained cells were manually counted and 
neutralization was measured as the percentage reduction of focus-forming units 
relative to non-neutralized virus controls. Samples were prepared in triplicate 
microtitre wells and counts were verified by separate investigators (DB and ET).
Competitive binding assays. Antibody specificity was mapped using a com-
petitive-binding enzyme-linked immunosorbent assay (ELISA). High-binding 
microtitre plates (Greiner) were coated overnight with recombinant Bal-strain 
gp120 and blocked with 2% milk powder to limit non-specific antibody binding. 
Each plate received threefold dilution series of patient sera and was incubated with 
50% saturating titres of biotinylated NAbs (b12, 2G12, 447-52D). An additional 
plate was pre-incubated with the CD4 peptide mimic M33 before incubation with 
biotinylated NAb 4.8d54. Bound NAb was detected with streptavidin horseradish 
peroxidase and TMB chromogen substrate. Serum-mediated inhibition of NAb 
binding was determined as the percentage reduction in light absorbance (A450 nm) 
compared with wells that received dilution buffer (PBS 0.05% Tween 20, 1% bovine 
serum albumin) instead of serum.
ELISpot for interferon-γ secreting CD8 +  T cells. This was performed using 
panels containing optimized HLA-matched peptides55. Fresh PBMCs were tested 
for T-cell responses using ex vivo Interferon-γ ELISpot assays. 96-well nitrocel-
lulose plates (Millipore) were coated with 0.05 µg ml − 1 recombinant anti-IFN-γ 
(Mabtech) in PBS overnight at 4 °C. Plates were then washed seven times with PBS 
and blocked with R10 for 2 h at 37 °C. PBMCs (2 × 105) were added to each well and 
then stimulated with peptide. The final concentration for peptide stimulation was 
10 µg ml − 1 and each peptide was tested in duplicate. Medium alone was used as a 
negative control and 1 µg ml − 1 phytohemagglutinin was used as a positive control 
for all assays. The assay plates were incubated for 18 h at 37 °C and, after extensive 
washing with PBS, a biotinylated secondary mouse anti-human IFN-γ monoclonal 
antibody (0.05 µg ml − 1; Mabtech) was added. The plates were developed using an 
alkaline phosphatase-conjugating substrate AP colour reagent A + B (BioRad).  
After 15 min, the colorimetric reaction was stopped by washing with tap water. 
Plates were air dried and spots were counted using an automated ELISpot reader 
(AID ELISpot Reader System). IFN-γ-producing T cells were expressed as spot-
forming units per 1×106 cells. The number of specific IFN-γ-secreting cells was cal-
culated by subtracting the unstimulated control value from the stimulated sample.
Sequence evolution and bioinformatics software. For sequence evaluation in 
evolutionary studies, PCR amplification of HIV env, followed by cloning and 
sequencing, was performed as previously described56. Analyses of evolution and 
site-specific selection were performed using BEAST27 and CODEML57. CODEML 
was used to identify sites that have been subjected to positive selection using site-
specific codon models. These models allow dN/dS to vary among sites, with values 
significantly above 1 indicating sites that had been under positive selection. We 
compared the fit of models M7 (which does not allow any sites to have a dN/dS of 
above 1) with M8 (which fits a class of sites with a dN/dS of above 1), using a likeli-
hood ratio rest. The empirical Bayesian approach implemented by CODEML was 
used to identify codons under positive selection, using a cut-off of  > 90%. BEAST 
was used to model the evolution of the viral sequences through time, using the log-
normal relaxed clock distribution to accommodate rate variation among branches. 
The multiple alignments contained 969 nucleotides. BEAST was run for 60 million 
steps, with the first 10% discarded as burn-in, and convergence was checked using 
Tracer. All analyses were repeated to ensure convergence. A preliminary BEAST 
analysis was performed that included the proviral sequence data, as these samples 
spanned a longer period of time than just the sequences obtained from plasma 
samples. The rate of evolution and effective population size were estimated from 
these time-structured sequences, and used in an analysis including only sequences 
obtained from plasma samples. 
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